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Abstract 
 
Patients with right ventricular (RV) pacemakers are at increased risk of left 
ventricular (LV) systolic dysfunction (LVSD) and chronic heart failure (CHF). I 
aimed 1) to establish the prevalence of LVSD in patients with long-term RV 
pacemakers listed for pulse generator replacement (PGR), 2) to evaluate the 
effects on LV function of reprogramming existing pacemakers to reduce RV 
pacing (RVP) and 3) to investigate whether upgrade to cardiac 
resynchronization therapy (CRT) at the time of PGR is beneficial in patients 
with unavoidable RV pacing and LVSD. 
 
Data were collected on 491 patients listed for PGR. Reduced left ventricular 
ejection fraction (LVEF) <50% was observed in 40%. Multivariable analysis 
revealed %RVP, serum creatinine and previous myocardial infarction (MI) to 
be independently related to the presence of LVSD.  
 
An audit was performed to investigate the effects of optimising pacemaker 
programming to avoid RV pacing in 66 patients. At 6m, RV pacing was 
reduced by a mean of 49%, with a mean improvement in LVEF of 6% and no 
reduction in exercise capacity, NT-pro-BNP or quality of life. 
 
Fifty patients with unavoidable RV pacing, LVSD, and mild symptoms of 
CHF, listed for PGR were randomized 1:1 to either standard RV-PGR or 
CRT. At 6 months there was a difference in change in median LVEF, 
improvements in exercise capacity, quality of life, and NT-proBNP in those 
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randomized to CRT. After 809 days, 17 patients had died or been 
hospitalized (6 CRT and 11 PGR) and two patients in the PGR arm required 
CRT for deteriorating CHF. 
 
In summary, LVSD is common in patients with standard RV pacemakers and 
relates to cardiovascular co-morbidities, careful reprogramming to avoid 
unnecessary RV pacing can improve LVEF without adversely affecting 
exercise capacity and quality of life and upgrading patients with unavoidable 
RV pacing to CRT at PGR improves LV function, and exercise tolerance and 
may reduce admissions and further upgrades. 
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Preface 
 
The relationship between right ventricular (RV) pacing and left ventricular 
systolic dysfunction (LVSD) and chronic heart failure (CHF) is established. 
The purpose of this series of investigations is to establish the prevalence of 
LVSD in a cohort of patients with existing RV pacemakers requiring a pulse 
generator replacement (PGR), and to determine the effects of optimising 
pacemaker therapy at PGR. 
 
The results of this work have underpinned two successful NIHR fellowship 
applications:  
The first is my primary supervisor, Dr Klaus Witte’s, NIHR Clinician Scientist 
award – OPT-pace. Klaus was awarded £588,878, OPT pace is a 5 year 
study further investigating the relationships between right ventricular pacing, 
cardiovascular co-morbidities and chronic heart failure. The study includes a 
randomised control trial of my right ventricular pacing avoidance algorithm 
and specialist heart failure therapy vs. standard pacemaker follow-up and 
also includes follow-up of patients with newly implanted pacemakers for 
bradycardia with the primary outcome of predicting who will develop left 
ventricular systolic dysfunction. 
 
The second successful application is my fellow Cardiac Physiologist Maria 
Paton’s NIHR ICA Doctoral Fellowship. Maria was awarded £300,393 to 
investigate if left ventricular systolic dysfunction related to right ventricular 
- xvi - 
pacing is progressive, or static. The study also includes an RCT of an 
enhanced version of my right ventricular pacing reduction algorithm, to 
further evaluate the effects of reducing not only the effects of reducing 
unnecessary right ventricular pacing on left ventricular function and heart 
failure symptoms, but also the effects on battery longevity and avoiding 
future battery replacements. 
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Chapter 1. Introduction to Pacemaker therapy 
1.1 Introduction 
A modern-day pacemaker is an implantable electronic device capable of 
delivering a regular pulse to the heart. Early pacemakers were designed to 
be electronic metronomes and modern iterations have added complex hard 
and software around that basic function to allow for programmability. 
Today’s pacemaker systems are fully implantable and consist of 1) a pulse 
generator that includes circuitry and a battery with around 8 years longevity 
and 2) the leads that deliver current to and sense intrinsic electrical activity 
in myocardium. (Fig 1) 
 
Figure 1.1 Pacemaker diagram 
 
A permanent implantable cardiac pacemaker is part of the recommended 
treatment for bradycardia by the National Institute for Health and Care 
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Excellence (NICE),(NICE, 2005) the European Society of Cardiology (ESC) 
(Brignole et al., 2013) and the American College of Cardiology (ACC) and 
American Heart Association (AHA).(Epstein et al., 2008) Pacemakers are 
associated with improved quality of life, improved longevity and symptomatic 
relief in patients with atrioventricular (AV) block, and sick sinus syndrome 
(SSS).(Shaw et al., 1985, Lamas et al., 1998, Ohm and Breivik, 1978, 
Mlynarski et al., 2009) In addition, the only effective treatment for 
symptomatic sinus bradycardia and chronotropic incompetence is cardiac 
pacing.(Epstein et al., 2008) Although supported by little data of improved 
efficacy,(Toff et al., 1997) it is generally thought that based upon quality of 
life years gained, dual chamber pacemakers might be more cost effective 
than single chamber in individuals in sinus rhythm (SR) with AV 
block.(Castelnuovo et al., 2005) 
 
Historically, the therapeutic use of cardiac pacing is seen as falling within the 
medical field of electro-diagnosis and electrotherapy,(Aquilina, 2006) more 
recently termed Electrophysiology. Over time, through observational, animal 
and human interventional studies, the pacemaker has developed from an 
externally powered device (dependent upon DC current), to a fully 
implantable device with battery longevity of more than 8 years.  
 
This section will first describe the history of cardiac pacemaker therapy, 
following this will be a review of the existing literature around the potential 
adverse effects of right ventricular pacing. I performed an extensive, 
systematic search of available literature resources, using MeSH search 
- 3 - 
terms- accessing Pubmed, MEDLINE, EMBASE, the Cochrane Central 
Register of Controlled Trials (CENTRAL, 2017), Conference Proceedings 
Citation Index - Science (CPCI-S), ClinicalTrials.gov, and the World Health 
Organization (WHO) International Clinical Trials Registry Platform (ICTRP). I 
did not apply any language restrictions, and searches included animal 
studies. (Relevo, 2012) 
   
1.2 History of heart rhythm, pacemaker therapy and 
electrophysiology 
Hippocrates (460-375 BC) provided an early insight into the detrimental 
effects of syncope, potentially related to bradycardia “Those who suffer from 
frequent and strong faints, without any manifest cause, die 
suddenly”,(Aquilina, 2006, Katz and Katz, 1962) and Aristotle (384-322 BC) 
described the heart as “the source of all movement, since the heart links the 
soul with the organs of life”.(Dunn, 2006)  Wang Shu-he (280BC) wrote 10 
books about the pulse in ancient China,(Wang et al., 2012) and 
Sphygmology, which deals with the theory of the pulse, arises from 
“Sphygmos” – the Greek term for the pulse(Aquilina, 2006), and in Roman 
times, Galen theorised that different pulse types related to 
disease.(Pasipoularides, 2014)  
 
The field of what is now referred to as Electrophysiology continued to 
develop, and in 1580 Geronimo Mercuriale formed the concept of syncope, 
and how syncope was related with a low pulse rate -  “Ubi pulsus sit rarus 
semper expectanda est syncope”, which roughly translates as “when the 
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pulse is rare, expect syncope”.(Aquilina, 2006) In 1600 William Harvey used 
a flick of his finger to restart a pigeon's heart following cardiac arrest, and he 
described and illustrated the circulatory system in 1628 (Fig 1.2.).(Ribatti, 
2009)  
 
Figure 1.2: Circulation by William Harvey 
 
In the 1640’s speculations on the bio-electrical properties of the 
cardiovascular system were published, and in 1717 Slovenian physician 
Marcus Gerbazius (1658 - 1718) first described symptoms of bradycardia 
related to complete atrio-ventricular (AV) block.(Aquilina, 2006) Following 
this, in 1761 Italian born anatomist and proclaimed “father of modern 
anatomical pathology” Giovanni Battista Morgagni (1682 - 1771), implied a 
causal relationship between bradycardia and syncope, with his clinical 
explanation of circulatory arrest.(Aquilina, 2006) 
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In 1774 the Registers of the Royal Human Society of London made the first 
reference to external stimulation of the heart in a young female 
patient,(Aquilina, 2006) and the first studies on the effects of electrical 
energy when applied to the body were conducted by Danish physicist 
Nickolev Abildgaard in 1775. Electrodes were placed on the sides of a hen's 
head, and an electric charge was applied which resulted in the birds death. 
Electrodes were applied over various parts of the hen's body, which failed to 
resuscitate the bird. However, the bird staggered to its feet and walked away 
following application of the electrodes to its chest, it was presumed that this 
defibrillated the heart, resulting in the bird’s successful 
resuscitation.(Chaikhouni, 2010) Scottish pioneer of experimental surgery 
John Hunter (1728 - 1793), recommended in 1776 that victims of drowning 
should be resuscitated through the application of electrical 
stimulation.(Chaikhouni, 2010) This was attempted by Charles Kite in 
London. In 1788 he reported on the resuscitation of a three year old girl 
through the use of an electrostatic generator and declared that: "…electricity 
is the most powerful stimulus we can apply…if it is able so powerfully to 
excite the action of the external muscles, it will be capable of reproducing 
the motion of the heart which is infinitely more irritable, and by that means 
accomplish our great desideratum, the renewal of the 
circulation.".(Eisenberg, 1994) 
 
In 1791 Italian physician and natural scientist Luigi Galvani (1737 – 1798) 
made a substantial contribution to modern cardiac electrophysiology when 
he published the findings of his experiments on frog hearts and muscles. He 
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announced that electrical activity existed within organic tissue. There 
followed a consensus that electrical activity had an effect on the 
heart.(Aquilina, 2006, Chaikhouni, 2010) To further strengthen the 
accumulating evidence within electrophysiology, reports exist of Prussian 
geographer, naturalist and explorer Alexander von Humboldt resuscitating a 
dead bird found in his garden via a blade of zinc in its beak and a shaft of 
silver in the rectum, through which he applied an electric shock.  His actions 
resulted in the bird to flapping its wings and attempting to walk.(Finger et al., 
2013)  
 
During 1800-1802 French anatomist and physiologist Marie Francois Xavier 
Bichat (1701-1802) and fellow countryman, physiologist and paediatrician 
Pierre-Hubert Nysten (1771-1818) experimented on decapitated humans. 
They reported that by using electric current they were able to make hearts 
beat again.(Aquilina, 2006) Following this, in 1804 the Italian born physicist 
Giovanni Aldini (1762 – 1834) described his animal and cadaver 
experiments, during which he is said to have “alleviated cardiac syncope”, 
through electrical currents.(Parent, 2004)  
 
In 1827 Irish surgeon Robert Adams (1791 - 1875) first described that 
cardiac rhythm dysfunction and cerebral symptoms may be related, when 
describing a patient with frequent syncope and a slow heart rate. And in 
1846, another Irishman William Stokes (1804 – 1878) provided further 
evidence of the relationship between syncope and bradycardia and provided 
a further detailed analysis of the case Adam’s presented.(Berry, 2006) 
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Swiss anatomist, physiologist and histologist Rudolph Albert von Kollicker 
(1817 – 1905) published his work on the heart’s “action currents” in 1855, 
demonstrating that each beat of a frog's heart produced an electric 
current.(Fye, 1999)  In 1872 the French neurologist Duchenne de Boulogne 
(1806 - 1875) performed a successful resuscitation of a child that had 
drowned by attaching an electrode to the leg and tapping the precordium 
with another electrode.(Parent, 2005)  
 
In 1882, a 46yr old female patient attended the clinic of German physician 
Hugo Von Ziemssen (1829 – 1902). She had recently had a chest tumour 
removed and had been left with her heart exposed, covered only by a thin 
layer of skin. Using an electric current, Von Ziemssen changed the heart rate 
by directly stimulation of the heart, and noted that stimulation only occurred if 
the rate of stimulation was greater that the underlying heart rate and that 
slower stimulation produced a slower and erratic heart rate. Figure 1.3 
shows recordings that clearly demonstrate ventricular activity produced by 
the electrical impulses.(Aquilina, 2006)  
 
 
Figure 1.3: Von Ziemssen’s recordings of ventricular activity 
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In 1889, Scottish pioneer of Electrophysiology John MacWilliam (1857 – 
1937) collated all of the available data to date and produced the basic 
concepts of pacing. He depicted the practice of applying electricity over the 
chest to “excite rhythmic contraction… to stimulate by direct means the 
action of the heart which has been suddenly enfeebled or arrested in 
diastole by causes of a temporary or transient character”,(Silverman and 
Fye, 2006, Aquilina, 2006) and thereby provided medicine with its first 
unified theory of cardiac pacing 
 
Further evidence of cardiac rhythm disturbances were provided by Dutch 
anatomist Karel Frederik Wenckebach (1864 – 1940) in 1899 with his 
description of type I second degree atrio-ventricular block in humans, this 
was achieved using sphygmographic methods of measuring the radial pulse 
as the electrocardiogram was still in development.(Fye, 1990) In 1906 
English cardiologist John Hay (1873 – 1959), using simultaneous recordings 
from the radial artery and jugular vein as the electrocardiograph still wasn’t 
widely available, produced a case report of type II second degree atrio-
ventricular block.(Barold and Luderitz, 2001)  
 
From the late 1800's to the early 1900's the invention of the 
electrocardiograph was a major technological advancement that would allow 
cardiology to further the understanding of arrhythmias, and therefore the 
development of arrhythmia therapy, including cardiac pacing. London based 
Physiologist, Augustus Desire’ Waller (1856- 1922) recorded the first human 
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surface electrocardiogram in 1887 using the Lippmann capillary 
electrometer, Figure 1.4. Waller described that “each beat of the heart gives 
an electric change, beginning at one end of the organ and ending at the 
other”.(Aquilina, 2006, Besterman and Creese, 1979)  
 
 
Figure 1.4: First human ECG recording by Waller 
 
Dutch physiologist, Willem Einthoven (1860 – 1927) further added to 
development of the electrocardiograph, with his recordings in 1892. He 
observed that the ECG had four deflections, and initially named them with 
the characters A, B, C, D, however later changed this to use P, Q, R, S and 
T. His work was met with scepticism within the scientific community, 
however Einthoven continued his work and described the Einthoven triangle 
in 1913 and used this as the basis for electrocardiographic calculations. The 
same year also saw the introduction of the bipolar electrode system, and 
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Einthoven was awarded the Nobel Prize for Physiology and Medicine in 
1924 for his work in electrocardiography.(Aquilina, 2006, Barold, 2003) 
 
In 1933, American cardiologist Frank Norman Wilson (1890 – 1952) 
expanded electrocardiography beyond using only the extremities - by 
introducing the unipolar chest wall electrodes, and following this in 1942 his 
fellow American cardiologist Emanuel Goldberger introduced the “unipolar 
amplified (augmented) extremity leads” This completed the 12-lead 
electrocardiogram as used today,(Aquilina, 2006, Johnston, 1952, AlGhatrif 
and Lindsay, 2012) and played an important role in the further advancement 
of pacemaker technology.  
 
Development of the first external cardiac pacemakers is credited to two 
individuals - Australian anaesthetist Mark Lidwill (1878 – 1969) and the 
American physiologist Albert S Hyman (1893 – 1972). Lidwill's device 
required the insertion of a needle into the patient’s ventricle, and ran on 
alternating current. In 1928 he saved the life of a new-born child in cardiac 
arrest using electrical stimulation of the heart. He reported this to the 
Australian Medical Society in 1929.(Aquilina, 2006, Mond et al., 2012, 
Furman, 2002) 
 
Hyman was the first to develop an external pacemaker device.  Hyman was 
interested in “reviving the stopped heart by means of intra-cardial therapy”. 
This therapy initially consisted of the injection of medication including 
epinephrine directly into the heart. Lidwell realised that it was the needle that 
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stimulated the heart to beat, through setting up an action current of injury as 
it punctured the heart, and not the drug itself.(Irnich et al., 1978, Aquilina, 
2006) 
 
Hyman's device (Figure 1.5) was described by himself as an “artificial 
pacemaker” in 1932. He is therefore credited with coining the term 
“pacemaker”, which is now universally accepted.  Hyman’s pacemaker was 
powered by a spring-wound hand-cranked motor, since mechanical power 
was more reliability than commercially available batteries.(Irnich et al., 1978, 
Aquilina, 2006) 
 
 
Figure 1.5: Albert Hymans Artificial Pacemaker 1932 
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Figure 1.6: Hyman’s pacemaker in a box 
 
The mechanism drove a DC current generator, and, through a bipolar 
electrical needle (Fig 1.7) inserted into the right atrium through the chest 
wall, electrical impulses were delivered. Pacing could be delivered at 30, 60 
or 120 pulses per minute as required. None of the three devices built 
survives and only two photographs are available.(Aquilina, 2006, Irnich et 
al., 1978) 
 
 
Figure 1.7: Hyman’s electrodes 
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Figure 1.8: Flow diagram of Hyman’s artificial pacemaker 
 
 
Figure 1.9: Hyman’s recordings  
 
Hyman’s device was met with opposition and suspicion from the medical 
community, who did not accept his use of electro-stimulation. Combined with 
technical issues, his progress was halted and he never published his work. 
Hyman found it difficult to find a local manufacturer, but eventually German 
company Siemens-Halske and their American partners Adlanco did agree to 
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manufacture a battery operated version. It was named the Hymanotor, (Fig 
1.10), but was unreliable during testing.(Irnich et al., 1978, Aquilina, 2006) 
 
Figure 1.10: The Hymanotor (Adlanco) 
 
In 1949 in Toronto, Canadian cardiothoracic surgeons Wilfred Bigelow (1913 
– 2005) and John Callaghan (1923 – 2004) began experimenting with 
hypothermia to induce bradycardia, reduce metabolism and allow cardiac 
surgery. Re-warming did not increase the heart rate as quickly as they 
required, so they began to experiment with sino-atrial node 
stimulation.(Aquilina, 2006, Kermode-Scott, Furman, 2002) Whilst 
experimenting on a dog, the heart stopped, and Bigelow recounted: “Out of 
interest and in desperation, I gave the left ventricle a good poke with a probe 
I was holding. All four chambers of the heart responded. Further pokes 
clearly indicated that the heart was beating normally with good blood 
pressure.” These hypothermia experiments further advanced the 
development of pacemaker therapy.(Aquilina, 2006, Furman, 2002) 
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During the 1940's and early 50's a physiological stimulator, manufactured by 
Grass Manufacturing Co (Fig 1.11), was the principle device used to 
generate electrical impulses. This device had the potential to stimulate the 
heart in clinical and laboratory situations. Stimulation rate, voltage output 
and pulse width could be adjusted.(Aquilina, 2006) 
 
 
Figure 1.11: The Grass stimulator 
 
In 1949, Canadian electrical engineer John Hopps (1919-1998), employed 
by the National Research Council of Canada, built the first electronic device 
purposefully designed as a cardiac pacemaker. This external device, (Fig 
1.12) driven by vacuum tubes, paced the atria via a trans-venous approach 
using a bipolar electrode catheter. This allowed atrial pacing to be delivered, 
without violent chest wall muscular contractions thereby controlling the heart 
relatively painlessly.(Aquilina, 2006, Hopps, 1981, Haddad et al., 2006) 
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Figure 1.12: Early external electronic pacemakers 
 
The 1950’s saw the development of mains-powered pacemakers. They were 
contained in large boxes and therefore had to have wheels and required 
mains electricity supply, limiting their portability.(Aquilina, 2006) 
 
In 1951, American cardiologist Paul Zoll (1911 – 1999), developed an 
external pacemaker, which was used to successfully treat heart block. Zoll’s 
device, “The electrodyne PM-65 pacemaker” (Fig 1.13), is credited as a 
major advancement in modern cardiac pacing technology. The device 
consisted of an electrocardiograph for cardiac rhythm monitoring and a pulse 
generator, which ran off mains electricity, to pace the heart.(Aquilina, 2006, 
Furman, 2002)  
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Figure 1.13: Paul Zoll’s external pacemaker 
 
The device was heavy, bulky, had to be transported using a cart, and as it 
was powered by mains electricity, could only go as far as the power cord 
would allow (Fig 1.14). It delivered electrical impulses through a pair of metal 
electrodes strapped to the patient's chest directly over the heart. The 
patients found the experience painful, as the electric shocks irritated the 
skin.(Aquilina, 2006, Furman, 2002) 
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Figure 1.14: Paul Zoll’s external pacemaker 
 
In 1952, Zoll reported two episodes, when his device was used to 
successfully treat two patients suffering from ventricular standstill (Fig. 1.15) 
and in 1956 Zoll used transthoracic electric shocks to treat ventricular 
fibrillation in human subjects. 
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Figure 1.15: Early Zoll paced ECG tracings 
 
In St. George's Hospital, London, in 1956 cardiologists Aubrey Leatham and 
Geoffrey Davies developed an external pacemaker used to resuscitate 
patients with heart block and asystole. Paul Zoll had just reported his studies 
on the use of external pacing to treat ventricular standstill, but there were 
major differences between the two devices. Zoll's pacemaker delivered 
“fixed pacing”, which paced irrespective of the patients underlying heart rate, 
whereas Leatham and Davies developed system with a “demand pacing” 
capability, meaning the device could pace the heart in relation to the 
patient’s underlying heart rate. The device still stimulated the heart through 
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the chest wall, and was manufactured by UK company Firth-Cleveland. The 
device included a battery, two electrical output settings, “duration of asystole 
permitted” and adjustable sensitivity controls for sensing of the underlying 
electrocardiogram.(John Camm et al., 2010, Aquilina, 2006) 
 
US cardiac surgeon Clarence Walton Lillehei (1918 – 1999) had performed 
open-heart surgery in Minnesota on over 300 children and young adults born 
with congenital heart disease by 1957. Complications encountered by his 
team during cardiac surgery were to be a major driving force in the 
advancement of cardiac pacing technology. Despite successful surgery, 
around 1 in 10 patients developed post-op complete heart block as a result 
of damage to the conduction system during surgery to repair ventricular 
septal defects, and mortality in these was 100%.(Gott, 2007) Medical 
intervention, was helpful in the short-term, but inevitably heart block would 
return.(Aquilina, 2006) 
 
Lillehei thought that pacing would temporarily provide support to the cardiac 
rhythm, and maintain heart rate whilst the conduction system was 
recovering, but realised that high voltage pacing delivered through the skin 
was painful and traumatic.  Following many experiments, Vincent Gott 
(1927) and William Weirich (1924 - 2014) demonstrated in animals that low 
voltage electrical impulses delivered by a wire positioned in the right 
ventricle, and connected to a Glass pulse generator, could stimulate the 
heart and restore cardiac rhythm.(Aquilina, 2006, Gott, 2007) 
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Lillehei and his team developed the “myocardial wire”, which consisted of 
numerous braided stainless steel wires covered in a Teflon sleeve (Fig 
1.16). One end of the wire was implanted directly into the heart and the other 
end was connected to the external pulse generator. To complete the circuit, 
a further electrode was buried under the skin. Only 1.5 volts was required to 
stimulate the heart, as the electrode was in direct contact with the 
myocardium. There was no damage to the heart, and once normal 
conduction had returned the wire could be easily removed by gentle 
traction.(Aquilina, 2006) 
 
 
Figure 1.16: Lillehei’s “myocardial wire” 
 
The first implant of the myocardial wire was on the 30th January 1957 in a 3-
year old girl who had developed complete heart block following surgery for 
Fallot’s tetralogy. The pacing procedure was successful - the patient 
regained sinus rhythm and survived. Following this, myocardial wires started 
to be implanted prophylactically ready for urgent use. Techniques were 
developed to allow implantation through a hollow needle to treat non-surgical 
cases of heart block.(Aquilina, 2006) 
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There were obvious drawbacks to the set-up at the time. The stimulator was 
large and immobile and relied on mains power supply. This was to be the 
most fatal flaw, highlighted when in October 1957, a power failure lasting 
three hours resulted in the death of a baby. This event prompted Lillehei to 
contact Earl Bakken, founder of Medtronic Inc. He asked him to design a 
portable, battery powered pacemaker, as he felt lack of mobility and an 
unreliable power source were the main drawbacks of the current 
system.(Aquilina, 2006) 
 
The late 1950’s – early 1960’s are often referred to as the “Golden Years” of 
Electrophysiology due to three landmark achievements 
 
1) The first battery-operated, wearable pacemaker in 1957. 
2) The first implantable permanent pacemaker 1958. 
3) The first long-term treatment of heart block with an implantable 
pacemaker in 1960.(Aquilina, 2006) 
 
American electrical engineer and TV repairman Earl E. Bakken (1924 – 
present) developed the first battery-operated, wearable pacemaker in 1957. 
Bakken co-founded Medtronic Inc, now the largest medical device company 
in the world, with his relative Palmer Hermundslie (1919-1970) in a garage in 
northeast Minneapolis in 1949. Their company began as a repair service and 
distributor for hospital electrical equipment but they also built bespoke 
equipment at the request of clinical and laboratory researchers. Their time in 
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hospital and university departments repairing equipment, allowed them to 
build relationships with physicians and their staff.(Aquilina, 2006, Steinhaus, 
2008) 
 
Clarence Walton Lillehei had assigned Bakken the task of developing a 
battery powered, portable pacemaker. Bakken’s initial attempts involved 
using a car battery as the power source for the pulse generator. This plan 
was abandoned early on. The car battery was deemed too inefficient and the 
pulse generator still had to be transported using a trolley. Bakken’s next 
attempt was an adaptation of an electronic, transistorised metronome he had 
seen advertised in an electronics journal. The device operated as a timing 
system, the circuit transmitted loud clicks through a speaker and the rate of 
the clicks was adjustable. Bakken disconnected the speaker, modified the 
circuit (Fig. 60) and placed it into a four inch square aluminium box, with an 
on-off switch and control knobs to adjust stimulus rate and the amplitude of 
energy delivered (Fig 1.18).(Aquilina, 2006, Steinhaus, 2008) 
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Figure 1.17: Bakken’s circuit 
 
 
Figure 1.18 Bakken’s pacemaker with leads 
 
Bakken took the device to the University lab where it was successfully tested 
on a dog. The following day when he returned to the hospital to continue 
work on a different project, he saw one of Lillehei's patients wearing the 
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device he had delivered the day before. Lillehei explained to Bakken that he 
had been informed by the lab that the pacemaker worked and he “wouldn’t 
allow a child to die because we hadn’t used the best technology available.” 
The first battery-powered pacemaker was in clinical use, following only four 
weeks of development. Subsequent modifications included handles and a 
strap to make the device “wearable” (Fig 1.19) a red neon light that flashed 
with each stimulus, and dials that were more childproof. Product literature 
was provided.(Aquilina, 2006, Steinhaus, 2008) 
 
Figure 1.19: Medtronic pacemaker 
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Figure 1.20: Wearable pacemaker 
 
 
Figure 1.21: Medtronic pacemaker product literature 
 
Despite the success of Bakken’s device, infections along the pacing wires 
were frequent.  Lillehei noted this in abstract he published in 1960: “The 
question of how long stimulation can be maintained appears to be related to 
- 27 - 
electrode materials, design and technique of implantation… The possibility 
of infection along the wire exists, but… can be minimised by tunnelling the 
wire for some distance before bringing it out on through the skin.” (Fig 1.22) 
Recurrent, post-operative heart block caused several deaths, and it became 
apparent that patients needed permanent, rather than temporary pacing for 
long-term survival. The myocardial wire became less effective as scar tissue 
developed around the stimulation site, requiring an increase in stimulus 
voltage to maintain capture and causing discomfort because of thoracic 
muscles twitching. It was apparent that a fully implantable system with 
different electrode materials was required.(Aquilina, 2006, Steinhaus, 2008) 
 
Figure 1.22: Lillehei’s paper 
 
On October 8th 1958, Swedish thoracic surgeon Ake Senning (1915 – 
2000), implanted the first implantable pacemaker, designed by medical 
engineer Rune Elmqvist (1906 – 1996), at the Karolinska Hospital in 
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Stockholm. The risk of infection from external pacemakers drove their desire 
to design a completely implantable device. A pulse generator with a 
rechargeable battery, which was recharged via induction, was implanted 
along with myocardial electrodes. The unit was hand-made (Fig 1.23) and 
consisted of the electronic circuit, nickel-cadmium batteries and the coil 
recharging antenna. These were placed in an epoxy resin case which had 
excellent bio-compatibility and was 55mm in diameter and 16mm thick. The 
impulses were delivered at amplitude of 2 volts and a pulse width of 1.5ms 
and the pulse rate was fixed at a constant rate of 70 to 80 beats per 
minute. The first device failed after a few hours, its replacement six weeks, 
and the third lasted until 1960. Anne H Larsson had a total of 26 
pacemakers in his lifetime, and has since passed away - he died aged 86 on 
28th December 2001. (Larsson et al., 2003). Senning reported the procedure 
at the Second International Conference on Medical electronics in 1959 and it 
was published as an abstract in 1960 (Fig 1.24).(Jeffrey and Parsonnet, 
1998, Aquilina, 2006)  
 
Figure 1.23: Senning and Elmqvist’s implantable pacemaker 
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Figure 1.24: Senning’s abstract 
 
American electrical engineer, Wilson Greatbatch (1919 – 2011) was 
developing an oscillator to help with the recording of tachycardic episodes 
when he accidentally discovered a way to make an implantable pacemaker. 
When designing his circuit he used a larger resistor by mistake, which made 
the circuit deliver a 1.8 millisecond pulse followed by a 1 second interval. 
Greatbatch realized that this device could pace a human heart. On the 7th 
May 1958, Greatbatch brought his pacemaker to the animal lab at the 
hospital. There, surgeons William Chardack (1919 – 2011) and Andrew 
Gage (1922 – present), exposed the heart of a dog and applied two pacing 
wires which were connected to Greatbach’s device, the heart began to beat 
in synchrony with the device.(Aquilina, 2006, Jeffrey and Parsonnet, 1998) 
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Following this, many experiments took place in animals and in 1959 
Greatbatch patented the implantable pacemaker. Chardack reported the first 
successful implant in June 1960 on a 77-year old man in complete heart 
block. In 1961, Chardack, Gage and Greatbatch reported a series of 
pacemaker implants in 15 patients. Later, Greatbatch invented the long-life 
lithium-iodine battery to power pacemakers.(Jeffrey and Parsonnet, 1998, 
Aquilina, 2006) 
 
The next major advancements in pacemaker technology came in the form of 
lead development. On the 4th April 1959 Professor of Surgery, Samuel 
Hunter (1921 – 2008) and Norman Roth (1931 - 1997), Chief Engineer at 
Medtronic, implanted a bipolar stainless steel electrode in a patient suffering 
from complete heart block following a myocardial infarction. The lead was 
constructed of two stainless steel wires secured in a silicone rubber base 
(Fig 1.25). 
 
Figure 1.25: Hunter-Roth electrodes 
 
A new lead was developed in 1959 by Swedish company Elema Schonander 
in partnership with telecoms company Ericcson. It was constructed from four 
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thin bands of stainless steel, which were wound around a polyester braid 
and insulated with soft polyethylene (Fig 1.26). It was designed to flex, and 
was estimated to last for at least 6 years.(Aquilina, 2006)  
 
Figure 1.26 Elema pacing lead 
 
Technology continued to develop to make pacemakers more reliable, 
programmable and automated in the therapy they delivered. The therapeutic 
aim changed from saving life to include improving quality of life and 
enhancing care. Trans-venous leads began to replace epicardial leads, to 
allow pacemakers to be implanted without a general anaesthetic and a 
thoracotomy. “Demand” pacemakers were developed which could sense 
underlying cardiac activity and only pace when required. The lithium-iodine 
battery was developed, resulting in increased pacemaker longevity, and 
leads were developed to provide “passive” or “active fixation” via tines or a 
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retractable screw. Titanium casing replaced the epoxy resin and silicone 
rubber, previously used to enclose the battery and circuitry and protect the 
internal components.(Aquilina, 2006) 
 
A non-invasive method of programming pacemakers was introduced in the 
1970's (Fig 1.27). This was achieved via a radio-frequency link, meaning 
most variables could be adjusted to follow the clinical requirements of the 
patient. Towards the end of the 1970's dual-chamber pacemakers were 
introduced, which could pace and sense both the atria and ventricles. This 
allowed a more synchronised pacing pattern to be delivered, which could 
replicate the heart’s own conduction pathway. In the 1980's (Fig 1.28) 
steroid-eluting pacemaker leads were introduced. The steroid from the lead 
tip decreased the inflammatory response evoked by the lead tip, and 
reduced the initial rise in capture threshold. In the 1980’s rate-responsive 
pacemakers were developed by including an accelerometer within the 
pacemaker to detect movement, thereby increasing or decreasing the pacing 
rate appropriately according to the activity level.(Aquilina, 2006) 
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Figure 1.27: Pacemakers of the 70’s 
 
 
Figure 1.28: Pacemakers of the 80’s  
 
Microprocessor-driven pacemakers were introduced in the 1990’s (Fig 1.29) 
allowing pacemakers to detect and store information using algorithms to 
detect episodes of tachycardia and percentage of pacing delivered. They 
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could modify their internal parameters automatically when required to do 
so.(Aquilina, 2006) 
 
Figure 1.29: Pacemakers of the 90's 
 
In the 1990’s, investigators began examining whether ventricular 
dyssynchrony might play a role in the failing heart and investigated 
pacemaker-like devices that stimulated several places in the heart 
simultaneously to minimise conduction delay. The efficacy of multisite pacing 
in humans was demonstrated in landmark studies by Cazeau et al, Auricchio 
et al, and Kass et al, and led to Cardiac Resynchronization Therapy (CRT) – 
the use of artificial electric cardiac stimulation for the principal purpose of 
changing ventricular function. (Cazeau et al., 1994, Auricchio et al., 1999, 
Kass et al., 1999) Bi-ventricular pacing, or CRT, was introduced as a 
treatment for patients with heart failure and left bundle branch block (LBBB). 
An additional lead is introduced via the coronary sinus to stimulate the 
epicardial surface of the left ventricle. This allows the right and left ventricles 
to be paced simultaneously to help resynchronise ventricular contraction, in 
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the presence of interventricular conduction delay. The improved contraction 
improves symptoms and survival (Figure 1.30).(Cleland et al., 2005)  
 
Figure 1.30: Medtronic CRT pacemaker 
 
Automaticity of pacemaker follow-up continued to progress, enabling follow-
up visits to be simpler and briefer. Technology was also developed to allow 
pacemaker data to be uploaded telephonically and via the internet, a term 
coined “Remote follow-up” (Fig 1.31).(Aquilina, 2006) 
 
Figure 1.31: Schematic diagram of Biotronik remote follow-up 
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1.3 Epidemiology of pacemakers in the UK 
In 2014, 45,131 pacemakers were implanted in the UK (Raatikainen et al., 
2015) - an increase from just over 44,500 in 2013.(Arribas et al., 2014) 
Figure 1.32 shows the UK (excluding Scotland due to incomplete data) 
implant rate from 2003-2013.(Group, 2014)   
 
Figure 1.32: New pacemaker implant rate 2003‐2013, adapted from CRM 
National Clinical Audit Report (Group, 2014) 
 
1.4 Effects of RV pacing on cardiac function 
Despite proven mortality and quality of life benefits of pacemaker 
implantation,(Lamas et al., 1998, Shaw et al., 1985, Ohm and Breivik, 1978, 
Mlynarski et al., 2009) long-term pacing in the right ventricle (RV) may be 
detrimental to left ventricular (LV) function in some individuals. Pacing the 
heart using a pacing lead situated in the RV apex has been standard clinical 
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practice for many years, but this practice has come into question with 
evidence directing a change in practice toward reducing unnecessary 
ventricular pacing where possible.  
 
The earliest recordings of the potential detrimental effects of RV pacing were 
published by Carl J Wiggers in 1925.(CJ, 1925) Wiggers observed adverse 
changes in LV intra-ventricular pressure curves recorded in dogs, during 
right ventricular pacing. But it was in the late 1980’s and early 1990’s that 
the association between persistent RV pacing and heart failure was 
recognised. Animal experiments of rapid chronic RV pacing were used to 
develop experimental models of congestive heart failure,(Wilson et al., 1987, 
Chow et al., 1990, Masaki et al., 1993, Travill et al., 1992, Armstrong et al., 
1986) and it was recognised that prolonged RV pacing was associated with 
adverse cardiac structural, haemodynamic and neuro-hormonal changes. 
Human studies comparing atrial to ventricular pacing demonstrated an 
association with RV pacing and increased incidence of congestive heart 
failure and atrial fibrillation (AF).(Feuer et al., 1989, Rosenqvist et al., 1986, 
Rosenqvist et al., 1988, Andersen et al., 1997, Andersen et al., 1994)  
 
It is now appreciated that disorganised ventricular activation, as recognised 
by electrocardiography, either spontaneous as with left bundle branch block 
(LBBB),(Xiao et al., 1991, Xiao et al., 1992, Grines et al., 1989, Wilensky et 
al., 1988, Shamim et al., 1999, Ozdemir et al., 2001, Duzenli et al., 2008) or 
iatrogenic with RV pacing,(Tse et al., 2002, Tse and Lau, 1997, Nielsen et 
al., 2000, Thackray et al., 2003, O'Keefe et al., 2005) is associated with 
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adverse clinical outcomes.(Andersen et al., 1997, Nielsen et al., 1998, 
Wilkoff et al., 2002, Sweeney et al., 2003) Electrical activation in RV pacing 
is similar to that in intrinsic LBBB. It originates at the RV apex and passes 
through the inter-ventricular septum, rather than the His-Purkinje system, 
then spreads through the LV myocardium with the latest area of activation 
being the LV infero-lateral,(Varma, 2008, Sweeney and Prinzen, 2006) or 
infero-posterior region,(Vassallo et al., 1986, Rodriguez et al., 2003, 
Auricchio et al., 2004) resulting in disorganised contraction.  
 
The acute adverse haemodynamic effect of pacing the RV is negatively 
correlated with QRS duration (used as a measure of ventricular activation 
time),(Park et al., 1985) and different sites of RV pacing change the strength 
of LV contraction, with a linear inverse relationship between the changes 
and changes in QRS duration.(Burkhoff et al., 1986) Animal,(Sweeney and 
Prinzen, 2006, Prinzen and Peschar, 2002) and human (Lieberman et al., 
2006) studies of RV pacing have shown a larger LV volume during RV 
pacing and also that pacing at different sites within the RV induces a 
rightwards shift of the pressure-volume relationship during LV contraction. 
These adverse changes are associated with a decrease in the ability of the 
LV to generate pressure (contractility), shown by a reduction in (+dP/dt) and 
a reduced stroke volume. Overall, RV apical pacing causes a reduction in 
LVEF of 5-10% in both long and short-term studies,(Tse et al., 2002, Tse 
and Lau, 1997, Nahlawi et al., 2004) and also has adverse effects on LV 
diastolic function.(Tse et al., 2002, Tse and Lau, 1997, Prinzen and Peschar, 
2002, Zile et al., 1987) In addition to the reduction in left ventricular ejection 
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fraction (LVEF), RV pacing causes adverse remodelling of the LV,(Lee et al., 
1994, Albertsen et al., 2008) and 27% of attendees at a pacemaker clinic 
have previously been found to have left ventricular systolic dysfunction 
(LVSD) and heart failure symptoms.(Thackray et al., 2003) The adverse 
effects of long-term RV pacing in patients with RV pacemakers may also 
contribute to hospitalisation due to heart failure, with hospitalisation rates of 
between 10-26% previously reported.(Sweeney et al., 2003, Zhang et al., 
2008) These adverse effects may,(Sweeney et al., 2003, Sharma et al., 
2005) or may not,(Riahi et al., 2012) be associated with the amount of RV 
pacing. Other factors and co-morbidities such as age, AF, impaired LV 
function and QRS duration may also contribute.(Riahi et al., 2012)   
 
Evidence of the clinical superiority of dual chamber (DDD) vs. single 
chamber ventricular (VVI) pacing, in terms of exercise capacity,(Karlof, 
1975, Kruse et al., 1982, Fananapazir et al., 1983, Perrins et al., 1983, 
Kristensson et al., 1985, Pehrsson et al., 1988, Rediker et al., 1988, Lau et 
al., 1990) quality of life,(Boon et al., 1987, Perrins et al., 1983) and mortality 
(Alpert et al., 1987, Alpert et al., 1986, Hesselson et al., 1992) led to DDD 
pacemakers being used more frequently. However, early DDD pacemakers 
had limited options for changing AV delays, which often led to permanent RV 
pacing, and any associated progressive symptoms of heart failure were 
attributed to progression of conduction disease, rather than reduced cardiac 
function associated with RV pacing.(Levine, 2010) 
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The “Danish” pacing trial, (Andersen et al., 1997) was a study of long-term 
outcomes (up to 8 years) of a previous prospective study in which 
225 patients with SSS were randomised to either single-
chamber atrial pacing (AAI) or single-chamber ventricular pacing 
(VVI).(Andersen et al., 1994) Previously there were no differences in 
mortality between groups (log rank test, p=0.12), but more patients in the 
VVI group had AF and thromboembolic events than those randomised to 
AAI.(Andersen et al., 1994) However, the Danish trial did show that in the 
long-term, VVI pacing was associated with increased all-cause mortality, 
(relative risk 0.66 [95% CI 0.44-0.99]; p=0.045) and cardiovascular mortality 
(0·47 [0·27–0·82], p=0·0065), and that those randomised to AAI were at 
lower risk of developing AF (relative risk 0·54 [95% CI 0·33–0·89], 
p=0·012).(Andersen et al., 1997) The rationale behind the reported adverse 
outcomes was that intrinsic AV conduction was maintained with AAI pacing, 
thus avoiding the abnormal ventricular depolarisation seen with RV pacing. 
 
The Pacemaker Selection in the Elderly (PASE) trial was prospective trial in 
which patients were randomised to receive either DDDR or VVIR 
pacemakers.(Lamas et al., 1998) 2010 patients with sinus-node dysfunction 
were assigned to DDDR or VVIR pacing and followed for a median of 33.1 
months. The primary end point (all-cause mortality or non-fatal stroke) did 
not differ between the groups (p=0.48), but in patients randomised to DDDR 
pacing the risk of developing AF was lower (hazard ratio, 0.79; 95 percent 
confidence interval, 0.66 to 0.94; P=0.008), and heart-failure QoL scores 
were better (p<0.001). Rates of hospitalization for heart failure, death and 
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stroke were not significantly different in unadjusted analyses and were only 
minimally significant in adjusted analyses.(Lamas et al., 1998) 
 
The Canadian Trial of Physiologic Pacing (CTOPP) was a randomised trial 
of 1474 patients receiving a DDDR or AAIR pacemaker vs a VVIR 
pacemaker, for bradycardia, with the rationale of examining the effects of 
physiological vs ventricular pacing on the primary outcome of cardiovascular 
death or stroke.(Connolly et al., 2000c) Annual occurrence of the primary 
outcome was 5.5% with ventricular pacing vs 4.9% 
with physiologic pacing (RRR, 9.4%; 95% CI: -10.5 to 25.7%; p=0.33). 
Annual AF rate was significantly lower in the physiologic-pacing group (5.3 v 
6.6% (RRR, 18%; 95% CI: 0.3 to 32.6%; p=0.05) Annual all-cause mortality 
and hospitalization for heart failure rates were lower in those paced 
physiologically, but did not reach statistical significance. However, there 
were more complications associated with physiologic pacing 9% v 3.8%, 
p<0.001).(Connolly et al., 2000c) 
 
The United Kingdom Pacing and Cardiovascular Events (UKPACE) trial 
compared elderly patients with atrioventricular block receiving single-
chamber ventricular pacing and dual-chamber pacing.(Toff et al., 2005) 2021 
patients aged 70 years or older were randomised to receive a single-
chamber ventricular pacemaker (VVI) or a dual-chamber pacemaker (DDD). 
The VVI group were randomised receive fixed-rate or rate responsive 
pacing. Mean annual mortality rate was 7.2% in the VVI group v 7.4% in 
the DDD (HR, 0.96; 95% CI: 0.83 to 1.11). There were no differences 
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between groups in annual rates of AF, heart failure or composite stroke, TIA 
or other thromboembolic outcomes. 
 
 From the accumulating evidence base towards AV sequential pacing being 
a more physiological way of pacing,(Karlof, 1975, Kruse et al., 1982, 
Fananapazir et al., 1983, Perrins et al., 1983, Kristensson et al., 1985, 
Pehrsson et al., 1988, Rediker et al., 1988, Lau et al., 1990, Boon et al., 
1987, Alpert et al., 1987, Alpert et al., 1986, Hesselson et al., 1992) and 
having evidence that VVI implantable cardioverter defibrillators reduced 
mortality in patients with heart failure,(1997a) device manufacturers began 
developing dual-chamber implantable cardioverter defibrillators (ICD’s). 
Dual-chamber ICD’s were immediately widely accepted, on the reasoning 
that the introduction of an atrial lead would be beneficial in terms of both 
improved haemodynamics from AV sequential pacing whilst also providing 
improved rhythm recognition, although no studies had been carried out to 
support this approach. It was the introduction of dual chamber pacing into 
ICD’s that rapidly led to the evidence of an association between RV pacing 
and CHF.  
 
The dual-chamber pacing or ventricular backup pacing in patients with an 
implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator 
(DAVID) Trial was designed, in the late 1990s. The trial had the objective of 
investigating the efficacy of dual-chamber pacing when compared with 
backup ventricular pacing in patients with standard ICD indications, without 
an indication for anti-bradycardia pacing. The primary endpoint was a 
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composite of death or worsening or new heart failure resulting in 
hospitalization.(Wilkoff et al., 2002, Wilkoff, 2001) Part of the inclusion 
criteria for participation in the DAVID trial was that the patient did not require 
ventricular pacing. In addition to standard anti-tachycardia therapies, 
participants were randomly allocated to either a back-up setting of VVI 40 
bpm or DDDR 70 bpm. The programming of the AV delay settings was at the 
individual investigators discretion at each of the study sites. Most of the 
physicians left the paced and sensed AV delays at factory settings of 
170/150 ms respectively.  
 
The study was terminated early in 2002, due to an increase in the primary 
endpoint in the DDD group compared to the VVI group. Participants 
randomised to DDDR pacing had much higher RV pacing than those 
programmed to VVI group (57.9 vs 1.5% p <0.001, 59.6% vs 0.6%, p <0.001 
and 58.9% vs 3.5%, p <0.001 at 3, 6 and 12 months respectively). Prompted 
by the results of the DAVID trial, the investigators of the Mode Selection Trial 
(MOST), MADIT II, and MIDAS,(Shukla et al., 2005, O'Keefe et al., 2005, 
Freudenberger et al., 2005, Steinberg et al., 2005) studies performed a 
retrospective analysis of their data, and arrived at a similar conclusion to the 
DAVID investigators – that high levels of RV pacing were associated with a 
higher incidence of LV dysfunction, heart failure, atrial fibrillation and 
hospitalisations.  
 
Two hypotheses arose from the outcome of the DAVID trial. First, that the 
adverse effects in the DDD group were due to high heart rate from being 
- 44 - 
paced at 70bpm with rate response activated, therefore increasing metabolic 
demand and worsening ischaemia, leading to ventricular dysfunction. The 
second hypothesis focussed on the AV delay settings, and how short AV 
delay settings can increase the amount of ventricular pacing. 
 
The DAVID II trial was designed to explore the first hypothesis; the 
investigators compared VVI pacing at 40 with AAI pacing at 70 in a further 
cohort of patients requiring ICD therapy, with no indication for pacemaker 
therapy. The study was completed and upon examination of the data, there 
was no significant difference between the groups, ruling out the higher heart 
rate as the cause of LV dysfunction and CHF. 
 
To explore the second hypothesis, the bradycardia settings of the ICDs that 
were implanted in the DAVID study were examined.(Sharma et al., 2005) It 
was found that a sub-group of patients had their AV delays extended by the 
physician to encourage intrinsic conduction. From this further data analysis, 
the investigators found a split of three groups with different characteristics: 
1) A ventricular pacing percentage >40%, related to higher incidence of 
LV dysfunction, heart failure and AF. 
2) Pacing at VVI 40 produced the lowest amount of ventricular pacing 
(<4%), but was not associated with the best outcomes. 
3) The patients in whom the physicians had programmed long AV delays 
had the lowest incidence of adverse effects. This group were paced 
around 11% in the right ventricle. It was considered that their better 
outcome, despite higher RV pacing when compared to the VVI pacing 
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group, was due to maintenance of AV synchrony provided by DDD 
pacing. 
 
Around the same time as the DAVID trial was being conducted, US 
pacemaker and ICD manufacturer Boston Scientific were conducting the 
Inhibition of Unnecessary RV Pacing with AVSH in ICD’s (INTRINSIC RV) 
trial.(Olshansky et al., 2007) The study design was very similar to DAVID 
apart from one key area - the AV delay settings were specified in the study 
protocol. The inclusion criteria for the INTRINSIC RV trial included an 
indication for an ICD and intact AV conduction, therefore not requiring RV 
pacing. There were two groups 1) a VVI group and 2) a DDD group. The 
DDD group was sub-divided into 2 groups 1) a permanent AV delay of 200 
ms (longer than DAVID trial) and 2) an AV delay of 200 ms plus Boston 
Scientific's own RV pacing avoidance algorithm - AV Search Hysteresis® 
(AVSH). AVSH could increase the AV delay up to 300 ms and would 
maintain this longer AV delay setting as long as intrinsic AV nodal 
conduction was intact. 
 
The results of the INTRINSIC RV trial were released in 2007, and were 
similar to the DAVID trial in that the patient group with >40% RV pacing had 
the highest incidence of LV dysfunction and heart failure. What was also 
similar to the DAVID trial was that the group programmed to VVI had the 
lowest amount of RV pacing but not the lowest incidence of heart failure. 
The lowest incidence of CHF and LV dysfunction was to be found in the 
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group programmed DDD with the AVSH RV pacing avoidance algorithm 
activated, despite this group having an RV pacing percentage of 11-19%.  
 
In acknowledgement of the gathering evidence of the potential adverse 
effects of RV pacing, pacemaker manufacturers began developing 
algorithms designed to reduce unnecessary RV pacing. This technology was 
aimed mainly at patients with sinus bradycardia or low grade/intermittent AV 
block, and is designed to deliver RV pacing when absolutely necessary to 
maintain patient safety. Despite the opinion of many cardiologists that 
permanent single-chamber atrial pacing was sufficient for patients with a 
sinus bradycardia pacing indication, concern existed that developing AV 
conduction system disease, or the disruption of AV nodal conduction through 
medical therapy, could not be ruled out as a future complication and could 
lead to problems in patients with only a single chamber atrial system 
implanted. Also, intact AV nodal conduction at rest does not reflect AV nodal 
conduction at higher heart rates, hence the enthusiasm for DDD systems 
remained, but the risk of RV pacing countered by the development of RV 
pacing avoidance algorithms.   
 
Two main methods of RV pacing reduction emerged; 
1.) AV Hysteresis 
The first was released by the majority of pacemaker manufacturers, and 
was based around extension the AV delay settings of the pacemaker by 
the pacemaker software. These algorithms are designed so that 
pacemaker software increases the AV delay settings incrementally, until 
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the pacemaker senses an intrinsically conducted ventricular beat, or the 
device reaches the predetermined AV delay upper limit. If a ventricular 
beat is not sensed within this time period the pacemaker paces the RV, 
producing a ventricular contraction thus maintaining AV synchrony and 
cardiac output. The pacemaker software continues extending the AV 
delay until intrinsic ventricular activity is sensed, or the ventricle is paced. 
If the AV delay reaches a pre-determined upper limit without a sensed 
ventricular event, the software reverts back to the original programmed 
settings, designed to represent a “physiological” PR interval duration. 
Studies have demonstrated the effectiveness of AV search hysteresis in 
reduction of RV pacing.(Olshansky et al., 2006, Pakarinen and Toivonen, 
2013, Kolb et al., 2011, Bauer et al., 2015, Yadav et al., 2016) 
 
2.) Atrial pacing with ventricular sensing based algorithms. 
The second method of unnecessary RV pacing avoidance algorithm was 
first introduced by US pacemaker manufacturer Medtronic, Medtronic 
named this algorithm Managed Ventricular Pacing® (MVP). MVP, also 
known as AAI-DDD or AAIR-DDDR, is designed to inhibit RV pacing 
following a sensed or intrinsic atrial event, until after the following atrial 
event, at which point a ventricular stimulus is delivered.  There is also a 
search function where the pacemaker software will search for intrinsic 
ventricular activity at set intervals. Trials have demonstrated the 
effectiveness of MVP over standard DDD programming, with significant 
reductions in RV pacing,(Gillis et al., 2006, Sweeney et al., 2004, 
Sweeney et al., 2005, Milasinovic et al., 2008, Rey et al., 2012) and 
reduction in atrial arrhythmia burden.(Rey et al., 2012) 
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French pacemaker manufacturers, Sorin-ELA, released an algorithm 
similar to MVP named AAIsafeR®.(Savoure et al., 2005, Pioger et al., 
2007) The difference between AAIsafeR and MVP is that it includes an 
AV delay which is programmable up to 450ms. This is designed to avoid 
RV pacing whilst also avoiding long pauses which can occur with the 
MVP algorithm, and can lead to presyncopal symptoms. AAIsafeR has 
been shown to be safe, (Thibault et al., 2009) and effective at reducing 
RV pacing.(Pioger et al., 2007)  
 
The SAVE PACe trial,(Sweeney et al., 2007) published in 2007, was a 
randomised study designed to assess the effects of reducing ventricular 
pacing, via both MVP and Search AV hysteresis algorithms vs standard 
DDD pacing in 1065 patients with sick sinus syndrome and normal A-V 
conduction on the time to the development of persistent AF. Over a mean 
follow-up period of 1.7±1.0 years, the median percentage of RV pacing was 
lower in the group randomised to DDD with RV pacing avoidance vs 
standard DDD pacing (9.1% vs. 99.0%, P<0.001). The risk of developing AF 
was lower in those allocated RV pacing avoidance (68 patients (12.7%) v vs 
42 (7.9%), with a hazard ratio for developing persistent AF of 0.60 (95% 
confidence interval, 0.41 to 0.88; p=0.009). There was no significant 
difference in mortality between the two groups (4.9% vs. 5.4%; 
p=0.54).(Sweeney et al., 2007) 
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Inevitably, comparisons of the effectiveness of AV hysteresis vs MVP 
algorithms at reducing ventricular pacing have been made, including a 
prospective study of 322 patients requiring DDD(R) pacemakers published in 
2008.(Purerfellner et al., 2008) The primary end point was a reduction in 
ventricular pacing after 1 month.  Patients were spilt into categories based 
upon their degree of AV block: permanent 3rd degree AVB, intermittent 3rd 
degree AV block, 2nd degree AV block, 1st degree AV block and no AV 
block. After 1 month, those with MVP activated vs Search AV+ had 
significantly lower median %VP in all categories except for permanent 3rd 
degree AV block.: no AV block (0.3 vs 2.9, P < 0.0001), 1st degree AV block 
(0.9% vs 80.6%, P < 0.0001), 2nd degree AV block (37.6 vs 99.3, P< 0.002), 
intermittent 3rd degree AV block (1.2 vs 42.2, P = 0.02), permanent 3rd 
degree AV block (98.9 vs 100, P = 1.00) suggesting that MVP is better at 
avoiding RV pacing than AV hysteresis. 
 
Results from a similar study were published in 2010. The IDEAL RVP 
study,(Murakami et al., 2010) sponsored by Medtronic, was designed to 
compare Medtronic's own AV Hysteresis algorithm (Search AV+) with MVP. 
This was a randomised, crossover study design in which patients received a 
Medtronic pacemaker and either the Search AV+ or MVP mode was 
activated for 1 month, and then changed to the other algorithm for a further 1 
month. The primary end point was again reduction in ventricular pacing 
percentage. Patients were again categorized into groups according to 
degree of AV block at recruitment: no AV block, 1st degree AV block, 2nd 
degree AV block, intermittent 3rd degree AV block, and permanent 3rd 
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degree AV block. Similar results to the 2008 study were confirmed in that 
MVP was more successful than AV search+ at reducing RV pacing in all 
patient groups, except for those with permanent 3rd degree AVB: no AV 
block (0.2 vs. 0.8%, P < 0.000), 1st degree AV block (2.3 vs. 27.4%, P = 
0.001), 2nd degree AV block (16.4% vs. 91.9%, P = 0.0052) intermittent 3rd 
degree AV block (37.7% vs. 92.7%, P = 0.0003) and permanent AV block 
(100% vs 100%, P = NS). 
 
A longer term study published in 2014,(Chen et al., 2014) randomised 385 
patients requiring a DDD pacemaker. Patients implanted with DDD 
pacemakers were allocated MVP or the Search AV+ algorithm.(99) The 
primary endpoint was reduction in percentage of VP collected at 1, 6 and 12-
month intervals in patients with sinus and AV node dysfunction. Of the 
recruited patients, 253 had SND and 72 had AVB. The %VP in the MVP 
group was significantly lower than in the SAV+ group at all follow-up 
intervals. At 12-months, median %VP in SND patients was 0.2% in the MVP 
group vs 1.4% in the SAV+ group (P < 0.0001) and median %VP in patients 
with AVB was 11.8% in the MVP group vs 98.1% in the SAV+ group (P < 
0.001). A trend in the correlation between %VP and AT/AF burden was 
observed. 
 
RV pacing avoidance algorithms can significantly reduce RV pacing but 
there remains a lack of evidence demonstrating the long-term clinical 
relevance of RV pacing avoidance on patient-orientated outcomes and they 
may even be deleterious.  
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1.5 Alternate right ventricular pacing sites 
As well as trying to avoid unnecessary RV pacing, alternative pacing sites 
emerged as options in the attempt to offset the potential negative effects of 
RV apical pacing in patients with mandated high levels of RV pacing due for 
example to CHB. RV pacing from the apex is considered to be suboptimal, 
due to the abnormal ventricular activation sequence produced, whereas 
pacing from the ventricular septum or right ventricular outflow tract (RVOT) 
was considered to be potentially less detrimental.(Manolis, 2006) The theory 
of pacing from these sites was that that ventricular activation would more 
resemble intrinsic conduction, as the origin of the paced beat would originate 
from near the heart’s own conduction pathway. Alternate pacing sites are 
considered particularly important for individuals predicted to be exposed to 
high amounts of ventricular pacing, or with underlying ventricular 
dysfunction. 
 
1.5.1 RV outflow tract pacing 
Pacing from the RV outflow tract has been studied the most 
comprehensively among alternative pacing sites. (Flevari et al., 2009, Hillock 
and Mond, 2012, Kaye et al., 2009, Mond et al., 2007, Rosso et al., 2010, 
Stambler et al., 2003, Vlay, 2006) A retrospective study of RV outflow tract 
vs RV apical pacing, demonstrated improved survival in 150 unselected 
patients,(Vanerio et al., 2008) whilst a small, non-randomised, study in 14 
patients could not establish a benefit of RV outflow tract pacing on LV 
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dyssynchrony.(Schwaab et al., 1999) A meta-analysis of 9 studies 
containing 217 patients compared RV outflow tract and RV apical pacing 
and established a positive haemodynamic effect of RV outflow tract over RV 
apical pacing,(de Cock et al., 2003) although many of the studies had short-
term follow-up periods. Further work, with longer follow-up duration and in-
depth dyssynchrony analysis is required to further investigate the effects of 
RV outflow tract vs RV apical pacing. 
 
1.5.2 RV septal pacing 
RV septal pacing has also been investigated as a potential alternative 
pacing site due to reports from short-term comparative studies of improved 
ventricular synchrony, shorter QRS duration, normal cardiac axis, better 
LVEF and reduced pacing lead issues.(Victor et al., 2006, Burri et al., 2007, 
Yu et al., 2007) However, longer term randomised studies have not 
confirmed that septal pacing is superior to RV apical pacing. Results from 
the Protect-Pace trial, which examined the effect of RV pacing lead site on 
LV function in patients with high-grade AV block, showed no significant 
differences between RV apical and RV septal pacing in heart failure 
hospitalization, mortality, AF burden or plasma brain natriuretic peptide 
levels.(Kaye et al., 2015) A further randomized study, of 98 patients with AV 
block, found no differences in LVEF and exercise capacity after 18 months 
of follow-up.(Kypta et al., 2008) 
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1.5.3 His Bundle pacing 
His bundle pacing has also been studied as an alternative pacing site to RV 
apical pacing. Deshmukh et al. were the first to investigate the feasibility of 
this strategy in 2001 in 12 human subjects with AF, Dilated Cardiomyopathy 
(DCM) and QRS duration <120ms, following previous work done in canine 
models. His bundle capture was maintained at long-term follow-up in 11 
patients (92%). After a mean follow-up period of 23.4 ± 8.3 months, LV end-
diastolic diameter had decreased from 51 ± 10 mm to 43 ± 8 mm (p 0.01) 
and LVEF had increased from 18.2 ± 9.8% to 28.6 ± 11.2% (p<0.05) 
(Deshmukh et al., 2000). His bundle pacing may result in favourable 
improvements in inter- and intra-ventricular dyssynchrony, myocardial 
perfusion and mitral regurgitation,(Occhetta et al., 2006, Zanon et al., 2008) 
although the second study showed no significant difference in NYHA class, 
LV volume, LVEF or plasma brain natriuretic peptide levels.(Zanon et al., 
2008) 
 
A meta-analysis published by Shimony et al.(Shimony et al., 2012) 
examined all of the randomized studies comparing RV apical pacing vs non-
apical pacing (His, para-His and mid-septal pacing). In total, 754 patients 
from 14 studies were analysed, 385 had ‘septal’ pacing with 369 having RV 
apical pacing. Beneficial effects on LVEF were demonstrated for follow-up 
periods of more than 12 months and for patients with LVEF less or equal to 
45%. Despite this, there were no significant differences demonstrated in 
measures of quality of life, functional tests (inc walking tests and pVO2) and 
morbidity/mortality rates. Despite evidence of some beneficial effects of 
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alternative pacing sites, at present, septal and direct His bundle pacing are 
not widely used in patients requiring permanent cardiac pacing largely due to 
problems with lead positioning and concerns about lead stability and 
electrical parameters when compared to RV apical pacing.(Epstein et al., 
2008) 
 
 
1.6 Cardiac Resynchronisation Therapy (CRT) 
De novo, and upgrade of existing right ventricular pacemakers to, CRT as a 
treatment option for patients with CHF will be discussed in the next chapter 
on heart failure. 
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Chapter 2. Introduction to Chronic Heart Failure (CHF) and 
its treatment 
 
2.1 Introduction to CHF 
Chronic heart failure (CHF) is a syndrome characterised by symptoms 
including fatigue, breathlessness at rest and during exertion and ankle 
swelling. A key feature is reduced cardiac output on exertion, as a result of 
one or more of many potential cardiac structural or functional abnormalities, 
which through neuro-hormonal activation, or direct haemodynamic effects 
has adverse systemic effects on kidneys, skeletal muscles, lung function, 
immune system, resulting in a poor prognosis, recurrent hospitalisations, 
and significantly reduced quality of life (QoL).(Dickstein et al., 2008) 
 
2.2 Terminology of CHF 
The terminology commonly used to define CHF is centred on the 
measurement of the left ventricular ejection fraction (LVEF). Patients with 
CHF are generally defined into two categories:  
 
1. Those with reduced LVEF (usually <40%), HF with reduced EF 
(HFrEF) or left ventricular systolic dysfunction (LVSD)) 
2. Those with normal LVEF (usually ≥50%), HF with preserved EF 
(HFpEF) or left ventricular diastolic dysfunction. 
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LVSD is defined as reduced LVEF due to reduced cardiac contractility, 
whereas LV diastolic dysfunction is reduced cardiac output due to impaired 
relaxation properties of the myocardium.(Ponikowski et al., 2016)   
Recently, a third category of CHF has been proposed: HF with mid-range 
EF (usually 40–49%) or HFmrEF, reflecting the lack of evidence for 
treatment for people with mild LV systolic dysfunction.(Ponikowski et al., 
2016) Defining CHF based on LV function is regarded by many as 
simplistic since the degree of cardiac dysfunction relates poorly to 
symptoms. However, other methods of definition lack clarity and only for 
HFrEF do we have therapies shown to reduce morbidity and mortality. 
Hence the classification of heart failure based around LV function 
remains.(Ponikowski et al., 2016) 
 
2.3 Epidemiology of CHF  
CHF is common in developed countries, with 1-2% of adults affected, rising 
to ≥10% of those aged over 70.(Mosterd and Hoes, 2007, Redfield et al., 
2003, Bleumink et al., 2004, Ceia et al., 2002) The overall incidence of CHF 
has remained stable over the last 2 decades,(Ho et al., 1993, Levy et al., 
2002) and although recent data based on hospitalization suggests that the 
incidence of CHF may be decreasing,(Gerber et al., 2015, Owan et al., 
2006) this might be the result of better treatment and more advanced 
outpatient programs. At age 55, the lifetime risk of developing CHF is higher 
in males (33%) than females (28%).(Bleumink et al., 2004)  
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Improvements in treatments for CHF and associated co-morbidities improve 
outcome and symptoms, but increase prevalence. The societal burden is 
increased further by lifestyle choices with more people than ever living 
alone, and the overall ageing of the population.  
 
Therapeutic advancements have improved treatment of CHF over time, but 
morbidity and mortality remain high. CHF is responsible for 5% of all hospital 
admissions, and is the most common cause for hospital admission in those 
over 65.(Yousaf et al., 2012, Mosterd and Hoes, 2007) Recent European 
data show that 12-month all-cause mortality rates were 17% for hospitalized 
patients and 7% for stable patients and 12-month hospitalization rates were 
44% for hospitalized patients and 32% for stable patients.(Maggioni et al., 
2013b)  
 
Patients with heart failure suffer a poor quality of life, worse than that 
experienced by others with other chronic conditions, such as COPD and 
many cancers not only due to the high risk of readmission,(Stewart et al., 
2001b) but also frequent GP visits (Stewart et al., 2001a) and persistent 
reduced physical capacity due to symptoms of breathlessness and 
fatigue.(Hobbs et al., 2002)  
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2.4 Diagnosis of CHF 
The primary symptoms of heart failure are breathlessness and fatigue 
resulting in exercise intolerance. These symptoms have poor 
specificity,(135-139) and although they can alert the physician to the 
prospect of underlying disease, the absence of symptoms does not exclude 
underlying disease. Accurate diagnosis of CHF necessitates a thorough 
clinical examination, usually combined with investigations to confirm the 
diagnosis, identify underlying aetiology and provide objective measurements 
of severity. 
 
Demonstration of underlying cardiac dysfunction is a key component of the 
diagnosis of CHF.(Ponikowski et al., 2016) However, cardiac dysfunction is 
the result of many different diseases which in addition to effects on the 
myocardium can also adversely affect the valves, conduction system or 
pericardium.  
 
Symptoms and echocardiographic evidence of LVSD are an accepted 
combination to make a diagnosis of CHF in the majority of patients. 
However, many patients with significant cardiac disease do not have overt 
symptoms or have deteriorated slowly and assume it is a normal part of 
ageing and do not seek help. The most common presenting symptoms of 
CHF are non-specific, and many patients with shortness of breath on 
exertion and ankle swelling do not have heart failure.(Davie et al., 1997, 
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Mant et al., 2009, Oudejans et al., 2011, Fonseca, 2006, Kelder et al., 
2011a) Additionally, there is no defined cut-off value of LVEF or any 
alternative measurement of cardiac function that can be used to define CHF. 
Therefore, many patients presenting with symptoms typical of CHF may 
have equivocal results from initial cardiac investigations. Also, symptoms in 
the presence of good LV systolic function may represent impaired relaxation 
of the left ventricle during diastole defined ‘diastolic dysfunction’ and may be 
described as having HFpEF. 
 
National and European guidance suggest plasma concentration of natriuretic 
peptides (NPs) should be used as an initial diagnostic test, in non-acute 
situations, if CHF is suspected. (National Clinical Guideline, 2010, 
Ponikowski et al., 2016) Elevated NPs can help identify those who may 
warrant further cardiac investigation, as those with normal plasma NP levels 
are the least likely to have CHF. (Ponikowski et al., 2016) It is recommended 
that serum concentrations of B-type natriuretic peptide (BNP) or N-terminal 
pro-B-type natriuretic peptide (NTproBNP) be measured. (National Clinical 
Guideline, 2010, Ponikowski et al., 2016) 
High levels of serum NPs are associated with poor outcomes, and therefore 
those with suspected CHF and a BNP level of >400 pg/ml (116 pmol/litre) or 
an NTproBNP level >2000 pg/ml (236 pmol/litre) require urgent referral for 
cardiology review and transthoracic echocardiography within 2 
weeks.(National Clinical Guideline, 2010) Those with a BNP level between 
100 and 400 pg/ml (29–116 pmol/litre) or an NTproBNP level between 400 
and 2000 pg/ml (47–236 pmol/litre), and symptoms of heart failure, are 
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considered at lower risk, and should have cardiology review and 
transthoracic echocardiography within 6 weeks.(National Clinical Guideline, 
2010) 
NPs may be elevated as a result of several cardiovascular and non-
cardiovascular reasons that may reduce their effectiveness in diagnosing 
CHF, AF, age and renal failure being the most important factors.(Maisel et 
al., 2008) NPs have been demonstrated to have high negative predictive 
values (0.94–0.98) in acute and non-acute settings, and low positive 
predictive values in the acute (0.66–0.67) and non-acute settings (0.44–
0.57).(Roberts et al., 2015, Zaphiriou et al., 2005, Fuat et al., 2006, 
Yamamoto et al., 2000, Cowie et al., 1997, Krishnaswamy et al., 2001, 
Kelder et al., 2011b) Therefore, the use of serum NP levels is recommended 
for ruling-out, rather than confirming, a diagnosis of CHF. (Ponikowski et al., 
2016) 
 
2.5 Pathophysiology and aetiology of CHF 
Ischaemic heart disease (IHD) is the most common cause of CHF in the 
developed world,(Felker et al., 2002) and can lead to CHF through different 
pathophysiological processes.(Cleland et al., 2003a, Cleland et al., 2003b) 
Myocardial infarction (MI) may result in permanent loss of cardiac myocytes 
and their replacement with scar but coronary occlusion may also result in a 
persistent (but not permanent) loss of myocardial contraction without 
permanent cell death (myocardial hibernation). Less severe or transient 
coronary occlusion with entirely reversible ischaemia usually does not lead 
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to left ventricular dysfunction, although recurrent ischaemia can lead to 
‘stunning’ with more short-term loss of contractility than hibernation. 
Hibernation, stunning and reversible ischaemia are potential therapeutic 
targets in CHF but until recently,(Velazquez et al., 2016) little evidence 
existed to guide management.  
Hypertension is a major risk factor in CHF and may be the biggest worldwide 
contributor to the development of the condition. This may be directly through 
increased afterload, or indirectly through hypertension being the biggest 
contributor to IHD.(Lloyd-Jones et al., 2002, Levy et al., 1996) Valvular heart 
disease, infiltration (amyloid, sarcoidosis), viral infection, idiopathic dilated 
cardiomyopathy (DCM) and tachycardia induced cardiomyopathy are also 
potential causes of CHF. These are collected into the term non-ischaemic 
cardiomyopathy or non-ischaemic heart failure and form in total around 30% 
of all cases in the western world.  
 
Many patients have asymptomatic cardiac dysfunction for years before they 
experience symptoms. A combination of increased LV stroke volume via LV 
remodelling, peripheral vasoconstriction as a result of increased renin-
angiotensin aldosterone system (RAAS) activation and increased heart rate 
and cardiac contractility via sympathetic nervous system activity can 
maintain filling pressures and cardiac output. 
 
Eventually these compensatory mechanisms fail, and further dilatation of the 
left ventricle no longer results in an increased stroke volume, but rather to an 
increase in end-diastolic pressure. High levels of angiotensin II and 
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adrenergic hormones persistently stimulate peripheral vasoconstriction, and 
cause salt and water retention leading to increased afterload and an 
increase in the circulating volume. These hormones also increase myocyte 
apoptosis, worsening LV function and further over-activation of 
compensatory mechanisms. ACE inhibitor and beta-blocker therapy can 
counter-act these causes of deterioration.(Cleland et al., 2001, Khand et al., 
2001) 
 
 
Figure 2.1 Pathophysiology of heart failure 
 
The underlying mechanisms involved in the pathophysiology of CHF 
(depicted in Fig 2.1) have been investigated from many different viewpoints 
over the last 50-60 years, which has led to various theories emerging, these 
theories are often referred to as “models”. (Katz and Konstam, 2008) 
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2.5.1 The Haemodynamic Model 
In the late 1960’s, Braunwauld et al defined CHF as “a clinical syndrome 
characterized by well-known symptoms and physical signs. . . . [It is] the 
pathological state in which an abnormality of myocardial function is 
responsible for the failure of the heart to pump blood at a rate 
commensurate with the requirements of the metabolizing tissues during 
ordinary activity”.(Braunwald et al., 1967) Evidence for the hemodynamic 
model of CHF came from both animal models, and human work, showing 
that CHF as a result of pressure overload results in reduction in contractility 
of cardiac myocytes.(Spann et al., 1967, van Der Velden et al., 2001) 
Haemodynamic changes in CHF can result from ventricular remodelling – 
which varies depending on the type of CHF in relation to ventricular 
function.(van Heerebeek et al., 2006) In patients with HFrEF, the LV cavity is 
often dilated, and there can be reduced LV mass. Both cardiomyocyte 
diameter and myocyte density are reduced in HFREF.(Borbély et al., 2005) 
In contrast patients with HFPEF usually have normal LV volume and LV wall 
hypertrophy, and as a result LV mass is increased.(Ohtani et al., 2012).  
The extracellular matrix (ECM) is often described as the scaffolding, or 
internal skeleton, of the ventricles(Owen and Spinale, 2010) as and such is 
an important determinant of ventricular structure and function. Following MI, 
remodelling of the ECM occurs with replacement fibrosis.(Gandhi et al., 
2011) This can result in thinning of the LV wall and impairment of LV pump 
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function. Fibrosis can also be stimulated by persistent activation of the renin-
angiotensin-aldosterone system.(Creemers and Pinto, 2010) 
2.5.2 Cardio-renal model 
 
Renal sodium and water retention are important mechanisms of the CHF 
syndrome - they play a critical role in the development of two fundamental 
symptoms of heart failure - shortness of breath and oedema. This realisation 
led the development of the cardio-renal model of HF. Diuretics and dietary 
sodium restriction are mainstays in CHF management, however intensive 
diuretic therapy can lead to renal failure which associated with high 
mortality.(Braunwald, 2013) 
 
2.5.3 Neuro-hormonal model 
 
Activation of the adrenergic nervous system plays an important part in 
increasing cardiac performance during increased demand. The adrenergic 
nervous system modulates myocardial contractility and redistributes blood 
flow to areas of demand.(Braunwald et al., 1967, Braunwald et al., 1963) In 
acute HF reduced cardiac output stimulates the adrenergic system to 
enhance cardiac and increase vasoconstriction, which raises blood pressure 
adding perfusion of vital organs. Prolonged activation of the adrenergic 
nervous system and renin-angiotensin-aldosterone is deleterious to the 
cardiovascular system, resulting in remodelling of the ventricles and 
myocardial injury. A vicious cycle begins in what has become known as the 
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neuro-hormonal model of HF. Blockade of these systems made their 
significance clear, when it was realised that blocking them improves survival 
in CHF patients.(Braunwald, 2013) 
2.5.4 Abnormal Ca2+ cycling model 
The significance of the contribution of Calcium (Ca2+) to cardiac contraction 
has been known since the work of Ringer in the early 1880’s.(Ringer, 1883) 
Dysregulation of Ca2+ fluxes are thought to be fundamental to the reduced 
cardiac contractility that occurs in some types CHF. (Braunwald, 2013) 
Abnormalities in Ca2+ handling has been established in some types of HF. A 
Ca2+ leak in diastole lowers the Ca2+ content of the Sarcoplasmic Reticulum, 
which reduces the amount of Ca2+ that is released during activation, which in 
turn reduces cardiac contractility.(Belevych et al., 2011) 
A further abnormality of Ca2+ fluxes that may affect cardiac function is 
reduced function of the SERCA2a pump. This reduces the 
Ca2+ concentration of the cardiac SR and therefore the amount of Ca2+ 
available for release during myocyte activation – resulting in ventricular 
systolic dysfunction and ventricular tachyarrhythmias.(Chen et al., 2004) 
This impairment in SERCA2a pump function reduces both the speed and 
quantity of Ca2+ removal from the cytoplasm, this reduces ventricular 
relaxation, causing diastolic dysfunction.(Braunwald, 2013) 
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2.5.4 Cell death model 
All types of HF are characterized by an increased rate of cell death or 
Apoptosis.(Konstantinidis et al., 2012) Apoptosis has been accredited to a 
number of stresses, such as increased levels of neurohormones; increased 
adrenergic activity; inflammation; oxidative stress; toxins, such as alcohol or 
cancer chemotherapeutic agents; and infiltrative processes. Apoptosis 
usually increases with aging and can also be increased under pressure 
overload. It is proposed that reduction of myocytes over time leads to 
CHF.(Olivetti et al., 1997) 
 
2.5.5 Genetic model 
A number of important genetic disorders have been discovered which have 
led to the genetic model of CHF.(Morita et al., 2005, Herman et al., 2012) 
Currently, the focus of genetics work is on examining the entire genome 
using genome-wide association studies.(Zeller et al., 2012) As CHF is a 
syndrome, genome-wide association studies are designed to search for 
associations with conditions which lead to CHF such as IHD, HTN, 
hyperlipidaemia, and diabetes mellitus.(Schunkert et al., 2011) 
 
2.6 Management of CHF 
This section will focus on the management of heart failure due to LVSD. The 
objectives of treatment in patients with heart failure are to improve 
symptoms, quality of life, and functional capacity, prevent hospitalisation and 
reduce mortality.(Ponikowski et al., 2016) 
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2.6.1 General Management of CHF 
Most general advice given to patients upon a diagnosis of CHF is not 
evidence based. I have used the guidelines published by the European 
Society of Cardiology working group on heart failure.(Ponikowski et al., 
2016)  
 
2.6.1.1 Diet 
Patients with heart failure should eat a healthy, well-balanced diet. Care 
should be taken to reduce salt intake. Patients on warfarin should be warned 
that alcohol consumption and changes in diet may result in loss of anti-
coagulant control. 
 
2.6.1.2 Exercise 
Patients should be encouraged to take regular exercise. Exercise has 
several benefits. Improved cardiovascular fitness will improve exertional 
capacity, help to minimise/reduce muscle wasting and could possibly 
improve prognosis. Traditionally, reduced function of the heart as a pump 
has been viewed as the sole cause of CHF. However, work over the last 20 
years suggests CHF as a complex pathophysiology initiated with cardiac 
dysfunction, which then involves adaptive changes in the musculoskeletal, 
neuroendocrine, cardiovascular, renal, haemostatic, inflammatory, and 
immune systems.(Piepoli and Coats, 2013) 
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The CHF syndrome is characterized by haemodynamic adaptation in the 
cardiovascular system, sympathetic activation, heightened immune 
response, systemic inflammation, and increased catabolism.(Piepoli and 
Coats, 2013) The physical deconditioning that occurs among CHF patients, 
along with increased catabolism, contributes to loss of muscle mass, which 
in turn adds to the decline in physical capacity seen in CHF over time. 
Furthermore, the chronic systemic inflammation seen in CHF changes 
skeletal muscle function and promotes muscle atrophy, which further 
contributes to reduced physical capacity.(Mann, 2002, Piepoli et al., 2010)   
Patients with CHF display an insufficient peripheral blood flow response to 
both exercise and pharmacologically induced vasodilatation.(Zelis et al., 
1975) thought to be due to ongoing vasoconstrictor drive, oedema of vessel 
walls, reduced peripheral vasculature, an impaired nitric oxide vasodilator 
system or heightened response of the vasoconstrictor endothelium system. 
(Drexler et al., 1993, Coats, 1996)  
The only therapy shown to improve functional capacity and reverse 
peripheral abnormalities in CHF is exercise training. And through exercise 
training, increases in skeletal muscle mass, mitochondrial function and 
density, and changes in skeletal muscle fibre type have been identified in 
patients with CHF.(Adamopoulos et al., 1993)  
Increases in physical activity are reported to reduce the risk of CHF 
hospitalisation whilst there does seem to be a dose response with physical 
activity beyond guideline recommendations achieving more significant 
reductions in CHF risk.(Pandey et al., 2015) Regular physical activity may 
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contribute to the reduction of other modifiable risks of CHF such as obesity 
and insulin resistance.(Kenchaiah et al., 2002) 
 
2.6.1.3 Travel 
Patients with CHF are at increased risk of venous thrombosis if inactive 
during long periods whilst travelling, and changes in diet and climate may 
effect diuretic and anti-coagulant requirements. Advice should include 
keeping sensibly hydrated and mobile during long journeys taking plenty of 
breaks.  
 
2.6.1.4 Smoking 
Smoking is a strong independent predictor of morbidity and mortality in 
patients with LVSD, whilst smoking cessation has a significant effect on 
reducing morbidity and mortality in patients with LVSD.(Suskin et al., 2001)  
 
2.6.1.5 Alcohol consumption 
There is a U-shaped relationship between alcohol intake and the risk of 
developing CHF. The lowest risk is associated with modest alcohol 
consumption.(Dorans et al., 2015, Goncalves et al., 2015, Larsson et al., 
2015) Whilst acute alcohol reduces cardiomyocyte contractility, it also leads 
to chronic changes including apoptosis, interstitial fibrosis eventually leading 
to an alcohol-induced cardiomyopathy.  
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2.6.2 Modification of risk factors to prevent CHF 
Substantial evidence exists that developing HF may be preventable or 
delayed though modification of risk factors, or treating asymptomatic LV 
systolic dysfunction.  
 
Control of hypertension can delay the onset of developing HF and may 
increase longevity.(Kostis et al., 1997, Beckett et al., 2008, Sciarretta et al., 
2011, Wright et al., 2015) Recently, the SPRINT study has shown that 
treating hypertension to a lower goal of systolic blood pressure (SBP) <120 
mmHg vs. <140 mmHg in older (≥75yrs), or high-risk subjects with 
hypertension, reduces the risk of cardiovascular disease, mortality and 
hospitalization for HF.(Wright et al., 2015) 
 
In patients with IHD, without LV systolic dysfunction or HF, angiotensin 
converting enzyme inhibitors (ACEI) prevent or delay the onset of HF and 
reduce cardiovascular and all-cause mortality.(Dagenais et al., 2006) Up-
titration of beta-blockers (BB) and renin–angiotensin system antagonists to 
maximum tolerated dosages may improve outcomes in patients with IHD, 
without HF and elevated plasma natriuretic peptides.(Ledwidge et al., 2013, 
Huelsmann et al., 2013) 
 
Primary percutaneous coronary intervention (PPCI) for ST segment 
elevation myocardial infarction (STEMI) reduces the risk of developing a 
substantial reduction in LVEF and development of LVSD and 
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CHF.(Windecker et al., 2014) Following an MI, particularly with associated 
LVSD, commencing an ACEI, a BB and a mineralocorticoid receptor 
antagonist (MRA), reduces CHF hospitalization and mortality.(Jong et al., 
2003, Pfeffer et al., 1992, Dargie, 2001, Montalescot et al., 2014, Pitt et al., 
2003) HMG-CoA reductase inhibitors (known as ‘statins’) also reduce the 
frequency of development of CHF.(Scirica et al., 2006, Kjekshus et al., 1997, 
Afilalo et al., 2007)  
 
2.7 Pharmacological therapy of CHF 
 
2.7.1 Angiotensin-converting enzyme inhibitors (ACEI) 
Angiotensin converting enzyme inhibitors (ACEI) inhibit the conversion of 
inactive angiotensin I to the active angiotensin II, which has vasoconstrictive, 
salt-retentive, and hypertrophic properties. ACEI also inhibit the kininase 
enzyme, which is involved in bradykinin degradation,(Brown and Vaughan, 
1998) the product of heightened renin-angiotensin system activity due to 
CHF and diuretic use. As a result there is arterial and venous dilatation, a 
slight drop in arterial blood pressure and improved renal blood flow. 
Blockade of these systems has favourable effects on cardiac and vascular 
structural remodelling. 
 
ACEIs are recommended in all patients with symptomatic CHF and LVSD 
where tolerated, based upon evidence of their efficacy in reducing mortality 
and morbidity, both in CHF (1987, 1992, Garg and Yusuf, 1995, Packer et 
al., 1999) and in acute LVSD following an MI for example.(1993, Pfeffer et 
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al., 1992, Kober et al., 1995) ACEIs should be up-titrated to the maximum 
tolerated dose to achieve inhibition of the renin–angiotensin–aldosterone 
system (RAAS).(Packer et al., 1999) Despite overwhelming evidence in 
support of ACEI use in CHF with LVSD and a dose response 
relationship,(Packer et al., 1999) there remains inadequate up-titration of 
ACEIs in normal clinical practice.(Maggioni et al., 2013a)   
 
 
2.7.2 Adrenergic receptor antagonists (beta-blockers) 
CHF is a state of chronic sympathetic nervous system activation, which 
increases heart rate, causes vasoconstriction, increases adverse 
remodelling, provokes arrhythmia and stimulates renin-angiotensin system 
activation and hypokalaemia.(Cleland et al., 1996) Persistently heightened 
sympathetic activation is predictive of a worse outcome, and is potentially 
causal.(Cleland et al., 1996, Cohn et al., 1984) β-adrenoceptor antagonists 
(BB) interfere with the effects of adrenaline and noradrenaline on β-
receptors, and therefore lower sympathetic nervous system activation. 
These agents, specifically those that block the beta-1 receptor improve 
many of the aspects of sympathetic activation, although agents that block a 
wider range of receptors may be more effective.(Poole-Wilson et al., 2003a, 
Poole-Wilson et al., 2002)  
 
In patients with symptomatic CHF due to LVSD BB reduce mortality and 
morbidity, on top of the effects due to ACEI and diuretic therapy.(Hjalmarson 
et al., 2000, Packer et al., 2001, 1999b, 1999a, Flather et al., 2005) Patients 
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admitted with acute, decompensated heart failure should be commenced on 
a BB cautiously, but the agents are beneficial even in patients with persistent 
fluid overload or acute heart failure.(Packer et al., 2001) Guidance suggests 
that beta-blockers and ACEIs can be started together as soon as the 
diagnosis of CHF is made. No evidence exists supporting commencing of a 
BB before an ACEI has been started, and it generally makes little difference 
which come first,(Krum et al., 2011) unless there is a contraindication to 
ACEI therapy.(Willenheimer et al., 2005) 
 
BB should be commenced at low dose, and gradually up-titrated to 
maximum tolerated dose with regular monitoring of heart rate and blood 
pressure. 
 
2.7.3 Mineralocorticoid/aldosterone receptor antagonists (MRAs) 
The MRAs, spironolactone and eplerenone, block the receptors that bind 
aldosterone and other steroid hormone receptors. MRAs are recommended 
in all symptomatic patients with CHF and LVEF ≤35%, alongside ACEIs and 
beta-blockers to reduce mortality and heart failure hospitalization.(Pitt et al., 
2003, Zannad et al., 2011) Close monitoring of potassium levels and renal 
function is recommended in those taking MRAs, with caution recommended 
in those with serum potassium levels >5.0 mmol/L.  
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2.7.4 Loop and thiazide diuretics 
Diuretics are recommended to manage the symptoms of CHF associated 
with fluid and salt retention, such as shortness of breath and peripheral and 
pulmonary oedema, and are shown to provide symptomatic relief.(Faris et 
al., 2002) Meta analyses have shown that in patients with chronic HF, when 
compared with placebo both loop and thiazide diuretics appear to reduce 
mortality and deteriorating HF and appear to improve exercise 
capacity,(Faris et al., 2012, Faris et al., 2002) although diuretics are yet to 
be tested in an RCT.(Ponikowski et al., 2016) 
 
Diuretics are divided into ‘loop’ or thiazide diuretics. Loop diuretics are the 
diuretics used most commonly in CHF. They work on the Loop of Henle and 
result in a very powerful diuresis over 4-8 hours. Thiazide diuretics are less 
potent but are longer acting than loop diuretics, they are more likely to cause 
hypokalaemia than loop diuretics. Loop and thiazide diuretics can be used 
together in patients with severe CHF and resistance to loop diuretics. The 
addition of a thiazide diuretic can provoke an extremely marked 
diuresis.(Channer et al., 1994) Careful monitoring of renal function is 
advised when loop and thiazide diuretics are combined due to the increased 
risk of dehydration and renal dysfunction.(Ponikowski et al., 2016) 
 
2.7.5 Angiotensin receptor neprilysin inhibitor (ARNI) 
Angiotensin receptor neprilysin inhibitors are a new class of agents that have 
been developed that act on the renin angiotensin aldosterone system 
(RAAS) and the neutral endopeptidase system. The first is LCZ696, which 
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combines a portion of valsartan and sacubitril (a neprilysin inhibitor) as a 
single substance. Inhibiting neprilysin slows down the degradation of 
naturetic peptides, bradykinin and other peptides. High circulating A-type 
natriuretic peptide (ANP) and BNP enhances diuresis, natriuresis, 
myocardial relaxation and prevent LV remodelling. Renin and aldosterone 
secretion are also inhibited by ANP and BNP. Selective AT1-receptor 
blockade moderates vasoconstriction and reduces sodium and water 
retention and reduces myocardial hypertrophy.(King et al., 2015, Mangiafico 
et al., 2013) 
  
A trial investigating the long-term effects of ARNIs (sacubitril/valsartan) 
compared with an ACEI (enalapril) showed the superiority of 
sacubitril/valsartan in reducing all-cause mortality, cardiovascular mortality 
and hospitalizations for worsening CHF. This was in a specific population of 
ambulatory patients with symptomatic heart failure, with LVEF ≤35%, 
elevated plasma BNP levels, and an estimated GFR (eGFR) ≥30 
mL/min/1.73 m2 of body surface area, who were able to tolerate both 
enalapril (10 mg b.i.d.) and sacubitril/valsartan (97/103 mg b.i.d.) at separate 
treatment points.(McMurray et al., 2014)  
 
2.7.6 If-channel inhibitor 
Ivabradine inhibits the If channel in the sinus node and slows the heart rate 
without appreciable effects on blood pressure. Because of its specific action 
on the sinus node, it is only useful in patients in sinus rhythm. Ivabradine 
reduced the combined endpoint of mortality or hospitalization for patients 
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with symptomatic heart failure and LVEF ≤35%, with a heart rate of  ≥70 
bpm in SR, hospitalized for heart failure within the previous 12 months, and 
already on maximally tolerated doses of beta-blocker, an ACEI (or ARB) and 
an MRA.(Swedberg et al., 2010) Ivabradine is approved for use in patients 
with heart failure, LVEF ≤35%, in sinus rhythm with a resting heart rate ≥75 
bpm, because of a survival benefit based on a subgroup analysis.(Bohm et 
al., 2013, Ponikowski et al., 2016) 
 
2.7.7 Angiotensin II type I receptor blockers (ARBs) 
ARBs are recommended as an alternative CHF therapy in those intolerant of 
an ACEI.(Granger et al., 2003) Candesartan has been shown to reduce 
cardiovascular mortality in a randomised trial,(Granger et al., 2003) and 
Valsartan showed a reduction in heart failure hospitalization in patients with 
CHF and LVSD on ACEIs. (Cohn and Tognoni, 2001) Combined ACEI/ARB 
therapy for CHF, which can lead to marked hyperkalaemia, is only useful in 
patients where other therapies are not tolerated or contra-indicated. 
Consequently, ARBs are indicated only in those intolerant of an ACEI. 
Combined ACEI/ARB should only be considered, under close supervision, in 
patients with symptomatic CHF receiving a BB and intolerant of an 
MRA.(Ponikowski et al., 2016) 
 
2.7.8 Digoxin 
Digoxin has been used for the treatment of CHF for over 2 centuries. It has 
mild inotropic and diuretic properties, moderates neuro-endocrine function 
and slows atrio-ventricular conduction.(Slatton et al., 1997, Gheorghiade et 
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al., 1995, Krum et al., 1995) Digoxin is predominantly used in CHF to 
modulate ventricular rate in patients with AF, but is only recommended when 
other available treatments are not an option.(Khand et al., 2002, Vamos et 
al., 2015, Van Gelder et al., 2010, Bavishi et al., 2015, Freeman et al., 2015, 
Washam et al., 2015)  The effects of digoxin in patients in AF and CHF have 
not been studied in RCTs, and recent evidence suggest potentially 
increased risk of mortality and CHF hospitalization. (Ouyang et al., 2015, 
Vamos et al., 2015) However, a recent meta-analysis of non-randomised 
studies concluded that digoxin has no adverse effect on mortality in patients 
with CHF in AF.(Ziff et al., 2015) 
 
Digoxin may be used in patients with symptomatic CHF in SR to reduce the 
risk of all-cause and heart failure hospitalization,(1997b) and also to improve 
symptoms,(Packer et al., 1993) but digoxin has no effect on mortality when 
used in conjunction with an ACEI.(1997b) 
 
The most effective dose of digoxin is uncertain. Low doses are mildly 
positively inotropic,(Slatton et al., 1997, Gheorghiade et al., 1995, Krum et 
al., 1995, van Veldhuisen et al., 1995) while higher doses, those usually 
reserved for rate control, can be associated with side effects such as 
arrhythmia, nausea, vomiting, confusion, and sudden death.(Rathore et al., 
2002) 
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2.7.9 Anti-arrhythmic agents  
Patients with heart failure, particularly those with ischaemic aetiology, are at 
increased risk of ventricular tachyarrhythmia and sudden cardiac death. 
Despite this, anti-arrhythmic agents do not improve survival in patients with 
CHF.(Bardy et al., 2005) Amiodarone, in combination with a beta-blocker, 
can be used to reduce the frequency and duration of symptomatic ventricular 
arrhythmias, but may have a negative impact on survival in those with 
severe CHF.(Bardy et al., 2005) (Torp-Pedersen et al., 2007) As such, other 
than beta-blockers, amiodarone and dofetilide, anti-arrhythmic agents are 
contra-indicated in CHF, due to increased risk of worsening heart failure and 
sudden death.(Kober et al., 2008, Torp-Pedersen et al., 2007) 
 
The best method for reducing ventricular arrhythmia in patients with CHF 
may be through optimisation of medical therapy including ACEIs, BB, MRAs 
and sacubitril/valsartan, which all reduce the risk of sudden death.(Pitt et al., 
1999, Kotecha et al., 2014, Cleland et al., 1999, Desai et al., 2015) 
 
2.8 Devices 
 
2.8.1 Implantable cardioverter-defibrillator (ICD) 
Cardiovascular mortality has decreased, due to the adoption of improved 
preventive and treatment practices to reduce the burden of coronary artery 
disease (CAD) and CHF, in high-income countries in the last 20 
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years.(Niemeijer et al., 2015, Priori et al., 2015) Despite this, cardiovascular 
disease remains responsible for approximately 17 million deaths each year 
worldwide, of which around 25% are sudden cardiac deaths (SCD).(Priori et 
al., 2015) Men are at higher risk of SCD than women, and the risk of SCD 
increases with age due to higher prevalence of CAD.(Eckart et al., 2011) 
The mortality rate from SCD is estimated to range from 1.40 per 100 000 
person-years [95% confidence interval (CI) 0.95, 1.98] in women to 6.68 per 
100 000 person-years (95% CI 6.24, 7.14) in men.(Eckart et al., 2011) 
 
Around 40% of patients with CHF suffer sudden or unexplained 
death.(Poole-Wilson et al., 2003b) This may be as a result of brady or 
tachyarrhythmias, but can also be due to coronary, vascular or cerebro-
vascular episodes. Medical therapy can improve, or reduce the deterioration, 
of cardiovascular function which can reduce the incidence of sudden death, 
but cannot treat arrhythmias should they occur. Antiarrhythmic medications 
can reduce the frequency and burden of tachy-arrhythmias, but can in fact 
worsen overall mortality.(Ponikowski et al., 2016) ICDs on the other hand 
treat both brady- and tachy-arrhythmia and could therefore reduce sudden 
cardiac death.  
 
2.8.2 Primary prevention ICD 
 
2.8.2.1 Where ICDs are proven to be of benefit 
A primary prevention ICD implantation is recommended in patients with CHF 
and LVSD, without documented ventricular arrhythmia, deemed to be at risk 
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of sudden cardiac death. Implantation of an ICD is recommended only when 
optimal medical therapy has failed to increase the LVEF above 
35%.(Ponikowski et al., 2016) The cut-off for ejection fraction is 
controversial, since the manuscripts on which the ESC guidelines are based 
included only 400 people with LVEF 30-35%.(Ponikowski et al., 2016) 
 
Despite this slight controversy, overall ICDs reduce the incidence of sudden 
arrhythmic death in patients with CHF and LVSD.(Theuns et al., 2010, Cook 
and Ridker, 2009) However, in patients with moderate or severe heart 
failure, this is usually offset by an increased incidence of death due to 
deteriorating CHF.(Bardy et al., 2005) ICDs are most cost-effective in 
patients with important LVSD, but mild symptoms where for every 100 
implants, 2 deaths per year are prevented.(Bardy et al., 2005) The benefit of 
ICD implantation is greater in those with CHF and ischaemic aetiology, 
rather than those with DCM, as patients with ischemic aetiology are at 
greater risk of sudden cardiac death.(Theuns et al., 2010) Patients with heart 
failure, LVSD and a long QRS duration are also at increased risk, although 
these patients are also usually offered cardiac resynchronisation therapy 
(CRT).(Bardy et al., 2005, Moss et al., 1996) 
 
2.8.2.2 Where ICDs are not proven to be of benefit  
ICD’s are of no benefit, within 40 days after an MI. Although sudden cardiac 
death is reduced, overall mortality is not, demonstrating clearly how 
deteriorating severe LVSD is a pre-terminal state and that treating 
arrhythmia is merely converting the nature of the death. In the studies that 
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have been carried out, preventing death due to arrhythmia merely increased 
death due to cardiogenic shock and heart failure.(Hohnloser et al., 2004, 
Steinbeck et al., 2009) A patient at particularly high risk of sudden 
arrhythmic death in whom contractile recovery is expected, could be offered 
a wearable defibrillator, for example, patients awaiting cardiac 
transplantation,(Opreanu et al., 2015) or patients with LVEF <35% following 
surgical or percutaneous coronary revascularisation.(Zishiri et al., 2013)  A 
lack of data from randomised trials means there is a limited evidence base 
for their use. 
 
ICD implantation is not recommended in NYHA Class IV patients with 
symptoms unresponsive to medical therapy, and unsuitable for CRT, a 
ventricular assist device or cardiac transplant, as such patients have 
significant risk of dying from pump failure.(Ponikowski et al., 2016) ICD 
therapy is unlikely to provide any benefit in patients with significant co-
morbidities that might die within a year from these rather than their 
CHF.(Sanders et al., 2005, Steinberg et al., 2014, Raphael et al., 2015, 
Miller et al., 2015) 
 
2.8.2.3 Practical issues around ICD therapy 
Before ICD implantation, patients should receive counselling regarding the 
reason for implantation, and also potential complications such as 
inappropriate therapy and implant complications such as infection and 
bleeding. Patients should also receive counselling around deactivation of 
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therapies when their heart failure gets worse, or they develop other 
important life threatening conditions.(Stewart et al., 2010) 
 
ICD’s should be programmed with long detection intervals,(Moss et al., 
2012) which reduces the risk of inappropriate therapy and also appropriate 
but unnecessary therapy for non-sustained ventricular tachycardia.(Moss et 
al., 2012, Gasparini et al., 2013, Cleland and Buga, 2010)  
 
2.8.2.4 What happens when the battery is flat? 
In the same way as drug treatment is reviewed, ICD treatment should be 
reconsidered at each appointment and certainly at the time of generator 
replacement. A procedure to replace an ICD generator due to battery 
depletion should follow a thorough assessment of the patient and the 
indication for ICD therapy. Controversy surrounds whether patients with an 
improvement of LVEF to >35% who have not required their device should 
receive a replacement device when the original generator has 
depleted.(Merchant et al., 2014, Yap et al., 2014, Kini et al., 2014, Erkapic et 
al., 2013, Alsheikh-Ali et al., 2008) 
 
2.8.2.5 New developments in ICD therapy 
By avoiding trans-venous leads and the intravascular complications 
associated with them, subcutaneous ICDs have some advantages over 
standard trans-venous systems and may be as effective at treating 
shockable ventricular arrhythmias.(Bardy et al., 2010, Aziz et al., 2014) They 
can be used in patients with difficult or absent venous access, but caution 
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should be taken in patient selection due to their inability to treat brady-
arrhythmia, provide CRT or anti-tachycardia pacing (ATP). More robust 
evidence from RCTs, around the performance of these devices, is 
required.(Olde Nordkamp et al., 2012, Burke et al., 2015) 
 
2.8.3 Secondary prevention ICD 
In survivors of cardiac arrest, and in those that have had symptomatic 
sustained ventricular arrhythmia, ICDs reduce mortality when compared with 
amiodarone, and should be considered when the intention is to improve 
survival.(Ponikowski et al., 2016) When considering an ICD implant the 
patient should be counselled, and their quality of life, LVEF (survival benefit 
is unproven with LVEF >35%) and existing life-limiting co-morbidities should 
be considered.(Ponikowski et al., 2016, 1997a, Connolly et al., 2000b, 
Connolly et al., 2000a)  
 
2.8.4 Cardiac resynchronisation therapy (CRT) 
CRT implantation improves cardiac function, heart failure symptoms, quality 
of life and mortality and morbidity in specific individuals.(Sohaib et al., 2015, 
Cleland et al., 2013) 
 
2.8.4.1 Prevalence and effect of conduction delay 
Normal left ventricular myocardial contraction is coordinated through 
specialised cardiomyocytes including the Purkinje conduction fibres and 
results in a synchronous contraction of the left ventricular myocardium.(Kirk 
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and Kass, 2013a) This coordinated conduction and contraction pattern may 
be impaired by disease of the conduction system or myocardium, (e.g. 
LBBB) or by stimulation of contraction outside of the normal conduction 
system (e.g. RV pacing).(Kirk and Kass, 2013a) Any disruption of the normal 
conduction system can result in altered LV contraction due to 
dyssnchronous contraction.  In such instances, overall LV contraction 
becomes un-coordinated and inefficient. This results in a reduction in LV 
systolic function.(Kirk and Kass, 2013a, Burkhoff et al., 1986, Park et al., 
1985) 
 
Almost 50% of patients with CHF and LVSD have ventricular conduction 
delays, such as LBBB.(Schuster et al., 2005, Ghio et al., 2004) The 
dyssynchrony that occurs as a result creates significant regional difference 
in myocardial work,(Vernooy et al., 2005) (Fig 2.1 A) the earliest activated 
regions have reduced work load, with the latest activated regions having 
increased work load, this is associated with regional changes in regional 
myocardial blood flow.(Prinzen et al., 1999, Rosen et al., 2009) Time 
differences between early and late activation sites result in a reduction in 
stroke volume (Fig 2.1 A).(Chakir et al., 2009) The greatest volume 
differences occur when the time differences in muscle activation are 
greatest, (Fig 2.1 B, shown by the arrows) during isovolumic contraction and 
late systole into early relaxation. Hence rate of pressure rise (dP/dtmax) and 
myocardial shortening after aortic valve closure are frequently used and 
sensitive measures of dyssynchrony. The overall effect of dyssynchrony on 
LV function, when viewed by pressure–volume loops,(Park et al., 
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1985) reveal a rightwards shift of the end-systolic pressure–volume 
relationship (Figure 2.1 C). Stroke volume (represented by loop width) and 
stroke work (represented by loop area) decline in the presence of 
dyssynchrony.(Kirk and Kass, 2013b) The effect is particularly relevant in the 
presence of LV systolic dysfunction, were dyssynchrony compounds the 
situation, worsening morbidity and mortality.(Bader et al., 2004)  
 
Dyssnchronous contraction has little impact on cardiac function in those with 
normal heart function.(Kirk and Kass, 2013b)  However, since the 1990’s 
dyssynchrony and its short-term effects on cardiac output, and long-term 
effects on cardiac function led to the concept that pacing might be able to 
improve conduction delay and reduce dyssynchrony. Ground-breaking 
studies by Cazeau et al, Auricchio et al, and Kass et al  (Cazeau et al., 1994, 
Auricchio et al., 1999, Kass et al., 1999) demonstrated the beneficial effects 
of multisite pacing in patients, leading to the development of cardiac 
resynchronization therapy (CRT), credited as being the first method of 
improving cardiac function via the use of artificial electrical stimulation.(Kirk 
and Kass, 2013b) 
 
2.8.4.2 How does CRT help? 
CRT involves electrically stimulating the right and left ventricles 
simultaneously. This usually involves a pacemaker lead positioned in the 
right ventricular apex, or on the right ventricular septum, and a pacemaker 
lead positioned to stimulate the left ventricular free wall.(Kirk and Kass, 
2013b) The left ventricular electrode is positioned via the coronary sinus, 
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into a lateral cardiac vein, thereby allowing simultaneous pacing, or, if 
required, optimised left and right timing.(Kirk and Kass, 2013b) The 
pacemaker is programmed to ensure biventricular stimulation occurs by 
having short atrio-ventricular delays. Individual optimization of the AV delay 
can improve LV systolic function in some patients, but devices are often set 
to default settings.(Spragg and Kass, 2006)  
 
A lateral LV lead position, which is often where conduction is most delayed, 
may be one of the most important factors for successful cardiac 
resynchronisation therapy,(Kirk and Kass, 2013b) whilst an apical position 
may be detrimental. (Singh et al., 2011, Thebault et al., 2012, Wilton et al., 
2014) Attempts have been made to identify the optimal LV lead position by 
using echocardiographic techniques to identify the latest region of LV 
activation. Two randomized studies have reported improved outcomes 
following heart failure hospitalization(Saba et al., 2013) and significant LV 
reverse remodelling(Khan et al., 2012) by using speckle-tracking 
echocardiography to guide LV lead placement to identify the latest activated 
LV segment. 
 
Most commonly, there is simultaneous biventricular stimulation in CRT, 
promoting a more coordinated LV contraction, which may improve LV 
systolic function within 1 beat,(Kass et al., 1999) (Fig 2.2 C) and improves 
LV stroke volume and work (Fig 2.2 D). These improvements in LV 
haemodynamics are achieved with no increase in myocardial oxygen 
consumption at rest, indicating an important improvement in LV mechanical 
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efficiency,(Ukkonen et al., 2003, Nelson et al., 2000) (Fig 2.2 F). Other work 
has shown that CRT enhances coronary blood flow, improving both volume 
and velocity.(Kyriacou et al., 2012)  
 
CRT reduces morbidity and mortality from CHF,(Cleland et al., 2005, Bristow 
et al., 2004) with the greatest effects seen in those patients with basal 
dyssynchrony.(Chalil et al., 2007, Gorcsan et al., 2010) On the other hand, 
implantation of CRT in those without LV dyssynchrony may be 
detrimental.(Auger et al., 2012) 
 
2.8.4.3 Personalisation of CRT programming for most effect 
Optimizing AV and VV delays in CRT can improve LV haemodynamics in 
some patients,(Kass et al., 1999, Spragg and Kass, 2006, Hay et al., 2004) 
but LV lead position and site of stimulation have the greatest influence on 
CRT performance.(Kirk and Kass, 2013b) Early RV stimulation creates an 
LBBB type ECG pattern and can exacerbate dyssynchrony, worsening LV 
dysfunction, hence frequently, the LV is stimulated first (creating an RBBB 
type ECG pattern).(Hay et al., 2004, Byrne et al., 2007, Mills et al., 2009) LV 
only pacing, with the LV lead positioned in the mid-lateral wall, may have 
similar haemodynamic benefits as biventricular pacing in patients with 
LBBB.(Kass et al., 1999, Boriani et al., 2012)  
 
2.8.4.4 How does CRT work?  
CRT is the only intervention that improves cardiac function both acutely and 
chronically whilst improving long-term survival.(Kirk and Kass, 2013b) CRT 
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was initially thought of as a purely mechanical therapy, and that 
resynchronising cardiac contraction would improve LV contraction and 
performance. This viewpoint focussed interest on methods to identify and 
measure dyssynchrony, such as QRS duration on the 12-lead ECG and later 
assessing dyssynchrony via trans-thoracic echocardiography using tissue-
Doppler. The mechanical effects of CRT no doubt contribute to its clinical 
effectiveness, but mounting evidence backs molecular and cellular changes 
that CRT induces, which are likely protagonists as well. CRT influences a 
range of structural and signalling pathway changes which occur in heart 
failure.(Kirk and Kass, 2013b) 
 
Figure 2.2 Regional and global pathophysiology of cardiac dyssynchrony, 
used with permission from Wolters Kluwer Health Inc. 
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CRT has been shown to improve functional mitral regurgitation (FMR), which 
is associated with worse outcome in those with DCM.(Cleland et al., 2005, 
van Bommel et al., 2011) FMR can be caused by LV chamber and mitral 
annular dilation causing poor coaptation of the mitral valve leaflets, papillary 
muscle dyssynchrony, and AV conduction delay which can worsen 
presystolic MR.(Brecker et al., 1992) CRT may reduce FMR by modulating 
each of these causes of FMR. A short AV delay reduces presystolic MR, 
improved LV synchrony reduces papillary muscle dyssynchrony and 
reductions in in LV volume reduce the effects of chamber and annular 
dilatation.(Murphy et al., 2006, Sutton et al., 2006) A small study of 34 
patients with reduced FMR following CRT showed >90% have reduced 
chamber volumes, suggesting this as the major likely mechanism for 
reduced FMR in CRT patients.(Solis et al., 2009) 
 
2.8.4.5 Does CRT work in everyone?  
Around 30% of CRT recipients do not “respond” to CRT. Efforts to predict 
response have been made, but no definitive reason has been proven.(Sung 
and Foster, 2011, Delgado and Bax, 2011) The Predictors of Response to 
CRT (PROSPECT) trial set out to prospectively examine a number of routine 
and advanced echocardiographic techniques against markers of clinical 
response in 300 patients over a six month follow-up period. The primary 
outcomes were left ventricular reverse remodelling and improvement in the 
heart failure Clinical Composite Score. (Yu et al., 2005a) When examined, 
the trial revealed that “no single echocardiographic measure of 
dyssynchrony may be recommended to improve patient selection for CRT 
beyond current guidelines”. (Chung et al., 2008)  
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Whereas medication can be discontinued in people for whom they seem not 
to be beneficial, this is not possible with CRT. Once the device is implanted, 
the risks have been encountered and the money spent. This ‘up front’ issue 
unique to devices, drives the need to identify the recipients most likely to 
benefit beyond current knowledge. At present a 30% non-response rate and 
ambiguity over predictors of response beyond QRS duration suggest the 
true mechanism of response to CRT is not fully understood, and further 
investigation is required. 
 
CRT primarily alters electric activation, which underlies the theory behind its 
use: that regional delay of activation can be reduced via coordinated 
activation through bi-ventricular stimulation.(Kirk and Kass, 2013b) A delay 
in electrical activation will result in a mechanical delay if electromechanical 
coupling is intact.(Russell et al., 2010) However, electromechanical 
association can also be affected through regional variation in wall stress, 
cardiac contractility, scarring or fibrosis.(Kirk and Kass, 2013b) Any form of 
uncoordinated contraction will worsen electromechanical delay in the regions 
which are activated latest and therefore usually exposed to the highest 
stress.(Russell et al., 2011, Kerckhoffs et al., 2012) Also, contraction can 
appear dyssnchronous even in the presence of normal electrical activation, 
due to regional variation in cardiac contractility,(Kass, 2008) for example, 
there is dyssnchronous right–left heart contraction in pulmonary 
hypertension,(Kalogeropoulos et al., 2008, Brili et al., 2013, Marcus et al., 
2008) without prolonged QRS duration,(Marcus et al., 2008) in this situation 
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dyssynchrony is thought to occur due to higher RV wall stress. Differences in 
the timing of myocardial contraction following myocardial infarction can 
appear as dyssynchrony, though this is less likely to be improved by 
CRT.(Abd-Elmoniem et al., 2012) 
 
2.8.4.6 Who do the guidelines say is eligible for CRT? 
Current ESC guidelines for CRT implantation can be seen in Table 2.1 
(adapted from ESC guidelines) and are largely based on QRS 
duration.(Ponikowski et al., 2016)  
Table 2.1 Current ESC guidelines for CRT implantation 
Recommendations Class Level 
CRT is recommended for symptomatic HF patients in SR with a QRS duration ≥ 150 
msec and LBBB QRS morphology with LVEF ≤35% despite OMT to improve 
symptoms and reduce morbidity and mortality. 
I A 
CRT should be considered for symptomatic HF patients in SR with a QRS duration ≥ 
150 msec and non-LBBB QRS morphology with LVEF ≤ 35% despite OMT to improve 
symptoms and reduce morbidity and mortality. 
IIa B 
CRT is recommended for symptomatic HF patients with HF in SR with a QRS duration 
of 130-149 msec and non-LBBB QRS morphology with LVEF ≤ 35% despite OMT to 
improve symptoms and reduce morbidity and mortality.  
I B 
CRT may be considered for symptomatic HF patients in sinus rhythm with a QRS 
duration of 130-149 msec and non-LBBB QRS morphology with LVEF ≤ 35% despite 
OMT to improve symptoms and reduce morbidity and mortality 
IIb B 
CRT rather than RV pacing is recommended for patients with HFrEF regardless of 
NYHA class, in SR or AF, with an indication for ventricular pacing and high degree AV 
block in order to reduce morbidity.   
I A 
CRT should be considered for patients with LVEF ≤ 35% in NYHA Class III-IV despite 
OMT to improve symptoms and reduce morbidity and mortality if they are in AF and 
have a QRS duration ≥ 130 msec and good rate control to ensure bi-ventricular capture 
is in place or the patient is expected to return to sinus rhythm 
IIa B 
Patients with HFrEF who have received an RV pacemaker or ICD and develop 
worsening HF despite OMT with a high proportion of RV pacing may be considered for 
upgrade to CRT. This does not apply to patients with stable HF 
IIb B 
CRT is contra-indicated in patients with a QRS duration < 130 msec 
III A 
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2.8.4.7 Assessment of eligibility – does echocardiography help? 
Although some studies have identified no relationship between QRS 
duration and variables of functional capacity or cardiac structural 
remodelling,(Yu et al., 2005b, Mollema et al., 2007) meta-analyses of 15 
large CRT trials revealed that QRS duration predicts two-thirds of those who 
respond to CRT.(Bax and Gorcsan, 2009) Other measures of cardiac 
dyssynchrony have concentrated on regional wall motion delay.(Kirk and 
Kass, 2013b) Tissue-Doppler derived methods of dyssynchrony analysis 
showed initial promise,(Bax et al., 2004, Van Bommel et al., 2010) however, 
the multi-centre Predictors of Response to Cardiac Resynchronization 
Therapy (PROSPECT) trial showed significant variability in dyssynchrony 
assessment, and that tissue-Doppler derived dyssynchrony assessment had 
poor predictive value.(Chung et al., 2008) More recently, other methods of 
dyssynchrony assessment have emerged including speckle tracking via 
transthoracic echocardiography,(Delgado et al., 2008, Gorcsan et al., 2007, 
Lim et al., 2008, Tanaka et al., 2010) 3D transthoracic 
echocardiography,(Auger et al., 2011, Kleijn et al., 2012, Russo et al., 2012, 
Marsan et al., 2008) and dyssynchrony assessment using cardiac MRI 
techniques.(Bilchick et al., 2008, Budge et al., 2012, Marsan et al., 
2009) The implications of ‘de-selecting’ people considered eligible on current 
standards are great so robust evidence is needed if any of these techniques 
to be widely accepted and used in the clinical setting.(Delgado and Bax, 
2011, Sung and Foster, 2011) Equally, careful clinical and health economic 
assessments are required before selecting people who do not fulfil current 
indications for a CRT device. 
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Mechanical dyssynchrony in the absence of electrical dyssynchrony can 
occur in some patients with heart failure and a narrow QRS complex. CRT 
as a treatment in this situation has been suggested,(Achilli et al., 2003, Yu et 
al., 2006) however, recent multi-centre showed no benefit of CRT in narrow 
QRS,(Beshai et al., 2007, Thibault et al., 2013, Ruschitzka et al., 2013) with 
2 trials terminated early due to futility and safety concerns.(Thibault et al., 
2013, Ruschitzka et al., 2013) Methods of dyssynchrony evaluation exist 
which combine electric and mechanical parameters,(Ghosh et al., 2011, 
Ramanathan et al., 2004) but lack rigorous evidence from clinical trials.(Kirk 
and Kass, 2013b) 
 
2.8.5 Upgrade of existing pacemakers to CRT 
As discussed in chapter 1, patients with permanent RV pacemakers often 
develop left ventricular dysfunction and heart failure due to the dyssynchrony 
that the pacemaker induces. Internationally, ‘upgrades’ to CRT represent 
between 23–28% of all CRT implants,(Leclercq, 2008) despite the fact that 
this approach has been tested only in small, often non-randomised studies. 
However, overall, the results from the four small randomized, crossover trials 
are promising.(Leclercq, 2008, Delnoy et al., 2011, Hoijer et al., 2006, van 
Geldorp et al., 2010) All of the trials had a similar design - periods of 
between 2–6 months duration of CRT was compared with periods of 
between 2–6 months of RV pacing. All participants had conventional RV 
pacing indications for bradycardia (mainly AV block), severe CHF symptoms 
(NYHA class III or IV) and LVEF <40%. When compared with the RV pacing 
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period, patients experienced fewer hospitalisations, improved LV function 
and improved symptoms during the CRT pacing period. 
 
The results from the randomised studies presented above are similar to 
those arising from several small longitudinal observational studies. In these 
observational studies, patients were upgraded to CRT due to worsening of 
CHF symptoms and deterioration of LV function associated with significant 
periods and volumes of RV pacing.(Baker et al., 2002, Eldadah et al., 2006, 
Laurenzi et al., 2007, Leon et al., 2002, Shimano et al., 2007, Valls-Bertault 
et al., 2004, Vatankulu et al., 2009)  Almost all of the participants were in 
NYHA class III or IV, and had an LVEF of <35% at the time of upgrade. 
Patients showed significant clinical improvement, improved cardiac function 
and reduced symptoms during the follow-up periods which ranged from 1–20 
months. 
 
Despite the lack of definitive data from large randomised control trials, there 
is accumulating evidence that patients with high volumes of RV pacing, 
reduced LVEF and CHF symptoms should be upgraded to CRT.  
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Chapter 3. Methodology 
 
My studies were designed to include surrogate endpoints of known 
prognostic value such as echocardiography, peak oxygen consumption 
(exercise capacity) and symptoms, as well as patient-orientated endpoints 
such as quality of life, symptoms and exercise capacity. In this chapter I 
shall describe the methodology for each endpoint and its relevance.  
 
3.1 Transthoracic Echocardiography (TTE) 
Transthoracic echocardiography, or cardiac ultrasound, is the term used 
when referring to cardiac imaging using ultrasound imaging techniques. This 
includes two and three-dimensional imaging, colour flow Doppler, continuous 
and pulsed wave Doppler, tissue Doppler imaging (TDI), myocardial 
deformation imaging (strain and strain rate) and contrast imaging. 
Transthoracic echocardiography (TTE) is the most frequently used method 
for cardiac and functional and structural assessment in patients with chronic 
heart failure (CHF), and most commonly focuses on LV size and systolic 
function.(Ponikowski et al., 2016, Lang et al., 2015) 
 
3.1.2 Measurement of LV dimensions and volumes 
Internal dimensions and volumes are the most frequently used variables to 
quantify LV cavity size. Measurements are made at specific points during the 
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cardiac cycle, usually end-diastole and end-systole, these dimensions can 
then be applied to equations used to derive parameters of LV function.(Lang 
et al., 2015) LV internal cavity and wall thickness dimensions should be 
measured in the parasternal long-axis view and measurements should be 
obtained at the level of the mitral valve leaflet tips. Dimensions can be 
obtained using M-mode imaging (Fig 3.1), or by using digital callipers (Fig 
3.2).(Lang et al., 2015)   
 
 
Figure 3.1 LV cavity dimension measurement using M-mode 
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Figure 3.2 LV cavity dimension measurement using digital callipers 
 
LV volumes can be measured using two or three dimensional 
echocardiography. Using linear measurements to calculate LV volumes is 
one method of measuring LV volumes, but they are considered inaccurate, 
as they rely on the assumption of a fixed geometric LV morphology. As such, 
the Teichholz and Quinones methods for measuring LV volumes are no 
longer recommended for clinical application.(Lang et al., 2015) 
Volumetric measurements are made by tracing round the internal border of 
the interface between the LV cavity and the myocardium. LV length is 
defined as the distance between the internal myocardial border at the LV 
apex, and the midpoint of a line drawn across the mitral annulus. It is 
recommended that LV volumes are measured from the apical four- and two-
chamber views.  
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3.1.3 Assessment of LV systolic function 
The most commonly used method for measuring LV systolic function from 2 
dimensional echocardiography is the left ventricular ejection fraction (LVEF), 
using the biplane method of disks summation (modified Simpson's rule) (Fig 
3.3). For measurement of LVEF LV end diastolic volume (LVEDV) and LV 
end systolic volume (LVESV) are obtained from apical four- and two-
chamber views. (Lang et al., 2015, Ponikowski et al., 2016)  
An LVEF of <50% will be used to determine left ventricular systolic 
dysfunction, as this was consensus around the time of beginning the study 
and is most frequently used to distinguish between HFrEF and 
HFpEF.(Owan et al., 2006, Hogg et al., 2004, Owan and Redfield, 2005, 
Vasan et al., 1995) However, discussion exists around whether <50% or 
<55% is the most evidence based method determining left ventricular 
systolic dysfunction.(Mahadevan et al., 2008)  
Doppler analysis can be used in the calculation of haemodynamic 
measurements, such as cardiac output and stroke volume, this is done using 
pulsed-wave Doppler in the left ventricular outflow tract (LVOT) using the 
velocity time integral method. (Lang et al., 2015, Ponikowski et al., 2016) 
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Figure 3.3 Simpson’s Bi-plane method of measuring LVEF 
 
3.1.4 Reliability of TTE 
 
TTE is a widely accepted imaging modality in measuring cardiac structure 
and function,(Palmieri et al., 1999) however TTE, and particularly LVEF, is 
limited by test-retest reliability.(Palmieri et al., 1999) Because of this, in 
research scenarios a large sample size is required to detect change with 
confidence.(Kalogeropoulos et al., 2012) Factors which may limit image 
acquisition in TTE include insufficient training, sub-standard equipment, poor 
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imaging, technical ability of the sonographer, experience of the sonographer 
and patient body habitus, to name a few.(Himelman et al., 1988) 
 
Therefore, acquiring accurate images in TTE, and in particular LVEF, relies 
upon operator skill and experience and image quality. To minimise variability 
it is recommended that cardiac ultrasound departments should aim for inter- 
and intra-operator variability for LVEF of 10%.(EACI, 2016) This should be 
achieved through the use of standard operating procedures, thereby 
ensuring standardisation among procedures.(EACI, 2016) To maintain 
consistency and to reduce inter and intra-observer variability the British, 
European and American societies of echocardiography recommend regular 
quality control and audit.((BSE), EACI, 2016) 
 
 
3.2 Echocardiography protocol 
All transthoracic echocardiographic assessments were carried out by the 
same British Society of Echocardiography (BSE) accredited sonographer, 
who collected datasets according to BSE guidelines.((BSE)) All participants 
had a full 2-dimensional transthoracic echocardiographic examination, with 
grey-scale and tissue Doppler images recorded. Images were obtained 
using a GE Vivid 7 ultrasound machine and stored offline, on the Echopac 
system, to allow offline analysis and measurements.  
 
- 101 - 
Left ventricular (LV) systolic function assessment was done using the 
modified Simpson’s bi-plane method - the 2 dimensional end systolic and 
end diastolic LV areas were measured in orthogonal planes using the apical 
4-chamber and 2-chamber views. Where relevant, the sonographer was 
blinded to the study arm and protocol, and the images requiring analysis 
were anonymised.  
 
3.3 Formal exercise testing 
Reduced exercise capacity, a common symptom in heart failure patients, 
occurs due to complex pathophysiological changes related to adverse 
changes in the complex relationship between peripheral and central systems 
involved in oxygen transport and utilisation during exertion. Formal exercise 
testing is recommended as part of comprehensive functional assessment, to 
allow exercise capacity to be measured objectively.  
 
3.4 Assessing exercise capacity 
Many methods of assessing exercise capacity are available. History taking, 
classification based on NYHA status and daily living questionnaires are all 
frequently used methods which give an impression of functional capacity and 
can be ascertained relatively easily. Symptoms relate modestly to objective 
measures of functional capacity, which suggests that patient reported 
symptoms may not be reliable measures of exercise intolerance,(ESC, 2001, 
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Wilson et al., 1999) and their use in assessing treatment effect may not be 
robust.(Arena et al., 2007) 
 
3.4.1 Cardio-pulmonary exercise (CPX) testing  
Exercise capacity in heart failure relies on a complex interplay between the 
neuro-hormonal, pulmonary and central and peripheral circulatory systems 
of the body.(ESC, 2001) The limitations of these systems, and an objective 
measure of exercise capacity, can be assessed by using cardio-pulmonary 
exercise (CPX) testing. 
 
3.4.2 Introduction to CPX testing  
CPX testing is recommended in patients with heart failure, to measure 
response to physical exertion. The results are used to assess severity of 
disease, prognosis and the effect of therapy.(Weber and Janicki, 1985, 
Myers and Gullestad, 1998, Cohn et al., 1993, Stelken et al., 1996, Chua et 
al., 1997, Stevenson et al., 1995, Guazzi et al., 1999, ESC, 2001) 
 
An objective assessment of exercise capacity can be made using specific 
maximal and sub-maximal parameters. Several CPX parameters have been 
studied including peak oxygen uptake (pVO2), oxygen uptake at anaerobic 
threshold (AT), exercise duration and the slope of ventilation vs. carbon 
dioxide production (VE/VCO2 slope).(ESC, 2001)  A familiarisation test is 
recommended when performing a CPX test in heart failure patients as 
results can vary, with one study requiring 11 tests to get reproducible 
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results.(Pinsky et al., 1990) Conversely, Witte et al found that following a 
familiarisation test, a peak CPX test is not a training stimulus, with 
reproducible results.(Witte et al., 2003) However, performing multiple 
familiarisation tests is impractical, and the most difference seems to occur 
between the first and second test, thought to be due to familiarisation with 
the equipment and technique.(ESC, 2001) 
 
3.4.3 CPX test overview 
Whilst performing a CPX test, individuals perform physical exertion whilst 
breathing room-air. The volume and concentration of inspired and expired 
oxygen (O2) and carbon-dioxide (CO2) and respiratory rates and volumes, 
are collected via a mouth-piece or face mask. Metabolic gas exchange data 
is analysed on a breath by breath basis by O2 and CO2 analysers. 
 
A CPX test is usually performed on an ergometer which allows workload to 
be measured and controlled, this usually takes place on a treadmill or 
stationary cycle, but can also be performed on an arm-crank cycle or rowing 
ergometer. To allow for accurate assessment of workload performed, a 
standard protocol is used, of which there are many available. CPX tests 
performed on cycle ergometers usually involve a ramping protocol, whereby 
the workload increases at a predetermined intensity every minute. Treadmill 
protocols usually involved a staged, or stepped, protocol where the workload 
increases is stages at predetermined time intervals. 
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3.4.4 Peak Oxygen Consumption (pVO2) and exercise intolerance 
Directly measured peak oxygen consumption (pVO2) is an established and 
reproducible measure of aerobic capacity and exercise tolerance in 
individuals with heart failure.(Bensimhon et al., 2008, Weber and Janicki, 
1985, Mancini et al., 1991, Myers et al., 2000, Meyer et al., 1997, Marburger 
et al., 1998, Behrens et al., 1994, Gullestad et al., 1998) ‘VO2 max’ is defined 
as a plateau in the maximum oxygen consumption reached during exercise, 
despite an increasing workload.(ESC, 2001) Oxygen uptake during CPX 
testing has a linear relationship with workload.(Hansen et al., 1984) This is 
decreased in cardiovascular, pulmonary and neuromuscular disease and 
can be increased with physical training.(Blomqvist and Saltin, 1983) 
 
 ‘VO2 max’ is usually not achieved in patients with heart failure, as they are 
frequently limited by fatigue or shortness of breath. ‘Peak VO2’ (pVO2), 
defined as ‘VO2 at peak exercise’ is a more appropriate term to describe the 
highest oxygen uptake achieved in patients with heart failure. pVO2 is more 
reliable than other indicators of exercise tolerance.(ESC, 2001) Exceeding 
the anaerobic threshold (AT) which occurs around 60–70% of pVO2, or a 
respiratory exchange ratio (RER) - ratio of VCO2 to VO2, exceeding 1·0 at 
peak exercise suggests adequate physical effort has been made.(ESC, 
2001) 
 
pVO2 is poorly correlated with resting haemodynamic parameters such as 
ejection fraction,(ESC, 2001) this is because haemodynamic parameters 
measured at rest do not accurately represent cardiac pumping function 
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during exercise, or cardiac functional reserve, which can be assessed during 
exercise.(ESC, 2001) During physical exertion peak VO2 correlates with 
maximal cardiac output, cardiac output in response to physical exertion is 
modulated by increases in heart rate and stroke volume,(Miyamura and 
Honda, 1972) and insufficient cardiac output is the principal determinant of 
impaired aerobic capacity and exercise tolerance in asymptomatic or mildly 
symptomatic heart failure patients.(ESC, 2001, Harrington and Coats, 1997) 
 
In patients with moderate to severe heart failure, the decreased vasodilation 
in skeletal muscle vasculature in response to exercise is an important 
determinant of reduced exercise tolerance and peak VO2.(ESC, 2001) 
Healthy subjects distribute around 90% of cardiac output to leg skeletal 
muscle during maximal exercise, whilst patients with heart failure distribute 
around 50– 60% of total cardiac output.(ESC, 2001) Impaired ability to 
redistribute cardiac output to the legs during exercise is most probably 
caused by many factors which include increased vascular resistance and 
endothelial dysfunction, the main mechanisms responsible for peripheral 
vascular dysfunction are increased neuro-hormonal activation.(ESC, 2001) 
Increased ergoreceptor activity has been demonstrated in patients with heart 
failure, which leads to inappropriate dyspnoea, hyperventilation and 
abnormal muscular fatigue/weakness. This is due to sympathetic respiratory 
and circulatory over-stimulation.(Piepoli et al., 1996) 
 
To summarise, the main cause of exercise intolerance in those with 
asymptomatic or mildly symptomatic heart failure is most likely reduced 
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cardiac output reserve, whereas those with moderate or severe heart failure 
are limited by a combination of reduced cardiac output reserve, and 
abnormal peripheral mechanisms.(ESC, 2001) 
 
3.4.5 Measuring pVO2 
During the test all gas exchange is measured breath by breath, and during 
exercise O2 uptake and CO2 production at the mouth represent O2 utilisation 
and CO2 production at the musculoskeletal level. VO2 is calculated as the 
product of minute ventilation (VE) and the oxygen fraction that can be utilised 
by exercising skeletal muscles during maximal and sub-maximal (anaerobic 
threshold (AT)) exercise.(K Wasserman, 2004)  
 
The value for pVO2 is dependent upon age, sex, body size and fitness level. 
VO2 is measured in absolute volume per minute (ml/min), but is divided by 
weight in kg to allow for comparison between individuals of differing body 
mass, i.e. ml/kg/min.(K Wasserman, 2004) 
 
3.4.6 Respiratory exchange ratio (RER) 
Whether pVO2 is representative of an individual’s maximal effort can be 
determined by using the respiratory exchange ratio (RER). The RER is the 
ratio of expired VCO2 to VO2 consumption (VCO2:VO2). As the ability of the 
skeletal muscles to respire aerobically is exceeded, the resultant increase in 
lactate production results in increased exhaled VCO2.  Therefore, an RER of 
1.0-1.1 suggests that the individual has achieved their cardio-pulmonary 
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limits, and has not terminated the test due to other limiting factors such as 
musculoskeletal pain or poor motivation.(K Wasserman, 2004, Mezzani et 
al., 2003) 
 
3.4.7 VE/VCO2 slope 
Heart failure patients display a steeper increase in respiratory rate during 
physical exertion, and increased ventilation rates, at given workloads.(ESC, 
2001, K Wasserman, 2004) The magnitude of such ventilatory abnormalities 
is represented by the increased slope of the relation between ventilation and 
CO2 production (VE/VCO2 slope), which is related to peak VO2.(ESC, 2001) 
This increased ventilation is due to haemodynamic mechanisms such as 
increased dead-space in the lung (caused by ventilation–perfusion mismatch 
in the lung), heightened hypoxic carotid chemo-sensitivity and skeletal 
muscle abnormalities (early accumulation of lactate in the blood, heightened 
ergoreflex activity, early blood lactate accumulation).(ESC, 2001, Piepoli et 
al., 1996, Chua et al., 1996) A steeper VE/VCO2 slope is related to adverse 
prognosis.(Ingle et al., 2007, Sun et al., 2002) 
 
3.4.8 End tidal carbon dioxide (PETCO2) 
The partial pressure of end tidal CO2 (PetCO2, mmHg) is measured during a 
CPX test. Low PetCO2 at rest, and during physical exertion, suggests 
hyperventilation and reflects lung ventilation/perfusion mismatch, low 
PETCO2 is a further indicator of disease severity and outcome.(Arena et al., 
2003, Yasunobu et al., 2005) 
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3.4.9 Sub-maximal exercise 
Measures of submaximal exercise capacity can be obtained from a CPX 
test, and are considered useful in situations where individuals are unable to 
complete a maximal effort CPX test. There is a linear increase in the slope of 
minute ventilation from the onset of exercise, however there is an abrupt 
change in the slope at the point where the metabolic demand, made by 
increasing exercise intensity, becomes too intense for aerobic metabolism to 
supple and skeletal muscles have to rely increasingly on anaerobic 
metabolism to continue exercising. 
 
An increase in anaerobic glycolysis leads to a rapid increase in blood lactate 
concentration, and as a result excess CO2 production via bicarbonate occurs 
to buffer the increased in H+ ions. At this point there is a deflection in the 
slope of VCO2 production, this deflection point is known as the ventilatory or 
anaerobic threshold (AT) expressed as VO2 in mL/kg/min.(Beaver et al., 
1986) 
 
AT is a universally recognised way of measuring sub-maximal exercise 
capacity, and can be used to assess the effects of an intervention on 
functional benefits based on its correlation to activities of daily 
living.(Wilmore et al., 1998) AT is generally occurs at around 70% of pVO2 in 
heart failure patients, which is lower than it would in normal 
subjects.(Shimizu et al., 1991, ESC, 2001) 
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3.4.10 Exercise protocols 
There is no common consensus concerning the most appropriate exercise 
test protocol with which to assess functional capacity in individuals with heart 
failure, the protocol is often chosen due to physician preference, and the 
most effective method has been a discussion point for many years.(ESC, 
2001, Balke and Ware, 1959, Bruce, 1971, Stuart and Ellestad, 1980, Weber 
et al., 1982, Page et al., 1994)  
 
Several incremental exercise protocols are available, and there can be 
considerable differences between protocols in terms of the mode of 
exercise, usually stationary cycle or treadmill, and also in exercise duration, 
the rate at which work is incremented and the duration of each stage. A 
gradually incrementing workload has been shown to be a more accurate 
reflection of exercise capacity than sudden increases in workload, especially 
in patients with heart failure.(ESC, 2001) 
 
The aim of a CPX test is to have a test that provides a gradual and 
consistent increase in workload, allowing adequate metabolic gas kinetic 
response, with an exercise time of between 8 and 12 minutes, this allows the 
most accurate assessment of pVO2.(Buchfuhrer et al., 1983, Fletcher et al., 
1995, ESC, 2001) Tests shorter than 8 minutes duration are considered to 
be off insufficient length to allow steady-state gas exchange to occur, and 
tests longer than 12 minutes are considered to be more limited by general 
fatigue, than cardiopulmonary limits.(K Wasserman, 2004)   
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3.4.11 Stationary cycle 
A stationary cycle is thought of as the most accurate method of performing a 
CPX test, as the legs are isolated and there can be no additional help from 
the arms.(K Wasserman, 2004) A stationary cycle protocol usually follows a 
protocol whereby the workload is gradually ramped up throughout the test 
until exhaustion is reached between 8 and 12 minutes. The workload is 
measured in Watts, and protocols typically increase in a set amount of Watts 
per minute e.g. 10W/min, 20W/min etc.(K Wasserman, 2004) 
 
3.4.12 Treadmill 
Treadmill protocols can lead to a 10-20% higher pVO2 than cycle 
protocols.(Page et al., 1994, Myers et al., 1991, Buchfuhrer et al., 1983, 
Fletcher et al., 1995, Myers and Froelicher, 1990) However, multicentre trials 
in heart failure have found comparable pVO2 values when using treadmill or 
stationary cycle.(Page et al., 1994) The Bruce protocol is the most frequently 
used treadmill protocol in cardiology settings, and this can be modified by 
the addition of 2 stages at the beginning, the 1st consisting of 3 minutes of 
exercise at 1.7mph at 0% gradient and the 2nd 1.7mph at 5% gradient. The 
‘Modified Bruce’ protocol is shown in Figure 3.4 often used in heart failure 
patients, as the standard Bruce protocol is considered too difficult and may 
result in a test of insufficient duration.(Bruce and McDonough, 1969)  
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Figure 3.4: Modified Bruce protocol 
 
The Naughton and Balke protocols are alternative treadmill protocols, with 
more gentle increments in speed and gradient than the Bruce protocol, 
however their more gentle profile may lead to excessive test duration, and 
therefore might be less likely to achieve a representative pVO2.(Balke and 
Ware, 1959, Nagle et al., 1965)   
 
3.4.13 CPX protocol 
Following consent, 12-lead ECG and gas exchange variables were collected 
for a period of six minutes to ensure steady-state conditions were achieved. 
The same experienced Cardiac Physiologist performed all of the CPX tests 
during the studies. A 12-lead, real-time, ECG was displayed during the 
resting, test and recovery phases. 12-lead ECGs were printed at baseline, 
end of each 3 minute stage, peak exercise and during recovery. 
 
All participants performed a symptom limited maximal CPX test on a 
treadmill using the modified Bruce protocol (Fig 3.4). During each test, 
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inspired and expired air was collected using a mouthpiece and metabolic 
gas exchange analysis was performed breath-by-breath using the 
MedGraphics Ultima CardioO2 equipment (Medical Graphics UK Limited, 
Gloucester, UK). The analyser was calibrated using the manufacturer 
recommended volume and automated gas calibration techniques before 
every exercise test.  
 
Patients were encouraged to perform a maximal exercise test prior to the 
test. Patients were instructed to exercise to exhaustion or to onset of 
symptoms. The test may also be terminated by the staff in the advent of 
ECG changes. All subjects were recovered for at least six minutes following 
the test, or until heart rate and any ECG changes returned to normal. All 
tests were carried out in the same exercise laboratory. All CPX and ECG 
data were recorded and stored securely for later analysis. Because of the 
numbers involved in the study it was deemed impractical to perform a 
familiarisation CPX. 
 
3.5 Assessing quality of life in CHF 
Quality of life is used in medicine to determine a patient’s quality of life from 
their own perspective.(Katschnig, 2006) Quality of life is significantly reduced 
in CHF, and measures of the quality of life in CHF patients are an important 
source of data in research.(Guyatt, 1993) The aim of measuring quality of 
life in research is to have an objective appraisal of how the physical and 
emotional effects of a condition affect an individual’s life.(Katschnig, 2006, 
Guyatt, 1993) Such data can be used during baseline assessment and as 
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outcome measures, and can be used to assess the impact of any 
intervention on an individual’s quality of life.(Soler-Soler and Permanyer-
Miralda, 1994, Guyatt, 1993) 
 
Quality of life is usually measured by patients completing questionnaires. 
Examples of questionnaires assess quality of life in patients with heart failure 
include: 
1. The Chronic Heart Failure Questionnaire 
2. The Minnesota Living with Heart Failure Questionnaire 
3. The Yale Scale 
4. The Quality of Life Questionnaire in Severe Heart Failure 
5. The Kansas City Cardiomyopathy Questionnaire. 
(Coelho et al., 2005) 
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Chapter 4. What is the prevalence of left ventricular 
dysfunction in pacemaker patients requiring a battery 
replacement? 
 
Hypothesis – “Left ventricular systolic dysfunction is related to 
right ventricular pacing percentage in a cohort of patients awaiting 
pacemaker battery replacement” 
4.1 Introduction 
Previous data have suggested that patients with pacemakers are at a higher 
risk of prevalent left ventricular systolic dysfunction (LVSD) and heart failure 
admissions. I set out to establish relationships between pacemaker variables 
and left ventricular function and interacting confounders. 
4.2 Methods 
The inclusion criteria was that all patients from 1st April 2008 – 21st 
December 2012, with a pacemaker implanted for bradycardia, referred for 
elective pacemaker generator replacement at Leeds General Infirmary were 
invited to attend the cardiology department at least one week before their 
procedure. Exclusion criteria included being unable to consent, aged under 
18, ICD or CRT device implanted and congenital heart disease. At the time 
of study commencement, around 125 battery replacements were performed 
each year. Patients with bradycardia pacemakers are followed annually at 
Leeds Teaching Hospitals NHS Trust, and are referred for battery 
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replacement when the estimated longevity of the battery was between 3-6 
months. Patients would be informed that they had been referred, and to 
expect an appointment through the post. Details of the existing device, such 
as potential lead connection problems, or the requirement of a new lead, 
would be assessed by a senior Cardiac Physiologist, and any potential 
problems reported to the physician performing the procedure. 
Echocardiographic variables including height, weight, blood pressure, 
symptomatic status (New York Heart Association category), medical therapy, 
past medical and cardiac history, date of first implantation, indication for 
implant and the number of pacemaker generator replacements were 
recorded. The implant indication was confirmed by reviewing the baseline 
electrocardiograph tracings and the medical records. The pacemaker was 
interrogated to document programmed settings and the percentage of right 
atrial and RV paced (%VP) beats. We multiplied the %VP with the number of 
years of pacing to gain some estimate of total volume of ventricular pacing 
(years of 100% VP).  
 
Each patient had a full transthoracic echocardiographic investigation (Vivid 
7, Vingmed, USA), and, in those without neuromuscular, skeletal, 
pulmonary, and other conditions preventing exercise testing, symptom-
limited, peak cardiopulmonary exercise testing using a treadmill, was carried 
out to establish exercise capacity including peak oxygen consumption 
(Medgraphics, USA), and heart rate and blood pressure responses to 
exercise. Blood tests were performed at this visit or prior to the battery 
replacement procedure, to measure renal function and blood count.  
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For hospitalisation and mortality 31st December 2012 was chosen as the 
censor date, and all patients attending the assessment were included in the 
final analysis. Mortality and hospitalisation data were ascertained from both 
electronic and paper records.  Data analysis was undertaken using SPSS 
version 18. Associations between variables were initially investigated using 
simple regression and later by multiple regression. Differences between 
groups were investigated using Student’s t-test and a Cox proportional 
hazard model was used to compute the hazard ratio and corresponding 95% 
confidence intervals for subsequent mortality or hospitalisation. The study 
was approved by the Leeds West Research Ethics Committee. A sample 
size calculation was not performed, the data collection was governed by time 
constraints and ceased on 31st December 2011.   
 
4.3 Results 
During the study period 508 patients underwent pacemaker generator 
replacement, a complete dataset was collected on 491 (97%) of these. 
Included in this cohort of 491 patients were 66 patients who took part in the 
study described in chapter 5. These 66 patients had their pacemaker 
programming optimized to reduce RV pacing, associated with statistically 
significant improvements in LV systolic function. Inclusion of these 66 
patients, with improvements to such an important prognostic marker as LV 
systolic function, may have influenced the mortality and admission rates 
reported in this chapter. Age, pacemaker variables and co-morbidities were 
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not different in those assessed and not. Table 4.1 shows demographic and 
basic pacemaker data. Cardiovascular co-morbidities (43% had ischaemic 
heart disease, 27% atrial fibrillation and 13% diabetes mellitus) and 
concurrent cardiovascular medical therapies were common.  
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Table 4.1: Pacemaker survey patient demographic data 
 
 
Values are means (95% CI), median for NYHA or % (or n) as indicated.  
AV; atrioventricular, eGRF; estimated glomerular filtration rate, MI; myocardial infarction, 
PCI; percutaneous coronary intervention, CABG; coronary artery bypass grafting, ACE-
inhibitor; angiotensin-converting-enzyme inhibitor. 
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4.3.1 Device prescription and programming 
Table 4.2 contains the device characteristics and detail of their 
programming. Patients in SR were more likely to have a dual chamber 
device implanted than patients in AF (93 v 49%), and there was no age 
difference between those with and without dual chamber devices. The most 
common indication for implantation was sinus node disease (54%), with 42% 
having an indication of AV block, including 27% of the total with third degree 
block (complete heart block (CHB)) at baseline (table 4.1). Patients with an 
implant indication for CHB had a higher %VP at the time of PGR (85 (3) v 50 
(2) % than those without CHB at implant, and although 78% of those with 
CHB at baseline had >80%VP at PGR, 12% had less than 40%VP at follow-
up (Fig 4.1) Additionally, 37% of patients implanted for AV-delay but not in 
CHB at baseline were receiving >80%VP at the time of PGR.  
 
37 (8%) of patients had an LVEF of <35%. These patients were referred to 
the heart failure clinic at LTHT for further management. The patients 
remained in the study for analysis purposes. 
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Table 4.2 Pacemaker, echocardiographic and cardiopulmonary exercise test 
variables in 491 pacemaker pulse generator replacement patients 
Devices and their programming % [n] 
Hardware (% [n]) 
Ventricular lead only 
Dual chamber sensing (VDD lead) 
Dual chamber pacing 
 
20 [96] 
0.5 [2] 
80 [393] 
Pacing mode (% [n]) 
AAI (R) 
VVI 
VVIR 
VDD 
DDD 
DDDR 
DDI (R) 
 
1 [4] 
13 [63] 
12 [61] 
5 [23] 
37 [183] 
25 [124] 
7 [33] 
Rate response on (% [n]) (48%) [236]  
Pacemaker variables Mean (CI) 
Base rate (/min) 62 (61-63) 
Max track rate (/min) 122 (120-124) 
Paced/sensed AV delay  (CHB) (ms) 192/168 (178-206/154-182) 
Paced/sensed AV delay (non-CHB) (ms) 246/219 (237-255/208-230) 
% paced atrium 46 (42-50) 
% paced ventricle 56 (52-60) 
>80% ventricular pacing 45 [220] 
Echocardiographic and CPX variables Mean (CI) or median (IQR) 
LVEF (%) 50 (48-52) 
LVEF <35%  37 (8%) 
LVEDD (mm) 48 (46-50) 
LA diameter (mm) 42 (40-44) 
E-wave velocity (mls) 0.80 (0.40) 
A-wave velocity (m/s) 1.00 (0.00) 
E/A ratio 0.78 (0.32) 
Peak VO2 (ml/kg/min) (n=159) 17.6 (16.6-18.6) 
VE/VCO2 slope 34 (10) 
 
Values are means (95% CI) except for LA diameter, E-wave, A-wave and E/A ratio which 
are median (IQR) and LVEF <35% which is n (%) 
AV; atrioventricular, CPX; cardiopulmonary exercise test, LVEF; left ventricular ejection 
fraction, LVEDD, left ventricular end-diastolic diameter, peak VO2; peak oxygen 
consumption, VE/VCO2 slope; ratio between ventilation and carbon dioxide output.  
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Figure 4.1 Percentage ventricular pacing at PGR in those with and without 
CHB at baseline. 
 
There was a weak relationship between age and %VP, (r=0.1; p=0.014) and 
although patients with >80%VP were older, the total volume of %VP was not 
related to age. There was no relationship between the presence of existing 
cardiovascular co-morbidities (myocardial infarction, percutaneous coronary 
angioplasty, hypertension, or cardiac surgery), seen in 50% of the population 
and the %VP. However, there was a relationship between %VP and renal 
function, (r=0.20; p=0.0077) and furosemide dose (r=0.2; p<0.02), and 
patients with >80%VP at PGR had significantly worse renal function (eGFR 
53 (2) v 60 (2); p=0.01). 
 
Rate response mode was more frequently activated in patients in AF (66 v 
41%), and was associated with a higher %VP in single chamber (but not in 
dual chamber) devices (%VP 78 (4) v 59 (7)%). As a result, patients with 
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single chamber devices experienced a higher %VP than those with dual 
chamber devices (71 (4) v 53 (3) %). 
 
4.3.2 Echocardiographic and Cardiopulmonary exercise test 
results 
 
Table 4.2 contains results of the echocardiographic and CPX results in 
patients attending for PGR. The incidence of LV systolic dysfunction 
(LVEF<50%) in all patients was 40%, but this was significantly higher (59%) 
in those with >80%VP than in those with <80%VP (22%) (Fig 4.2) and in 
those with cardiovascular co-morbidities (Fig 4.3). Patients with LV systolic 
dysfunction were more likely to be taking β-blockers (79 v 47%) and ACE-
inhibitors (or angiotensin receptor blockers)(83 v 63%), although daily doses 
were not optimal (mean bisoprolol equivalent 4.5 (0.5)mg). 
 
Figure 4.2 The incidence of LV systolic dysfunction, based on pacing 
percentage 
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Figure 4.3 Frequency of left ventricular systolic dysfunction in patients with 
or without cardiovascular co-morbidity (hypertension, type 2 diabetes 
mellitus, and apparent coronary artery disease), split by percentage of 
ventricular pacing 
 
Patients with CHB at baseline had worse LV systolic function (LVEF 46 (1) v 
52 (1)%) and were more likely to have LV systolic dysfunction (Χ2=7.6) at 
PGR than those with intact AV conduction, but the differences between 
those with and without >80%VP at PGR were greater (LVEF 55 (1) v 46 
(1)%  and Χ2=48).  
 
For most patients, it was their first PGR (78% [n=283]). Although patients 
with previous generator replacements had a higher amount of ventricular 
pacing than those attending for their first replacement, (54 (2) v 63 (4)%VP), 
and had a higher total volume of pacing (4 (0.2) v 11 (1) years of 100% VP), 
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there was no relationship between the number of previous generator 
replacements (ANOVA p=0.28) and LVEF or presence of LVSD. 
 
Simple regression suggested relationships between LVEF and age (r=0.15 
p=0.006), %VP at PGR (r=0.40; p<0.0001), years of 100% VP (r=0.24; 
p<0.0001), serum creatinine (r=0.26; p<0.0001), paced QRS (r=0.41; 
p=0.0003), and furosemide dose (r=0.32; p=0.0001). In a multivariable 
model %VP at PGR and previous myocardial infarction remained significant 
(table 4.3), pVO2, VE/VCo2 slope, LVEF and QRS duration were not 
significant in this model. Figure 4.4 shows the receiver operator curve for 
predicting LVEF <50% using %VP at PGR, creatinine, and previous 
myocardial infarction. Using three variables: %VP, years of 100%VP and 
previous MI, our model has a negative predictive value of 91%, a positive 
predictive value of 51% with a c-statistic of 0.74. 
 
Table 4.3 Multivariable model of predictors of the presence of impaired left 
ventricular function 
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Figure 4.4: Receiver-operating characteristic (ROC) curve for left ventricular 
dysfunction (LVEF <50%) with ≥80% right ventricular pacing and 
previous myocardial infarction. 
 
Peak oxygen consumption was available in 159 (33%) patients. Patients with 
pacemakers have significantly limited exercise capacity, which is lowest in 
those with the highest amount of ventricular pacing (>80%VP) (peak oxygen 
consumption 15 (1) v 20 (1)). Fig 4.5 shows the relationship between RV 
pacing and peak VO2 (r
2
 =0.07; p=0.006) in this cohort. Fig 4.6 shows the 
relationship between RV pacing and LVEF (r2 = 0.16; p<0.0001). And In 
multiple regression, peak oxygen consumption is related to age, renal 
function and furosemide requirement rather than any marker of pacemaker 
activity.  
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Figure 4.5 The relationship between right ventricular pacing and peak 
oxygen consumption at baseline 
 
 
Figure 4.6 The relationship between right ventricular pacing and LVEF at 
baseline 
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4.4 Outcome data 
In our prospective analysis of outcome we excluded 25 patients who were 
enrolled into a randomised study of upgrade to cardiac resynchronisation 
therapy. This left a population of 466. After a mean follow-up time of 668 
(19) days, 56 patients (12%) were dead (n=34) or had been hospitalised 
(n=22) for heart failure. Univariable predictors of mortality or hospitalisation 
for heart failure are shown in table 4.4. On multivariable analysis, only 
LVEF≥50% was independently associated with better survival (HR 0.48 
(0.25-0.94)). The Kaplan Meier curves for patients with and without LVEF 
<50% and with and without %VP>80% are shown in Figure 4.6.  
 
Table 4.4: Univariable cox-regression analysis of predictors of combined 
mortality or hospitalisation for heart failure 
 
LVEF; left ventricular ejection fraction 
 
 
Hazard Ratio 
95% confidence intervals of 
hazard ratios p-value 
 Low High 
Age (per year) 1.035 1.007 1.064 0.014 
% ventricular pacing (per %) 1.01 1.002 1.018 0.017 
LVEF <50% (y/n) 2.44 1.28 4.66 0.007 
Creatinine (per µmol) 1.011 1.006 1.015 <0.001 
Haemoglobin (per g/dL) 0.68 0.57 0.81 <0.001 
Furosemide (per mg) 1.018 1.008 1.029 0.001 
pVo2 (ml/min/kg) 0.863 0.754 0.989 0.0335 
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Figure 4.6: Kaplan Meier curve for survival out of hospital in patients with 
pacemakers divided by left ventricular ejection fraction and percentage 
of ventricular pacing prior to generator replacement 
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4.5 Discussion 
The present data are the first to systematically explore a current cohort of 
patients undergoing standard pacemaker generator replacement. The data 
demonstrate a high prevalence of LV dysfunction and co-morbidity and a 
mortality rate only modestly lower than that of heart failure patients of similar 
age.(Cubbon et al., 2011) The degree of LV dysfunction is independently 
related to the amount of RV pacing and, particularly when combined with a 
high percentage of ventricular pacing, LV dysfunction suggests an adverse 
prognosis. 
 
In retrospective analyses,(Brunner et al., 2004, Jahangir et al., 1999, Shen 
et al., 1994, Shen et al., 1996, Jelic et al., 1992, Mayosi et al., 1999) and 
one prospective study,(Sweeney et al., 2008) of patients receiving new 
pacemakers, the most consistent feature predicting outcome was LVSD at 
baseline although age, coronary artery disease, co-morbidities (chronic 
airways disease and diabetes mellitus), paced QRS (for subsequent 
hospitalisation), and atrio-ventricular block are also associated with a worse 
outcome. In our cohort pacing mode or indication was not relevant once 
%VP and the presence of LV dysfunction had been taken into account. 
 
Additionally, by demonstrating a dose-response relationship between the 
amount of ventricular pacing and the degree of LV dysfunction, we have 
fulfilled one of the requirements for causality.(Shukla et al., 2005) The weak 
relationship between age and LVEF, and the poor association between %VP 
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and cardiovascular co-morbidities suggest that the relationship between RV 
pacing and LV dysfunction is causative rather than merely associative.  
 
We have been able to construct a model based upon simple pacemaker-
related and clinical variables (>80%VP, years 100%VP, and previous 
myocardial infarction) that has a negative predictive value of 91% for LVSD 
and a c-statistic of 0.74 (0.68-0.81). This would form an easy way to select 
patients who might benefit from a more extensive review. 
 
4.5.1 Aetiology of RV pacing associated LV dysfunction 
RV pacing induces ventricular dyssynchrony,(Bordachar et al., 2003) similar 
to that seen in intrinsic left bundle branch block (LBBB),(Witte et al., 2006, 
Varma, 2008, Tops et al., 2006, Tops et al., 2009, Tops et al., 2007) which 
leads to altered regional blood flow and wall stress and increases cardiac 
sympathetic activity.(Lee et al., 1994) Endomyocardial biopsies in patients 
with long-term pacemakers reveal increased fibrosis, fat deposition, and 
mitochondrial morphological changes.(Karpawich et al., 1999) The severity 
of these perfusion abnormalities, the regional wall motion abnormalities, and 
degree of left ventricular dysfunction are directly related to the duration of 
ventricular pacing,(Tse and Lau, 1997) although subtle changes can be 
identified after only 18 months.(Tse et al., 2002) 
 
Hence, RV apical pacing, by leading to adverse LV remodelling, LV 
dilatation, and asymmetrical hypertrophy,(Thambo et al., 2004) could either 
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induce LV dysfunction or accentuate pre-existing latent LV dysfunction 
present as a result of other co-morbidity of which most patients receiving 
pacemakers (and generator replacements) have at least one. Most patients 
undergoing pacemaker implantation do not have cardiac imaging prior to the 
procedure, and there are also no large follow-up studies of patients 
undergoing RV pacing examining changes in LV function, so which features 
identify patients at high risk of future LV dysfunction is unknown.  
 
4.5.2 Medical management of RV pacing associated LV 
dysfunction 
 
Medical therapy for symptomatic and asymptomatic pacemaker-associated 
LV dysfunction is under-investigated. Patients with pacemakers and heart 
failure were often excluded from trials of medical therapy and studies 
specifically looking at patients with pacemakers and LV dysfunction are 
rare.(Suwa et al., 1998) Furthermore, although the large studies of heart 
failure and asymptomatic LVSD did not exclude pacemaker patients, sub-
study analysis in patients with pacemakers was not done. In our cohort, this 
lack of knowledge is reflected by the finding that patients with LV dysfunction 
were not on optimal medical therapy.  
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4.5.3 Device based management of RV pacing associated LV 
dysfunction 
 
As RV pacing contributes to poorer outcomes,(Wilkoff et al., 2002) reducing 
RV pacing may improve LV function or prevent further deterioration. But 
although >80%VP in VVI mode and >40%VP in DDD mode are associated 
with an increased rate of hospitalisation for heart failure, (Sweeney et al., 
2003) it is unknown whether there is a threshold of %VP below which the 
risk of subsequent or deteriorating LVSD is low and whether this is different 
in patients with established LVSD or a combination of risk factors. Large 
prospective observational datasets are required to identify whether there is a 
threshold of acceptable %VP below which LVSD is unlikely to occur or 
worsen.  
 
Patients with sinus node disease have a low %VP and a low frequency of 
LVSD but in those with A-V delay, reprogramming to reduce RV pacing, can 
reduce the incidence of atrial arrhythmia,(Kolb et al., 2011, Sweeney et al., 
2007, Gillis et al., 2006, Murakami et al., 2010, Nitardy et al., 2009, Davy et 
al., 2012). Whether such adjustments and algorithms are safe and cost-
effective is unknown.(Kolb et al., 2011)  
 
Patients with standard pacemakers and heart failure, with high levels of right 
ventricular pacing due complete heart block or a slow response to atrial 
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fibrillation, often have their pacemaker upgraded to a cardiac 
resynchronisation therapy (CRT) device. Non-randomised data identify that 
this leads to similar improvements as in de-novo CRT implants, in terms of 
clinical variables and measures of LV function,(Witte et al., 2006, Laurenzi 
et al., 2007) and only two randomised (cross-over) studies have been 
completed. In the first study, in 10 patients with symptomatic heart failure, 
there were acute improvements in LV function, symptom scores and B-type 
natriuretic peptide levels following CRT.(Laurenzi et al., 2007) In the second 
study, involving 36 patients with LV dysfunction (LVEF <40%) without CHF 
symptoms, there were improvements in cardiac function following upgrade 
to biventricular pacing.(van Geldorp et al., 2010) However, an upgrade 
procedure is not without risk in patients with existing pacemakers, with risk 
of infection meaning that an upgrade procedure cannot be assumed to be 
benign. In the latter study, 5 patients required second (or third) procedures 
(including one mini-thoracotomy) to achieve LV pacing. There are no 
randomised trials in patients on optimal CHF medical therapy investigating 
the morbidity and mortality effect of upgrading to CRT in patients with 
chronic RV pacing and LV dysfunction with or without heart failure 
symptoms and a registry of successful implants, although useful, is not 
enough.(Bogale et al., 2011) 
 
4.5.4 Preventing RV pacing associated LV dysfunction 
These results have implications for the use of CRT in patients requiring a 
pacemaker for bradycardia thought to be ‘at risk’ of developing LVSD. 
Complete heart block at implant only modestly predicts high %VP at future 
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follow-up, however 65% of patients with low grade AV node disease, without 
CHB at implant, go on to pace more than >80%VP. Therefore, CHB at 
baseline represents only 80% of those requiring >80%VP at PGR. In 
addition, despite a high %VP, some patients seem resistant to the 
potentially deleterious effects of RV apical pacing, so not all patients with 
high degree A-V block will have high %VP at PGR, and not all patients with 
high %VP go on to develop LVSD. Not all patients in this cohort with LV 
dysfunction were taking optimal medical therapy and the incremental benefit 
of implanting a CRT device at baseline or at PGR for rate support is not 
clear.  
 
4.6 Limitations 
This dataset does not include patients that did not survive to PGR, and 
therefore represents a selected population. However, even this group has a 
significant subsequent morbidity and mortality so a PGR may be an 
appropriate time point to review pacemaker and medical therapy. Patients 
with an LVEF of <35% were referred to the heart failure service for review. 
These patients remained in the study for analysis, which may skew the 
results as they have not followed the usual care pathway for pacemaker 
patients.  Patients did not perform a familiarisation CPX which may influence 
the results, however performing a familiarisation test was not practical with 
the number of recruits and time constraints.  
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4.7 Conclusions 
Patients with RV pacemakers referred for elective PGR have a high 
incidence of left ventricular systolic dysfunction and low peak exercise 
capacity, strongly related to the amount of RV pacing to which they are 
exposed. Those with left ventricular systolic dysfunction and high amounts of 
RV pacing are at high risk of subsequent mortality. Simple variables can 
identify those patients who might benefit from a more comprehensive review 
around the time of generator replacement. Whether there are clinical and 
economic benefits of using the opportunity of elective generator replacement 
to optimise medical and device therapy in patients with cardiac dysfunction 
is unknown.  
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Chapter 5. What are the effects of a strategy to reduce right 
ventricular pacing on left ventricular function? 
 
Hypothesis – “Reducing unnecessary right ventricular pacing 
improves left ventricular systolic function, in a cohort of patients 
awaiting pacemaker battery replacement”  
 
5.1 Introduction 
During the survey of pacemaker patients coming for generator replacement, 
it became apparent that many patients had high amounts of right ventricular 
pacing despite reliable underlying intrinsic activity. The aim of the present 
project was therefore to establish the effects of reprogramming pacemakers 
to reduce RV pacing on LV function, exercise capacity, neurohormonal 
levels and symptoms.  
 
Reducing unnecessary right ventricular pacing may have important clinical 
significance. It is well established that right ventricular pacing contributes 
towards the development of LVSD, CHF and AF, which may all contribute 
toward poor outcomes and quality of life. Therefore reducing unnecessary 
right ventricular pacing could influence outcomes and quality of life. 
Reducing unnecessary right ventricular pacing may also prolong battery life 
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and extend the life of the pacemaker, or even prevent battery replacement in 
some individuals.  
 
5.2 Methods 
All patients referred for a PGR at Leeds General Infirmary were invited to 
attend a comprehensive pre-procedure assessment as described previously. 
In all patients with avoidable RV pacing seen over a six month period, we 
followed a pre-specified algorithm outlined in Figure 5.1 
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Figure 5.1: Leeds RV pacing avoidance algorithm 
 
First, the day-time base rate (BR) was reduced to 50 beats per minute, and 
the sleep rate (or hysteresis where available) to 40 beats/minute. Rate 
responsive pacing was deactivated in patients without chronotropic 
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incompetence. In those with SR and low-grade/intermittent heart block we 
extended AV delays to avoid RV pacing, and patients with significantly long 
PR intervals were offered a replacement generator capable of avoiding RV 
pacing through software such as the managed ventricular pacing (MVP) 
algorithm by Medtronic. During routine follow-up at 6 months, patients in 
whom we had made changes to their pacemaker prescription or 
programming were reassessed in the same way as previously mentioned. 
The project was designed as an audit to prospectively evaluate the effect of 
this new pacing-avoidance protocol introduced to the Leeds Pacemaker 
Clinic. At the time of conducting the audit there was no standard operating 
procedure regarding device programming, devices were programmed to the 
personal preference of the cardiac physiologist or were left at manufacturers 
standard settings.  
 
Patients with significant heart failure, life-threatening and/or severe co-
morbidities (severe chronic airways disease or terminal malignancy) were 
excluded. Patients with an LVEF ≤50% and unavoidable RV pacing were 
also excluded from our audit, since these were randomised into a 
randomised control trial of upgrade to CRT versus standard PGR. 
 
The primary endpoint was change in LV ejection fraction (LVEF) from 
baseline to six months. Transthoracic echocardiographic images were 
recorded on a Vivid 7 imaging system and stored offline on a commercially 
available analysis system (Echopac, GE, USA). Images were anonymised 
and analysed in random fashion.  LV ejection fraction was calculated using 
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the mean from three non-paced, normally conducted beats using the 
modified Simpson’s rule (bi-plane). The study was powered based upon an 
estimate of an improvement in LVEF of 5% of on a baseline LV ejection 
fraction of 45% (SD 12) in patients requiring >50% ventricular pacing, based 
upon previous studies of CRT and our own pilot data.(Foley et al., 2009) 
With these variables, we calculated a proposed cohort of at least 63 
individuals to allow us a power of 0.8 and a significance of 0.05. 
 
Secondary endpoints were exercise capacity measured by peak oxygen 
consumption (pVO2), quality of life and NT-proBNP levels. Peak oxygen 
consumption was calculated from the last 15s of a symptom-limited 
incremental peak exercise test on a treadmill, using breath-by-breath 
analysis (Medgraphics, St Paul, USA). To measure quality of life, we used 
the EuroQoL-HF questionnaire,(Cleland et al., 2000) which is sensitive to 
change in symptoms,(Witte et al., 2005) and relates to outcomes in CHF. 
For purpose of analysis, quality of life scores from the EuroQoL-HF were 
converted to a percentage of the maximum score possible. NYHA 
classification was not used as patients with significant heart failure and 
airways disease were excluded. 
 
Data analysis was undertaken using SPSS version 18. Normally distributed 
continuous data are presented as means (95% confidence intervals (CI)). 
Continuous variables with a skewness statistic outside the range of -1 and 
+1, are presented as median and interquartile range (IQR). To investigate 
differences between groups (atrial fibrillation and sinus rhythm) Student’s t-
- 141 - 
tests for normally distributed variables and Mann-Whitney U test for non-
parametric variables (NT-pro-BNP and quality of life) were used. Normally 
distributed baseline and follow-up data (echocardiographic and 
cardiopulmonary variables) were analysed using paired t-tests and quality of 
life and NT-pro-BNP were analysed using two sided Wilcoxon rank sum 
tests. Correlation coefficients were calculated for continuous baseline 
variables and for changes in LVEF, and ventricular pacing at follow-up. We 
corrected for multiple testing using the false discovery rate.(Benjamini Y, 
1995) For all analyses the entire cohort was analysed initially, and then sub-
divided by atrial rhythm AF vs. sinus rhythm.  
 
5.3 Results 
Baseline characteristics for the patients included in the audit are presented 
in table 5.1. Programming of the pacemaker parameters at baseline was 
consistent with usual practice, with a low BR, reasonably extended A-V 
delays for those in SR, and rate-adaptive pacing activated in 68% of 
patients. The only pacing variable different between the two groups was the 
frequency of rate-adaptive pacing which was more common in patients with 
AF (Χ2 7.1; p=0.008).  
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Table 5.1: Baseline variables in 66 patients with RV pacemakers 
 
Values for continuous variables are means (95% CI), or median (IQR) where indicated and for 
categorical variables are ‘n’ [%] 
MI; myocardial infarction, CVA; cerebrovascular accident, CABG, coronary artery bypass grafting, 
DBP; diastolic blood pressure, SBP; systolic blood pressure, CHB; complete heart block, ACE-
inhibitor; angiotensin-converting enzyme inhibitor, GFR; glomerular filtration rate, LVEF, left ventricular 
ejection fraction, LVEDD, left ventricular end-diastolic diameter, LVESD; left ventricular end-systolic 
diameter, PAP; pulmonary artery pressure, pVO2; peak oxygen consumption. 
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Clinical and echocardiographic variables were usual for a cohort of patients 
with an average of 10 years of right ventricular pacing.(Davy et al., 2012) 
Patients in AF were more likely to have heart failure symptoms (63% v 51% 
in NYHA class II; Χ2=6.0; p<0.05), larger cardiac dimensions (LVEDD 55mm 
(52-57) v 49 (46-51); p=0.003) and higher NT-pro-BNP levels at baseline 
(1778 (IQR ng/L 2366) v 485 (IQR 1301); p=0.003). LVEF, past medical 
history and medical therapy were the same across AF and SR patients. 
 
There was a correlation between ventricular pacing percentage (%VP) at 
baseline and LVEF in patients in sinus rhythm (r=0.5; p=0.03), but no 
relationship between %VP at baseline and sensed/paced A-V delays. Also, 
there was also a relationship between BR and LVEF (r=0.36; p=0.003), and 
although this remained significant in patients with AF on when %VP was 
added into multiple regression, (r=0.4; p=0.05), LVEF and BR were not 
independently related in patients with SR. 
 
The reduction in base rate to 50 bpm and the de-activation of rate-adaptive 
pacing was not tolerated in two of the patients. Both patients were in AF and 
had their pacemakers reprogrammed to their original settings after one 
week. These patients were included in the intention to treat analysis.  
 
All patients returned for their 6-month reassessment. At the next pacemaker 
follow-up mean resting heart rates were lower by 8 (6-10) beats per minute 
(p<0.0001), with no difference between patients in SR or AF. 21 (68%) of the 
patients in SR received a device with a pacing avoidance algorithm (in whom 
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programmed AV delays could be shortened), the remainder had a mean 
increase in AV delay of 100ms.  
 
The pacing avoidance strategy reduced mean RV pacing percentage by 49 
(41-57)%, (p<0.0001) from baseline and was higher in patients in SR than in 
those in AF (-61 (49-73 v -40 (30-50)%; p=0.01). There was an additional 
reduction in %VP in patients prescribed with devices containing pacing 
avoidance algorithms, (-67 (52-80) v -53 (28-76), this did not reach 
significance.  
 
The programming changes as a whole were associated with an 
improvement in LVEF of 6% (p<0.0001 from baseline) and a reduction in LV 
cavity dimensions, see Table 5.2.  
 
Table 5.2: Changes in clinical variables following reprogramming to avoid 
RV pacing  
Values for continuous variables are means (95% CI), or median (IQR) where indicated.  
LVEF, left ventricular ejection fraction, LVEDD, left ventricular end-diastolic diameter, 
LVESD, left ventricular end-systolic diameter, PAP; pulmonary artery pressure, pVO2; peak 
oxygen consumption. P-values correspond to paired t-tests for normally distributed data and 
Wilcoxon rank sum tests for quality of life and NT-pro-BNP data 
 
  Pre-intervention Post-intervention p-value 
Proportion of ventricular paced beats (%) 78 (72-83) 28 (20-36) <0.0001 
Quality of life (%) (median, IQR) 83 (18) 87 (20) 0.43 
B-type natriuretic peptide (pmol/L) (median, IQR) 1368 (2121) 1250 (1649) 0.26 
LVEF (%) 43 (39-45) 48 (45-51) <0.0001 
LVEDD (mm) 52 (50-54) 50 (49-52) 0.03 
LVESD 40 (38-42) 38 (36-40) 0.007 
PAP (mmHg) 38 (34-42) 38 (33-42) 0.22 
NYHA 2 2 0.18 
Peak heart rate (beats/min) 126 (118-134) 124 (116-132) 0.12 
pVO2 (ml/kg/min) 19 (17-21) 20 (17-23) 0.39 
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The ΔVP% achieved using the pacing avoidance algorithm was higher in 
patients in SR, but there was no difference in the response for LVEF by atrial 
rhythm (or by strategy), although patients with AF had a greater magnitude 
of improvement in LVEDD (p<0.02 between SR and AF). There was no 
overall change in NT-pro-BNP levels, quality of life or exercise variables 
(including peak heart rates) in the cohort as a whole or when divided by 
atrial rhythm. 
 
For the entire cohort, there was a relationship between ΔVP% and change in 
LVEF (r=0.26; p=0.04) (Figure 5.2) and a trend towards a relationship 
between ΔVP% and change in NT-pro-BNP levels (r=0.27; p=0.07). This 
latter relationship was significant in patients with AF (r=0.44; p=0.03). Also, 
in patients in AF, despite no improvement in exercise capacity, there were 
significant inverse relationships between the change in pVO2 and reduction 
in RV pacing (r=0.66; p=0.005). Mean quality of life was not influenced by 
reductions in pacing percentage in either the SR or AF group. 
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Figure 5.2: The relationship between change in right ventricular pacing 
percentage (V-pace) and change in left ventricular ejection fraction 
(LVEF) function at six months 
 
The data presented in Fig 5.2 may be influenced by two cases with 
significant changes to their LVEF. The first individual had a significant 
improvement in their LVEF of 32%, and a reduction in RV pacing by 95%. 
This 74 year male patient had 1st degree AV block, a PR interval of 350ms 
and no known history of IHD. Right ventricular pacing could not be avoided 
by extending his AV-delays, so following the pacing reduction algorithm we 
the patient was implanted with a Medtronic Adapta pacemaker, with MVP 
mode activated. The second patient was a 79 year old male in AF. There 
was a reduction in LVEF of 12% and a minor increase in RV pacing 
percentage of 2%. This patient’s clinical situation had deteriorated and was 
referred to the heart failure clinic for further evaluation.  
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5.4 Discussion 
These data provide the first evidence that reducing unnecessary RV pacing, 
across a wide range of patients, is associated with improved LV systolic 
function without adversely affecting exercise capacity or quality of life. The 
data demonstrating that the degree of RV pacing reduction achieved relates 
to the degree of improvement in LV function and (in the atrial fibrillation 
group) the degree of improvement in exercise capacity and NT-pro-BNP, are 
especially powerful. They add to the already existing hypothesis that that RV 
pacing is not merely associated with cardiac dysfunction, but also 
contributes to it.  
 
Heart failure or asymptomatic LVSD is a common finding in patients with 
permanent pacemakers,(Thackray et al., 2003) and is associated with a poor 
overall outcome, particularly in patients requiring a high proportion of 
ventricular pacing. As a result of this observation, cardiac resynchronisation 
therapy (CRT) upgrades to existing pacemaker systems are 
common.(Bogale et al., 2011) Data from large randomised studies 
examining the benefits of upgrade to CRT on LV function, neuro-hormonal 
activation, quality of life and heart failure hospitalisation are required. 
Randomised studies would also need to investigate complication rates as 
upgrading existing devices carries higher risk of subsequent complication 
than performing a new implant.(Nery et al., 2010) The high prevalence of 
heart failure in patients requiring a pacemaker for bradycardia has led to 
studies examining the use of CRT in this setting (Curtis et al., 2013). 
Unfortunately, due to methodological issues with the single large trial, this 
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strategy is unlikely to be accepted without further evidence.(Witte, 2014) 
These data clearly demonstrate that careful reduction of unnecessary RV 
pacing through reprogramming or pacing avoidance algorithms, can 
successfully avoid RV pacing or reduce it to levels below which an adverse 
effect is less likely.(Sweeney et al., 2003) Adding this finding to the previous 
observation, outlined in the previous chapter, that an implant indication of 
intermittent complete heart block at implant, is not a reliable guide to the 
need for long-term frequent RV pacing, nor is reliably associated with 
subsequent LVSD (unlike %RV pacing in the preceding year), means that 
selecting patients in whom CRT for bradycardia is likely to be of benefit 
remains difficult based on current evidence. 
 
The de-activation of rate-adaptive pacing was well tolerated by both groups 
of patients in this audit. Rate-adaptive pacing is an algorithm designed to 
increase HR in those with chronotropic incompetence during times of 
increased demand. Various methods of sensing the presence of increasing 
demand are available including motion sensors such as accelerometer and 
piezoelectric systems which sense motion, transthoracic impedance sensors 
which are designed to detect changes in breathing associated with 
increased demand, measurement of changes in QT duration associated with 
exercise, and sensors designed to which detect changes in contractility such 
as Livanova’s SonR lead and Biotronik’s CLS system.(Malinowski, 1998, 
Jutzy et al., 1990, Sulke et al., 1991, Lazarus and Mitchell, 1996, Candinas 
et al., 1997) There was no reduction in pVO2 or peak heart rate during 
cardiopulmonary exercise testing and no difference in quality of life. Rate-
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adaptive pacing in pacemaker patients without CHF is associated with a greater 
cardiac output rise during exercise,(McMeekin et al., 1990) and although 
studies have shown improvements in exercise capacity ranging from 
minimal,(Batey et al., 1990, Carmouche et al., 1998) to significant,(Capucci et 
al., 1992) there is no consistency on improvement in measures of quality of life 
in either AF or SR.(Lau et al., 1989, Trappe et al., 1988, Haywood et al., 1993) 
The literature is equally inconsistent about whether rate-adaptive CRT pacing 
does,(Tse et al., 2005, Sims et al., 2011) or does not,(Van Thielen et al., 2008) 
improve exercise tolerance in patients with CHF, but there does seem to be no 
positive effect on quality of life.(Martin et al., 2012) Therefore, these data are 
consistent with current evidence that rate-adaptive pacing offers little benefit in 
most patients with pacemakers implanted for bradycardia, but de-activating 
rate-adaptive pacing can reduce %VP and improve, or preserve, left ventricular 
systolic function. Furthermore, what is likely, but unproven, is that careful 
reprogramming, providing a ‘sleep’ or hysteresis rate, and in doing so reducing 
%VP, has the long-term benefit of prolonging battery life. 
 
68% of patients with SR (n=21) received a pacemaker with a pacing-
avoidance algorithm at PGR. Previous work investigating these algorithms 
has focussed on their efficacy at reducing RV pacing and associated AF in 
patients with sinus node disease.(Kolb et al., 2011, Sweeney et al., 2007, 
Davy et al., 2012) These data endorse for the first time that the reduction of 
unnecessary RV pacing with these algorithms contributes to an improvement 
in LVEF.  
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Finally, this dataset contributes to the literature in one further critical way. 
There is some inconsistency about whether RV pacing contributes to LV 
dysfunction,(Riahi et al., 2012) or is merely associated with it. By reducing 
the exposure to a proposed aetiological factor, in this case RV pacing, and 
observing an improvement in a condition, we have confirmed one of the 
rules of causation.(Hill, 1965) 
 
5.5 Limitations 
This study is a significant proof of concept analysis of data, collected from a 
non-selected cohort of consecutive patients, to a clinic designed to assess 
patients prior to PGR. The intervention was not applied in a randomised, 
double blind fashion and the results of the analysis must be interpreted in 
light of this. But, programming changes and data collection followed a robust 
standardized process in consecutive patients. And the analysis of the 
echocardiographic images, cardio-pulmonary exercise test and NT-pro-BNP 
results, and pacing data presented in this report was performed on an 
intention-to-treat basis in a randomised, blinded fashion by a single 
experienced cardiac physiologist. We were careful to avoid altering medical 
therapy over the six month follow-up period, although the patients’ usual 
physicians were free to do so. Hence we are confident that the changes 
presented are purely due to modifications in pacemaker therapy. A larger 
study would require randomization to correct for non-device treatments.  
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Other limitations include that the study was carried out in a single centre and 
that the outcomes variables are surrogates for hospitalization and 
mortality.(Foley et al., 2009) The shortcomings of surrogate endpoints are 
typical of proof of concept small scale studies. In order to establish the 
benefits of pacemaker reprogramming to reduce unnecessary RV pacing, on 
heart failure events in an unselected population of patients a larger 
randomised, placebo-controlled study with longer follow-up is required to 
provide robust efficacy and cost effectiveness data.  
 
5.6 Conclusions 
In an unselected cohort of consecutive patients without complete heart 
block, I have demonstrated that reducing RV pacing is possible with no 
adverse effects on symptoms, exercise capacity or quality of life. This 
strategy is associated with improved LVEF, suggesting that RV pacing 
contributes to LV dysfunction in patients with pacemakers. The time of PGR 
might be an opportunity to optimise pacing prescription. 
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Chapter 6. Cardiac resynchronization therapy in pacemaker-
dependent patients with left ventricular dysfunction. 
 
Hypothesis – Upgrading to cardiac resynchronization therapy, at 
the time of battery replacement, improves left ventricular systolic 
function in a cohort of patients awaiting pacemaker battery 
replacement. 
6.1 Introduction 
It is increasingly recognised that patients with complete heart block, 
dependent upon their pacemaker, are at increased risk of prevalent left 
ventricular systolic dysfunction and increased risk of presenting with heart 
failure in the future. (Zhang et al., 2008) There is enthusiasm to implant a 
CRT device into people with complete heart block and left ventricular systolic 
dysfunction, although in patients with modest LVSD and few symptoms, 
there are few data to support this practice. I became aware that in addition to 
a dilemma at the time of initial implant, this is also a problem at generator 
replacement. I have described in chapter 4 that I found a high prevalence of 
mildly symptomatic left ventricular systolic dysfunction in these people. 
There was no published evidence to describe what should be done in the 
absence of reprogramming options. An upgrade procedure to CRT is a 
logical option, but comes at a cost in terms of complications, and cost. The 
aim of this study therefore was to investigate the effect of elective CRT 
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upgrade at pacemaker generator replacement versus standard care in 
patients with mildly symptomatic LVSD and mandatory RV pacing.  
 
6.2 Methods 
Adult patients, referred for a pacemaker pulse generator replacement were 
recruited into a randomised, placebo-controlled trial of pacemaker upgrade 
to CRT versus standard pulse generator replacement (PGR), see Fig 6.1. 
Inclusion criteria included unavoidable high rates of RV pacing (>80%), 
LVSD (left ventricular ejection fraction (LVEF) <50%), and mild to no 
symptoms of heart failure. Exclusion criteria included life-threatening or 
severe co-morbidity (severe chronic airways disease or terminal 
malignancy), suboptimal non-invasive imaging quality, recent heart failure 
hospitalisation, documented ventricular tachy-arrhythmia, and inability or 
unwillingness to provide consent.  
 
As previously described, all patients listed for pacemaker pulse generator 
replacement at Leeds General Infirmary were invited to attend an 
assessment session prior to the procedure. Each subject underwent 
transthoracic echocardiography, completed a quality of life questionnaire, 
had a blood test for renal function, blood count and N-terminal proB-type 
natriuretic peptide (NT-proBNP) measurement, and where possible, a 
treadmill based cardiopulmonary exercise test was performed to document 
peak oxygen consumption (pVO2).  
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Figure 6.1: Study protocol 
 
After the assessment, consecutive patients eligible to participate in the 
present study, were offered an information sheet, and those interested in 
taking part were asked to sign a consent form. Subjects were randomised, 
via a telephone randomisation service provided by the clinical trials unit at 
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the University of Leeds School of Medicine, to receive either a standard 
PGR or upgrade to CRT. 
 
Upgrade to CRT or PGR was performed within two weeks of the date of 
consent. In patients randomised to receive upgrade to CRT all implants were 
performed by the same, experienced consultant cardiologist. Venous 
access, coronary sinus cannulation and left ventricular lead placement were 
performed as usual practice, with a lateral position of the left ventricular lead 
electrodes attempted. To limit infection risk, the pacemaker capsule was not 
opened until the left ventricular lead was optimally positioned. Following this, 
the right heart leads were electrically tested as normal, and all three leads 
were connected to either a Medtronic Insync III or Consulta P generator 
(Medtronic, Minneapolis, USA). This pacemaker was then programmed to 
simultaneous left and right ventricular stimulation, other pacemaker variables 
were kept unchanged. Echocardiographic or electrical optimisation was not 
performed. Patients receiving a standard PGR were scheduled via the usual 
method, and had their procedure performed by a consultant or specialist 
registrar. Patients maintained their usual pacemaker follow-up schedule and 
were invited back for a repeat assessment at six months post upgrade/PGR. 
 
The primary endpoint was the difference, in the change in LVEF from 
baseline to six months, between the two groups. Transthoracic 
echocardiographic images were recorded on a Vivid 7 imaging system and 
stored offline on a commercially available analysis system (Echopac, GE, 
USA). Anonymised images were analysed in random fashion at the end of 
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the study by a single blinded observer. Based upon existing observational 
work, a clinically significant improvement in LVEF of 5% in the CRT arm, and 
no change in LVEF in the PGR group at six months was estimated. In the 
sample size calculation, an LV lead implant failure rate of around 8% was 
allowed for, and a loss to follow up of 5% was also included. To have a 
power of 90% in a two-sided independent samples t-test to detect the 5% 
difference we calculated that we would need to recruit 50 patients (25 to 
each arm).  
 
Secondary endpoints included exercise capacity measured by peak oxygen 
consumption (pVO2), NT-proBNP levels and quality of life. pVO2 was 
calculated from the last 30s of a symptom-limited incremental peak exercise 
tolerance test on a treadmill or stationary cycle. Gas exchange was 
measured using breath-by-breath analysis (Medgraphics, St Paul, USA). To 
assess quality of life, the EuroQoL-HF questionnaire was used.(Cleland et 
al., 2000) The EuroQoL-HF questionnaire is sensitive to symptom changes 
and relates to outcomes, in CHF.(Witte et al., 2005, Cleland et al., 2003a) To 
simplify analysis, quality of life scores from the EuroQoL-HF were converted 
to a percentage of the expected maximum. A combined endpoint of all-
cause hospitalisation and mortality until the end of the follow-up period for all 
patients was completed. Digital and paper hospital and general practice 
records were accessed to confirm cause and duration of admission and 
cause of death. 
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Baseline variables were presented as means (95% confidence intervals). 
Analysis of baseline and follow-up data was undertaken on an intention-to-
treat basis.  The study was approved by Leeds West Local Research Ethics 
Committee and Research and Development at Leeds Teaching Hospitals 
NHS Trust. SPSS version 18 was used for data analysis. 
 
6.2 Results 
Baseline characteristics for the enrolled patients can be seen in table 6.1. 
The indication for pacemaker implant was CHB in all but five patients, whose 
initial indication was SSS but who had later developed AV conduction tissue 
disease. Patients randomized to CRT implant had a longer procedural time 
and a higher mean radiation dose than those receiving an RV-PGR (Table 
6.2). There were no immediate post-procedural or early complications, and 
there were no long-term complications up to the censor date of 1 May 2012. 
In the CRT arm, there was one implant failure due to superior vena cava 
stenosis, therefore it was not possible to implant an LV lead. This patient 
received a RV-PGR, but as per the pre-specified analysis plan, was included 
in the CRT arm for the analysis.  
 
Table 6.3 shows the changes from baseline to 6 months in patients 
randomized to upgrade to CRT or standard RV-PGR. In the CRT group 
there was an improvement in LV function (Figure 6.2 and 6.3). In patients 
randomized to CRT there was also an improvement in peak exercise 
capacity, AT (which could not be measured in 7 patients) an improvement in 
- 158 - 
quality of life and a reduction in NT-proBNP levels. There was no 
heterogeneity in any of the four outcomes with respect to baseline atrial 
rhythm, with patients in AF demonstrating an improvement in cardiac 
function, exercise capacity, BNP, and quality of life from baseline, of similar 
degree to the changes seen in patients with sinus rhythm. The only variable 
to behave differently by atrial rhythm was ΔLV end-diastolic diameter 
(LVEDD), which did not change in patients with sinus rhythm but was 
significantly reduced by CRT in patients with atrial fibrillation (P ¼ 0.019). 
So, although CRT was associated with a reduction in LVEDD overall, it did 
not reach statistical significance for the group overall. 
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Table 6.1: Baseline variables 
 
 
Values are means (CI).  
MI; myocardial infarction, CVA; cerebrovascular accident, CABG, coronary artery bypass 
grafting, DBP; diastolic blood pressure, SBP; systolic blood pressure, CHB; complete heart 
block, ACE-inhibitor; angiotensin-converting enzyme inhibitor, GFR; glomerular filtration 
rate, LVEF, left ventricular ejection fraction, LVEDD, left ventricular end-diastolic diameter, 
PAP; pulmonary artery pressure, pVO2; peak oxygen consumption. 
 
 
  CRT (n=25) RV (n=25) 
Age (years) 77 (73-81) 77 (73-81) 
Sex (male) 16 16 
Height (cm) 164 (156-172) 166 (162-170) 
Weight (kg) 82 (74-90) 73 (67-80) 
Remote MI (n) 5 6 
Remote CVA (n) 1 1 
Hypertension (n) 14 10 
Diabetes mellitus (n) 4 7 
CABG (n) 6 7 
Heart rate (bts/min) 77 (71-83) 68 (62-74) 
DBP (mmHg) 66 (70-62) 71 (65-77) 
SBP (mmHg) 120 (110-130) 139 (125-153) 
Sinus rhythm (n) 20 17 
QRS duration (ms) 168 (160-176) 159 (149-169) 
Years of pacing (years) 10 (8-12) 12 (10-14) 
Beta-blocker (n) 14 13 
ACE inhibitor (n) 18 19 
Warfarin (n) 5 6 
Quality of life (%) 82 (76-88) 87 (83-91) 
Creatinine (μmol/L) 117 (107-127) 119 (105-133) 
Estimated GFR (l/min) 56 (50-62) 55 (49-61) 
Haemoglobin (g/dL) 13.6 (13.0-14.2) 13.4 (12.6-14.2) 
B-type natriuretic peptide (pmol/L) 1613 (570-2656) 977 (471-1483) 
LVEF (%) 39 (35-43) 41 (37-45) 
LVEDD (mm) 50.6 (47.7-53.5) 49.2 (46.2-52.1) 
PAP (mmHg) 34 (28-40) 33 (29-37) 
pVo2 (ml/kg/min) 14.2 (12-16) 15.8 (13-18) 
AT (ml/kg/min) 11.1 (9-13) 11.3 (9-13) 
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Table 6.2: Implant data 
 
Values are means (CI) 
 
Table 6.3: Changes in outcomes variables between groups from baseline to 
six months 
 CRT (n=25) RV (n=24) p-value 
Δ LVEF (%) 9 (6-12) -1.5 (-4.5-0.8) <0.0001 
Δ pVO2 (ml/kg/min) 2.1 (0.5-2.7) -0.5 (-1.6-0.4) 0.007 
Δ Quality of life (%) 2.3 (-0.3-11.1) -2.0 (-3.5-0.0) 0.007 
Δ NT-proBNP (pmol/L) -56 (-437-218) 85 (-15-492) 0.03 
Δ AT (ml/kg/min)  0.7 (0.1-1.2) - 0.4 (-1.1-0.2) 0.01 
 
Values are medians (interquartile range) 
LVEF; left ventricular ejection fraction, pVO2; peak oxygen consumption, N-terminal pro B-
type natriuretic peptide 
 
 
Figure 6.2: Median change in left ventricular ejection fraction (LVEF) in 
cardiac resynchronisation therapy (CRT) group and standard right 
ventricular pulse generator group (RV-PGR) from baseline to follow-up 
at six months. 
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Figure 6.3: The effect of CRT or RV-PGR on left ventricular ejection fraction 
(LVEF) at six months. 
 
Mean follow-up duration at the censor date of 1 May 2012 was 809 (729 – 
880) days. During this time three patients had died, one in the CRT arm and 
two in the RV-PGR arm. The combined exploratory endpoint of death or all-
cause hospitalization was not statistically different between the arms: 17 
patients had died or been hospitalized for any cause (6 in CRT group and 11 
in the RV-PGR group). Mean (CI) days in hospital was 8 (4 – 12) days, with 
a trend to fewer days in hospital in those randomized to CRT than those 
receiving standard PGR [4 (2 – 7) vs. 11 (6 – 16) days; p=0.047]. Two 
patients in the RV-PGR were upgraded to CRT for worsening heart failure 
within this extended follow-up period. 
 
6.3 Discussion 
Upgrade to CRT at the time of standard pacemaker PGR in patients with un-
avoidable RV pacing and LVSD leads to clinically and statistically 
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significantly improved LV function, quality of life, and exercise capacity, and 
reductions in N-terminal pro-B-type natriuretic peptide levels. Upgrade to 
CRT was associated with fewer all-cause hospitalizations and fewer 
subsequent interventions, and if this pattern is reproduced in larger studies, 
it may therefore be cost-effective. 
 
Heart failure or asymptomatic LVSD is a common finding in patients with 
permanent pacemakers implanted for bradycardia,(Thackray et al., 2003, 
Wilkoff et al., 2002) and is associated with a poor overall outcome, 
particularly in patients requiring a high amount of ventricular pacing. What 
the optimal management plan of pacemaker-associated LVSD has never 
been formally established. Many of the studies of device and medical 
therapy for CHF have excluded patients with pacemakers, and the numbers 
have been inadequate to justify a subgroup analysis, in those that did not 
exclude this group. Specifically, CRT improves cardiac function, symptoms 
and outcomes in CHF patients,(Cleland et al., 2000, Cazeau et al., 2001, 
Abraham et al., 2002, Bristow et al., 2004) and is indicated (class I 
recommendation, level of evidence A) for patients with LVSD (LVEF ≤35%), 
ongoing or prior CHF symptoms (NYHA class III and IV) and surface ECG 
interventricular conduction delay,(McMurray et al., 2012, Daubert et al., 
2012, Epstein et al., 2013) but thus far has not been the focus of a 
randomized controlled study in patients with RV pacemakers and high levels 
of RV pacing due to heart block. 
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Observational studies have proposed that upgrading existing RV pacing 
systems to CRT in patients with CHF leads to comparable improvements in 
cardiac function and symptoms as new CRT implants,(Tang et al., 2010, 
Nagele et al., 2008, Wokhlu et al., 2009, Frohlich et al., 2010) and 
international guidelines briefly discuss the potential of upgrading existing RV 
pacemakers to CRT as part of the management of severe CHF but 
acknowledge the lack of data to support such a policy. Regardless of the 
lack of randomized data, upgrades of existing pacemakers to CRT devices 
are frequently performed in Europe and the USA.(Marinskis et al., 2012, 
Poole et al., 2010) The data from European studies suggest that patients 
receiving an upgrade to CRT have no greater mortality or complication risk 
than those receiving a new implant of mortality or complications.(Marinskis 
et al., 2012) There have only been two other randomized studies of 
upgrading existing right ventricular pacemakers to CRT. Both were done in 
patients who were younger than those included in this study. In the 1st study, 
in 10 patients with heart failure, there were acute improvements in LV 
function, symptoms, and BNP levels following upgrade to CRT.(Hoijer et al., 
2006) In the 2nd study, 36 patients with existing right ventricular pacemakers, 
LV systolic dysfunction (LVEF <40%) and without heart failure symptoms, 
demonstrated improved cardiac function following upgrade to CRT.(van 
Geldorp et al., 2010) 
 
Performing an upgrade to an existing RV pacemaker carries a higher 
complication risk than performing a new implant.(Poole et al., 2010, Nery et 
al., 2010) This is due to potential damage to existing leads, possibility of 
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limited venous access and risk of infection.(Jones et al., 2008, Bongiorni et 
al., 2008) In the 2nd randomised study discussed above, 5 of the 36 patients 
enrolled required further intervention (including one thoracotomy) to achieve 
CRT pacing. The ‘Resynchronization – defibrillation for ambulatory heart 
failure trial’ (RAFT) randomized patients referred for ICD without severe 
heart failure symptoms to a standard ICD or CRT-D. Patients recruited to the 
study with existing pacemakers did not benefit from upgrade to CRT, even if 
their paced QRS duration was <200 ms. (Bogale et al., 2011) Therefore, it 
cannot be assumed that an upgrade to CRT, in a patient with severe CHF 
and an existing pacemaker will be beneficial. 
 
Preliminary data, of a randomized controlled trial data in patients with LV 
systolic dysfunction requiring a pacemaker to treat bradycardia, 
demonstrated better LV function in those receiving CRT vs. RV 
pacing.(Kindermann et al., 2006) 
 
The ‘Biventricular versus right ventricular pacing in heart failure patients with 
atrioventricular block’ (BLOCK HF) study suggests that patients requiring a 
pacemaker for AV block, with mild LVSD, will benefit from de novo CRT over 
RV pacing in terms of the effects of CRT on a combined outcome of all-
cause mortality, heart failure hospitalization, and deterioration in LV function. 
(Curtis et al., 2013) Higher complication rates than what would occur with 
standard RV pacing were reported, as all patients were implanted with a 
CRT device. Further questions remain as to whether this approach is 
clinically or cost-effective vs. carefully programmed RV pacing. 
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The present study is the first randomized, placebo controlled study on how 
patients with an existing RV pacemaker requiring a battery replacement and 
mildly symptomatic LVSD should be managed. CRT reduces hospitalisations 
in patients with mild symptoms, LVSD and conduction delay.(Linde et al., 
2008, Moss et al., 2009) The present study provides additional data about 
CRT in patients with standard pacemakers, high levels of RV pacing and 
mild symptoms of heart failure. The study results propose a strategy that 
may allow additional procedures, and their additional risks and costs, to be 
avoided in some patients. If this data suggesting reduced hospitalizations 
were to be reproduced in further studies, this strategy might be cost-effective 
also. 
 
6.4 Limitations 
The present study is an important proof of concept study, but requires further 
evaluation of efficacy and cost effectiveness. The study has limitations 
including being single centre, both the study physician and patients were un-
blinded and the end-points are surrogates for prognosis. Surrogate 
endpoints can be disadvantageous in small proof-of-concept studies, and LV 
ejection fraction has come under scrutiny in recent CRT studies as a poor 
marker for outcome.(Foley et al., 2009) However, there was consistent 
change in each of my endpoints including exercise capacity and quality of 
life, and the extended follow-up data suggest potential benefits in definitive 
outcomes, requiring a larger study or longer follow-up to confirm. 
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6.5 Conclusions 
Heart failure is common in patients with pacemakers and relates to 
hospitalization and mortality,(Thackray et al., 2003, Wilkoff et al., 2002) but 
patients with pacemakers were frequently excluded from studies of medical 
therapy for heart failure, the benefits of medical or device therapy in this 
population is unknown. My data demonstrate that LVSD combined with 
unavoidable RV pacing responds to upgrade to CRT, and that upgrade to 
CRT at the time of PGR may be an opportunity to optimize pacing therapy. 
Further evaluation of whether a coordinated programme of risk stratification, 
device programming, device prescription and optimized medical therapy at 
the time of PGR could lead to improved outcomes and cost-effective patient 
care is justified in this patient group. 
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Chapter 7. Discussion 
 
Pacemakers are an extremely effective treatment for bradycardia, with 
robust evidence in support of their positive effects on mortality and quality of 
life. The field of electrophysiology has progressed from early recognition of 
the link between the pulse and syncope in around 400 BC, through curiosity 
driven experiments of the effects of electrical stimulation on animal hearts, to 
modern pacemaker therapy. Current pacemakers are a complex, reliable 
medical technology that not only treat bradycardia, but also provide a wealth 
of diagnostic including information on heart rhythm abnormalities, patient 
activity and can also transmit diagnostic information via the 
telecommunications network. 
 
However, pacemakers represent a double-edged sword. They treat 
bradycardia effectively, whilst also putting patients at risk of LVSD due to the 
detrimental effects of RV pacing. RV pacing is still an accepted way to 
induce experimental left ventricular systolic dysfunction (LVSD) in animal 
models of chronic heart failure (CHF), and landmark trials such as - the 
Dual-chamber pacing or ventricular backup pacing in patients with an 
implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator 
(DAVID) trial, provided robust evidence of the potential adverse effects in 
humans. This led to a drive by the pacemaker industry to develop device 
based algorithms to reduce unnecessary RV pacing where possible. 
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This thesis provides novel information that right ventricular (RV) pacing is a 
contributory factor in the development of left ventricular systolic dysfunction 
(LVSD) and chronic heart failure (CHF). It does this by providing 
observational and interventional datasets to describe causation.  
 
My data include the first study to systematically explore a current cohort of 
patients undergoing standard pacemaker generator replacement (Chapter 
4). I have identified a dose-response in RV pacing and LVSD and that the 
effect of this is related to co-morbidities especially coronary artery disease or 
myocardial infarction. My data suggest that patents at higher risk of 
prevalence HF or LVSD can be identified using simple clinical and 
pacemaker-related variables. I also demonstrated that LVSD was the 
strongest predictor of mortality in patients with an RV pacemaker.  
 
Chapter 5 describes the first ever study to explore the effects of RV pacing 
avoidance on LV function. I have shown that reducing unnecessary RV 
pacing improves LV systolic function without impairing exercise capacity and 
quality of life in a representative group of consecutive patients 
 
Chapter 6 includes data from the first randomized, placebo controlled study 
on the effects of elective CRT upgrade in people with mild or no symptoms 
of heart failure and LVSD requiring PGR. I proved that this approach 
improves LVEF, exercise capacity and symptoms even in these mildly 
symptomatic patients, while it also seems to lead to reduced hospitalisations 
and mortality.  
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At present the follow-up of pacemakers is limited to technical aspects of the 
device functionality.  The totality of my data indicates that pacemaker 
patients should have a regular review of indication, programming and 
cardiac function which could be undertaken by non-physician specialists 
working and empowered by series of guidelines based upon my work that 
could be particularly important at the time at which battery replacement is 
contemplated. Widespread clinical adoption of the evidence provided in this 
thesis, by identifying patients at risk of heart failure, and describing possible 
therapeutic options including optimisation of programming and pre-emptive 
CRT could improve the quality of life and prognosis of patients with 
pacemakers throughout the world, whilst also being cost-effective in 
reducing further expensive upgrade procedures and reducing admissions.  
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List of Abbreviations 
 
American Heart Association    AHA 
Angiotensin-converting enzyme inhibitors   ACEI    
Atrial Fibrillation      AF 
Atrioventricular      AV 
Atrioventricular Node     AVN 
Anaerobic Threshold     AT 
Beats per Minute      BPM 
Beta-Blocker       BB 
British Society of Echocardiography   BSE 
Cardiac Resynchronisation Therapy   CRT 
Cardiopulmonary Exercise Test     CPX 
Chronic Heart Failure     CHF 
Cardiac Output      CO 
Complete Heart Block      CHB 
Coronary Artery Bypass Grafting    CABG 
Coronary Artery Disease     CAD 
Diabetes Mellitus       DM 
Dilated Cardiomyopathy     DCM 
Ejection Fraction      EF 
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Electrocardiograph       ECG 
European Society of Cardiology    ESC 
Heart Failure with mid-range Ejection Fraction  HFmrEF 
Heart Failure with Preserved Ejection Fraction  HFpEF 
Heart Failure with Reduced Ejection Fraction  HFrEF  
Heart Rate       HR 
Hypertension       HTN 
Implantable Cardioverter Defibrillator    ICD 
Ischaemic Heart Disease      IHD 
Left Bundle Branch Block      LBBB 
Left Ventricle       LV 
Left Ventricular Ejection Fraction    LVEF 
Left Ventricular Systolic Dysfunction   LVSD 
Myocardial Infarction      MI  
National Institute for Health and Care Excellence NICE 
Naturetic Peptides      NP 
New York Heart Association     NYHA 
Peak Oxygen Consumption     pVO2 
Percutaneous Coronary Intervention    PCI 
Pulse Generator Replacement    PGR 
Renin Angiotensin Aldosterone System   RAAS 
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Randomised Control Trial     RCT 
Right Ventricle      RV 
Right Ventricular Outflow Tract    RVOT 
Sick Sinus Syndrome     SSS 
Sinus Node       SN 
Sinus Node Disease     SND 
Sinus Rhythm       SR 
Standard Deviation      SD 
Standard Error      SE 
Superior Vena Cava      SVC 
Transthoracic Echocardiogram    TTE 
Ventilation       VE 
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Appendix A – What is the prevalence of left ventricular 
dysfunction in pacemaker patients requiring a battery 
replacement? - Ethical approval  
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Appendix B – What is the prevalence of left ventricular 
dysfunction in pacemaker patients requiring a battery 
replacement? -  LTHT R&D approval 
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Appendix C – Cardiac resynchronization therapy in 
pacemaker-dependent patients with left ventricular 
dysfunction - ethical approval 
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Appendix D – Cardiac resynchronization therapy in 
pacemaker-dependent patients with left ventricular 
dysfunction - LTHT R&D approval 
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